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Summary of Thesis
There is a need for a topical formulation for invasive forms of Basal cell 
carcinoma (BCC), a tumour caused by constitutive activation of the Sonic 
Hedgehog (SHH) signal transduction pathway. It has been shown that the 
expression of a subset of SHH target genes are augmented by EGF in GLI 
over-expressing keratinocytes suggesting inhibition of SHH and EGF 
signalling as potential targets.
Keratinocyte monolayer cultures in the presence of recombinant SHH and EGF 
were used to determine whether the subset of target genes would be increased 
when full SHH signalling was activated, a necessary requirement to test SHH 
inhibitors acting upstream of GLI. Activation of the SHH pathway was not 
fully achieved. Keratinocytes were therefore co-cultured with fibroblasts to 
find out if paracrine signalling was needed for SHH signalling induction. When 
this also did not activate the pathway, scanning electron microscopy was 
carried out to determine whether keratinocytes cultured under various 
conditions were capable of forming a primary cilium which is needed for SHH 
signalling activity. Only in co-cultures where keratinocytes were allowed to 
stratify at the air:liquid interface were primary cilia induced.
Franz-type diffusion cells were used to probe whether inhibitors to PI3K/AKT 
and MEK/ERK (LY294002 and PD98059 respectively) arms of the EGF 
pathway could successfully permeate through full thickness skin, which they 
were able to do. However, cyclopamine (SHH pathway inhibitor) proved to be 
highly insoluble and difficult to use in combination.
BCC samples were compared using immunohistochemistry of EGF pathway 
components to show whether the EGF pathway is important in BCC 
development in vivo. The results showed variable expression of EGF receptor 
and p-AKT but p-ERK was virtually absent from BCC tumours.
Despite the ability to modulate SHH signalling, EGF pathway inhibitors 
targeting p-AKT and p-ERK may not be useful for treating basal cell 
carcinoma. Alternative SHH signalling inhibitors such as those that target the 
formation of the primary cilium may be highly effective.
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Chapter 1 
General Introduction
1
1. Introduction
1.1 Skin Structure
The skin is a complex organ that protects the body from toxic substances and 
infection by micro-organisms, maintains its temperature, and regulates water loss 
(Williams, 2003). It also has immunological functions, protects against UV  
damage, synthesises vitamin D and is important for attraction and social 
interactions (Graham-Brown, 2007).
The skin has three main layers (Figure 1.1): epidermis, dermis and subcutaneous 
adipose (Candi et al, 2005). The epidermis and appendages are derived from 
embryonic ectoderm while the dermis is derived from mesoderm (Graham-Brown, 
2007).
1.1.1 Subcutaneous Fat Layer (Hypodermis)
The subcutaneous fat layer is several millimetres thick and separates the skin from 
the underlying fascia and muscle. It insulates the body, provides physical 
protection, absorbs shock and stores energy (Graham-Brown, 2007; Young, 2006). 
It consists o f  loose connective tissue and adipose cells. It contains major blood 
vessels and long hair follicles (e.g. scalp) extend into this layer (Graham-Brown, 
2007; Young, 2006).
1.1.2 Dermis
The dermis is 3-5mm thick, a major component o f  the skin and provides bulk and 
mechanical strength (Young, 2006). It consists o f  connective tissue made from 
interlacing fibres embedded in mucopolysaccharides and supports appendage 
structures such as hair follicles and sebaceous glands. The fibres are constructed 
from collagen and some elastin, which confer strength and elasticity to this tissue. 
The dermis is richly supplied with blood vessels, lymphatics, nerves and sensory 
receptors (Graham-Brown, 2007). The main cell types are fibroblasts (synthesize
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connective tissue matrix), mast cells (specialised secretory cells) and macrophages 
(phagocytic cells from bone marrow that scavenge cell debris)
Figure 1.1: The Basic Structure o f Skin (adapted from  online source: University o f  
Virginia, Cell Biology Handout: Skin, 2004).
1.1.3 Basement Membrane
The basement membrane lies immediately below the basal layer o f the epidermis. 
It is made up o f three layers: lamina lucida, lamina densa (hemidesmosomes 
attach to the lamina densa and dermal collagen) and sublamina densa. These 
layers are detailed in Figure 1.2 (Graham-Brown, 2007).
3
Intracellular
Lamina lucida 
Lamina densa
Sub-basal 
lamina densa
Extracellular
Figure 1.2: Layers o f  the Basement Membrane (from Nievers et al, 1999).
1.1.4 Epidermis
The epidermal-dermal interface is not flat but undulating to increase the surface 
area o f contact and improve connectivity between these tissues. The dermis has 
cone-like projections (‘dermal papillae’) which reach into corresponding slots in 
the epidermis ( ‘rete ridges’) to form two sets o f inter-locking cones. The epidermis 
has four well-defined sub-layers (Figure 1.3): Stratum basale (or basal layer), 
stratum sp'mosum (or spinous layer), stratum granulosum (or granular layer) and 
stratum corneum (or cornified layer). The thickness o f the epidermis differs 
depending on body site, being thickest on the soles o f the feet and palms o f the 
hands (Graham-Brown, 2007). Intercellular adhesion and cohesion are mediated 
within the epidermis by adherens junctions, which connect the actin cytoskeleton 
o f neighbouring cells together and by desmosomes, which connect keratin- 
filaments (cytoskeleton) within adjacent cells together to form a continuous 
network (Candi et al, 2005).
Keratinocytes move upwards from the proliferative basal layer through the spinous 
layer, where they lose their mitotic activity and alter their gene expression to
Anchoring
Intermediate filaments (keratins 5 & 
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synthesise specialised proteins. Differentiation continues into the granular layer 
where the comified envelope is formed. The cells become anucleate at this stage, 
lose their organelles and flatten to form ‘dead’ comeocytes. In normal human skin 
it takes approximately 30 days for basal cells to reach the skin surface (Young, 
2006). Thus, cell proliferation, differentiation and death occur sequentially, and 
each process is characterised by the expression o f  specific differentiation-related 
proteins (Candi et al, 2005).
1.1.4.1 Stratum Basale
The stratum basale is the deepest portion o f  the epidermis and consists o f  a single 
layer o f  cuboidal cells. Keratinocytes are continuously produced in this layer by 
sufficient cell division to generate the overlying stratified epithelial strata (Young 
et al 2006). Basal keratinocytes are anchored to the basement membrane by 
hemidesmosomes, an interaction mediated by transmembrane proteins such as 
integrins (Graham-Brown, 2007; Candi et al., 2005; Young, 2006). The 
intermediate filaments (IF) within epidermal basal cells are formed by 
polymerisation o f  two keratin proteins, K5 and K14 in basal cells, which form a 
three-dimensional network within the cells. Keratins terminate at the 
hemidesmosome (BMZ surface) and at the desmosome (lateral and apical 
surfaces). These two keratins also persist as cells move into the suprabasal layers.
MERKel cells (associated with nerve endings in touch sensitive areas) occur on 
the dermal side o f  the basement membrane. Langerhans cells are also found in the 
epidermis and these present antigens to lymphocytes in the draining lymph nodes 
thus providing the skin with constant immune surveillance (Williams, 2003).
Melanocytes produce melanin in granules (melanosomes), which is transferred to 
keratinocytes and forms a cap over the nucleus to protect DNA from solar UV  
radiation. Two types o f  melanin are present in these granules in order to absorb 
UV irradiation: a brown/black pigment called eumelanin and a yellow/red pigment 
called phaeomelanin. Darker and lighter skin types contain the same number o f
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melanocytes, but darker skinned people have more active melanocytes which 
produce increased levels o f pigment and a higher ratio o f eumelanin. However, 
chronic exposure to sunlight can also induce an increase in melanocytes numbers 
(Candi et al., 2005; Williams, 2003).
Figure 1.3: Section o f Normal Human Skin stained with Haematoxylin and Eosin to 
Demonstrate the Different Layers and Cell Types.
1.1.4.2 S tra tum  Spinosum
The spinous or prickle cell layer is so named because o f the spiky appearance of 
the cells, after histology processing. As well as keratinocytes, Langerhans cells are 
present in the spinous layer and are the first line o f immunological defence against 
environmental antigens. These cells are probably modified macrophages and 
contain ‘Birbeck’ granules (Graham-Brown, 2007). Keratin intermediate filaments 
and desmosomes increase in number in these cells (Young et al., 2006), and the 
predominant keratins expressed in this layer (K1 and K10) are termed 
‘differentiation-related’.
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1.1.4.3 Stratum Granulosum
The stratum granulosum consists o f  cells which acquire granular structures 
(keratohyalin and lamellar granules). The layer is so named because the 
keratohyalin granules (KHG) are visible by light microscopy. There are two types 
o f  KHG, F-granules that produce profilaggrin and L-granules that produce loricrin 
(a major cornified envelope protein). Filaggrin helps to bundle keratin filaments 
tightly together to promote the collapse o f the cell into a flattened comeocyte 
(Candi et al., 2005; Young, 2006). Lamellar granules (also called Odland bodies) 
contribute to barrier function o f the epidermis by discharging specialised lipids 
(e.g. ceramides) and enzymes into the spaces between granular cells. This prevents 
substances entering the tissue through channels between the dead cells o f the 
stratum com eum  (Graham-Brown, 2007) and is a m ajor com ponent o f the 
epidermal barrier.
1.1.4.4 Stratum  Lucidum
This layer is 3 to 5 cells thick and so-named because o f its translucent appearance 
when viewed under the microscope. It is only present in areas o f  thick skin such as 
the soles o f  feet. The cell nucleus disintegrates in this layer and there is increased 
keratinisation and cell flattening (Graham-Brown, 2007).
1.1.4.5 Stratum  Corneum
The stratum corneum  is a horny layer o f flattened keratinised cells, with no nuclei 
or cytoplasm ic organelles. The keratin filaments have been cross-linked by 
formation o f  disulfide (S-S) bonds and tightly bundled by the action o f  filaggrin. 
Transglutam inase (a Ca2+ dependent enzyme) covalently links glutamine to lysine 
in adjacent polypeptides, forming isopeptide cross-links between envelope 
proteins to provide mechanical strength (Candi et al., 2005; Young, 2006). The 
cornified cell envelope provides further mechanical strength as well as forming an 
important part o f  the essential barrier function (Graham -Brown, 2007). Cells are 
locked together where adjacent cells overlap their margins and the high lipid 
content between the cells acts as a permeability barrier (Young, 2006). With
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general wear and tear, as well as the activity o f  specialised proteases, the cells are 
sloughed o ff  the skin surface in an active process called desquamation (Graham- 
Brown, 2007).
1.1.4.6 Epiderm al Appendages
During embryonic development, the epidermis produces appendages by down- 
growth and specific re-programming o f  epithelial cells. During this time, 
molecular signalling between the epidermal cells (keratinocytes) and dermal cells 
(fibroblasts) is essential. These epithelial-mesenchymal interactions produce three 
main appendage structures: hair follicle, sebaceous gland and eccrine sweat gland 
(Figures 1.4 and 1.5). This region also contains an area termed the “bulge” that 
represents a stem cell niche and contains multipotent, slow cycling cells which act 
as a renewal source for the hair follicle, sebaceous gland and probably the sweat 
gland. In addition, during wound repair, these cells can also migrate to repopulate 
damaged epidermis.
The hair follicle is an invagination and down-growth o f  epidermal keratinocytes. 
This initially forms the infundibulum and then the outer root sheath (ORS) o f the 
hair follicle. The sebaceous duct branches o ff the hair follicle below the 
infundibulum. Epithelial cell down-growth from the epidermis also forms the 
eccrine sweat gland and duct. Eccrine glands are innervated to regulate body 
temperature by secreting water containing NaCl to cool the body by evaporation. 
Apocrine glands in skin produce sweat and open into the hair follicle canal. They 
are larger than eccrine sweat glands and are only present in certain areas such as 
the arm pit and groin.
The pilosebaceous unit (PSU) is a term that describes the hair follicle, arrector pili 
muscle and sebaceous gland, as a single structural entity (Figures 1.4 and 1.5). 
While PSUs are present over most o f  the body, large PSUs are particularly 
prevalent on the face, chest and back and PSUs are absent from the hands and feet. 
The arrector pili muscle is a bundle o f  smooth muscle fibres, which attaches to the 
follicle below the sebaceous gland and just beneath the epidermis (BMZ o f  rete
S
ridges). Contraction produces erection o f the hair as experienced during fright. The 
sebaceous gland discharges an oily secretion (sebum) into the hair follicle via the 
sebaceous duct, and this coats the hair fibre and skin surface with lipid (Young, 
2006). PSU o f the face, back and chest only have small vellus hair follicles and 
principally excrete sebum onto the skin surface.
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Figure 1.4: Haematoxylin and Eosin Stained Section o f Normal Human Skin showing 
the Infundibulum, Upper Hair Follicle, Sebaceous Glands and Bulge.
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Figure 1.5: Diagrams o f  the Lower Hair Follicle, Eccrine Sweat Gland and Sebaceous 
Gland (adapted from  online source: University o f Virginia, Celt Biology Handout: Skin, 
2004).
The hair follicle is continuous with the epidermis and separated from the dermis 
by a basement membrane and collagen capsule. There are two types o f hair follicle
10
present in human skin: vellus (fine) hair and terminal (thick) hair. The terminal 
hair follicles on the scalp are larger than the vellus follicles on the body but the 
structure is basically the same (Figures 1.5 and 1.6).
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Figure 1.6: Haematoxylin and Eosin Stained Section o f Normal Human Skin showing 
the Lower Hair Follicle.
There are 3 bumps on the original epidermal invagination during appendage 
formation, which form the sebaceous gland, apocrine sweat gland and bulge. Cells 
from the bulge produce the entire hair follicle including the hair fibre, inner root 
sheath (IRS) and companion layer (CL). Cells from the bulge move down the ORS
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and populate the bulb matrix region. Epithelial-mesenchymal interactions between 
the dermal papilla and matrix induce all seven distinct lineages o f  specialised hair 
follicle cell layers which all have distinct differentiation programmes and are able 
to produce the hair fibre and the follicle.
The inner three epithelial layers (medulla, cortex and cuticle) undergo 
keratinisation to form the hair shaft and the outer three layers (cuticle, Huxley, 
Henley) form the inner root sheath (IRS). The inner root sheath is separated from 
the outer root sheath (ORS) by the companion layer (CL). The ORS is surrounded 
by a glassy membrane, which is a specialised basement membrane. At the base o f  
the follicle, a mass o f  epithelial cells (hair matrix) surrounds the dermal papilla, an 
inductive mesenchymal cluster (Young, 2006). This mass o f  cells produce progeny 
which terminally differentiate to form all layers o f  the hair shaft and inner root 
sheath (Alonso and Fuchs, 2006).
The cortex o f  the hair fibre is composed o f  trichocytes that express hair specific 
keratins. Nails have a similar structure to the hair fibre but are formed as a flat 
(curved) plate o f  hair specific and epithelial keratins which originate from the nail 
fold, also an invagination o f  the epidermis (Graham-Brown, 2007; Bowden, 1987; 
Bowden, 1993).
Hair follicles undergo cycles o f  growth, regression and rest (Figure 1.7), known as 
anagen, catagen and telogen respectively (Alonso and Fuchs 2006). Anagen can 
last 2-3 years and determines the length o f  the hair fibre, while catagen lasts for 
approximately 2-3 weeks and telogen 2-3 months. During the early anagen phase, 
there is down-growth o f  the hair follicle and from mid anagen, proliferation in the 
bulb (matrix) produces the hair shaft (HS), inner root sheath (IRS) and companion 
layer (CL). The cells o f  the HS and IRS gain high tensile strength because they are 
packed with keratin filaments cross-linked to high sulphur matrix proteins 
(keratin-associated proteins or KAPs). The IRS supports the HS until the upper
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During catagen, the lower part o f  the follicle regresses by apoptosis o f  the ORS 
and bulb epithelial cells. The bottom o f  the HS forms a rounded structure called 
the club, this regresses upwards to the upper part o f  the follicle (Alonso and Fuchs,
2006). Club hairs are only loosely attached and are easily shed. During telogen the 
follicle remains in a resting phase until anagen is initiated by the activation o f  one 
or two quiescent stem cells at the follicle base. This enables proliferation o f  cells 
close to the dermal papilla (DP) and formation o f  a new hair bulb, after which IRS 
and HS differentiation returns.
1.2 Cancer
Cancer is a collection o f  diseases which all feature the unrestrained growth o f  
cells, but while a malignant tumour invades other tissues, a benign tumour is not 
invasive but remains “m situ” (Pasternak, 1999). The rate o f  death from cancer is 
second only to cardiovascular disorders, and most frequently caused by disruption 
o f  vital organs due to extensive growth o f  invading cancer cells (metastasis) but 
release o f  toxins into the circulation can also contribute (King and Robins, 2006). 
There are many causes o f  cancer, including inherited genetic defects and lifestyle 
factors such as exposure to UV (ultraviolet) light, diet and smoking (King and 
Robins, 2006). Pathology is used to distinguish between benign and malignant 
growth to define cancer subtypes which can help to determine the prognosis as 
well as aiding selection o f  appropriate therapy. Epidemiology can also give clues 
to the cause o f  some cancers by looking at the incidence in different populations 
(King and Robins, 2006).
Cancer is caused by loss o f  cell proliferation control and lack o f  DNA damage 
repair usually due to an accumulation o f  different gene mutations in a single cell. 
Changes in oncogenes (regulatory genes, whose activity is increased after genetic 
alteration o f  one allele causing a change in protein function) or tumour suppressor 
genes (encode inhibitory proteins) are major contributory factors. Thus, in simple 
terms, mutation o f  p53 affects the cell cycle check point, allows unrestricted 
growth o f  cells which then form a tumour (usually monoclonal in origin). Cancer
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cells also continue to change their behaviour as they develop due to genetic 
instability. A  tumour cell mass can be influenced by several factors including cell­
cell contacts, immune attack, cell death, proliferation, differentiation, blood supply 
and the extracellular matrix.
1.2.1 Skin Cancers
Skin cancers, are generally classified into malignant melanoma and a collection o f  
non-melanoma skin cancers, including squamous cell carcinoma (SCC) and basal 
cell carcinoma (BCC). Non-melanoma skin cancers tend to be less aggressive and 
are rarely lethal. BCC is the most common cancer in Caucasians (90% o f  all skin 
cancers indentified) and the major causative factor is UV  light (Daya-Grosjean and 
Couve-Privat, 2005). Other causes include: X-rays, y-rays, industrial oils, tars, 
bitumen and soot. UV B damage causes C to T (or CC to TT) structural changes in 
the DNA o f  epidermal basal cells (Athar et al., 2006). BCCs are thought to have a 
deeper origin in skin than SCCs and the most likely cause o f  this difference is 
based on wavelength dependent penetration o f  UV (Lacour, 2002).
Tumorigenesis usually requires an accumulation o f  changes that often involve 
more than one gene in a cell. Also, as these changes are usually required in both 
alleles, tumours are actually quite a rare occurrence, usually developing in later 
life probably due to accumulated age-related errors in DN A repair and long-term 
UV exposure. However, the risk is increased if  one allele is already changed, such 
as in patients with Gorlins Syndrome (Basal Cell Nevus Syndrome) who are bom  
with a mutation in one allele o f  either the patched (PTCH) or smoothened (SMO) 
gene. There is also a predisposition for those with some genetic conditions that 
affect repair mechanisms, such as xeroderma pigmentosm (an autosomal recessive 
genetic disorder o f  DN A repair in which the body's normal ability to remove 
damage caused by U V  light is deficient) or in immunosuppressed individuals 
because the immune system normally removes defective cells (Graham-Brown,
2007).
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While it is unusual for mutations in a single gene to cause a tumour, in the case o f  
BCCs, homozygous mutations in PTCH, or occasionally SMO genes are sufficient 
to cause tumorigenesis, making BCCs a common tumour. Additional mutations 
may also occur (in p53 for example) but these are thought to affect tumour 
aggressiveness and growth patterns rather than initiating tumorigenesis.
1.2.2 Basal Cell Carcinoma
BCCs are malignant but not generally metastatic and often referred to as 
carcinoma in situ. They generally grow slowly, but can be unpleasant for the 
patient if  not removed, because they can grow very large and may bleed (Daya- 
Grosjean and Couve-Privat, 2005). The incidence increases with age and most 
patients are over 50 years old when referred (Bastiaens et al., 1998).
There are 3 broad categories o f  BCC: nodular, morpheaform and superficial. 
Nodular lesions on the skin surface (60% o f  cases) appear smooth, round and 
waxy. The surrounding skin is thin, bleeds easily and lesions are generally slightly 
raised, red and ulcerated with a pearly border (Figure 1.8A). The histology o f  
these tumours shows that they grow into a nodular morphology pushing down into 
the dermis (Figure 1.8D). Morpheaform BCCs (30% o f  cases) are fast growing 
and appear flat, shiny, and yellow on the surface (Figure 1.8B). Histology shows 
they extend deep into the skin with tiny root like projections (Figure 1.8E). 
Superficial BCCs (10% o f  cases) appear as a red mark on the skin surface (Figure 
1.8C) and histology shows only superficial growth along the basement membrane 
(Figure 1.8F). Superficial BCCs are the most accessible to topical treatment.
16
Figure 1.8: Three Broad Categories o f Basal Ceil Carcinoma (Nodular, Morpheaform 
and Superficial). Clinical appearance o f BCC (A-C) and typical histology after staining 
with haematoxylin and eosin (D-F). Nodular BCC (A, D), morpheaform BCC (B, E) and 
superficial BCC (C, F). (Data from online sources.aafp, 2004; skin cancer guide, 2004; 
treat skin cancer: basal cell carcinoma, 2004; emedicine: Medscape: Basal Cell 
Carcinoma, 2004; Loyola University: Strith School o f Medicine: Med Dean, 2004)
1 .2 .3  S u r g ic a l T r e a tm e n t o f  B C C
Surgery is often the treatment of preference in order to remove the tumour prior to 
further growth. However, this leads to scarring, is inconvenient to the patient, and 
costly in terms o f health care professional time and equipment requirements.
1 .2 .4  D r u g  T h e r a p y
A topical formulation would be useful for treating BCCs on areas o f skin where 
surgery is not advised (e.g. eyelids or close to the ear), for reducing the size o f 
large tumours prior to excision, and to prevent tumour recurrence (possibly caused 
by altered stem cells that remain after surgery). A major benefit o f topical 
formulations is that they are specific to the area o f application and therefore any 
side effects caused by the drugs will be localised.
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Imiquimod cream (Aldara) has been used to treat superficial BCCs o f  less than 
2cm in diameter (Vidal and Alomar, 2004). It activates the immune system 
through toll-like receptor 7 (on the surface o f  antigen presenting cells), leading to 
secretion o f  pro-inflammatory cytokines. Clinical trials have shown that 
imiquimod is too toxic to be the treatment o f  choice, as it causes unpleasant but 
transitory adverse effects: erosion, ulceration, eiythema, oedema, flaking/scaling, 
scabbing and inflammation (Quirk et al., 2006). Imiquimod is not indicated for 
treating nodular or morpheaform subtypes due to recurrence o f  these tumour types 
at the same site after treatment, which may be partly due to inadequate delivery to 
these deeper BCCs (Chang et al., 2005).
1.3 Sonic Hedgehog (SHH) Signal Transduction Pathway 
and Mutations in BCC Lesions
1.3.1 Sonic Hedgehog (SHH)
Sonic hedgehog is required for embryonic development o f  hair follicles (Sato et 
al., 1999) and postnatally for development beyond the germ stage o f  hair follicle 
morphogenesis (Chiang et al., 1999). The anagen phase o f  hair follicle cycling is 
induced by SHH (Paladini et al., 2005; Sato et al., 1999) and studies suggest that 
SHH responsiveness is restricted to the growth phase (anagen) in mouse hair 
follicles (Oro and Higgins, 2003).
Epidermis derived SHH functions as a paracrine signal regulating development o f  
the mesenchymal component o f  the hair follicle (Chiang et al., 1999). It has also 
been suggested that SHH signals the epithelial cells o f  developing follicles, as it is 
required for the initial down-growth o f  epidermal keratinocytes (Chiang et al., 
1999; St-Jacques et al., 1998).
Hedgehog (HH) is a protein originally identified in drosophila development and so 
named because D. melanogaster embryos develop as prickly round shapes
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(resembling a hedgehog) when HH signalling is lost (Nusslein-Volhard and 
Wieschaus, 1980). Drosophila is a model organism which has been used to 
identify many developmental genes including Notch and Wnt. It is particularly 
useful for genetic experiments because it has a short reproductive cycle and is easy 
to handle in the laboratory (Hausman, 2004). There are three homologues o f  
hedgehog in humans (Ingham and McMahon, 2001): Sonic Hedgehog (SHH), 
Indian Hedgehog (IHH) and Desert Hedgehog (DHH). Holoprosencephaly is a 
phenotype which arises from mutations that affect SHH signalling, producing a 
phenotype o f  close set eyes with a common scleral rim. Sonic the Hedgehog, a 
computer game character, also has these characteristics which led to the gene 
being named after him.
The hedgehog signalling pathway is essential during embryonic development, but 
is switched o ff  in most adult tissues (Athar et al., 2006). However, SHH maintains 
stem cell populations and regulates the growth o f  hair follicles and sebaceous 
glands in adults (Athar et al., 2006). SHH is needed for down-growth o f  the 
epidermis and morphogenesis o f  the hair follicle (St-Jacques et al., 1998). SHH is 
also veiy important for other aspects o f  embryogenesis, including neural tube 
patterning, formation o f  the adjacent ventral somites, development o f  left-right 
symmetry, polarising activity in the limbs as well as morphogenesis o f  the axial 
skeleton, limbs, lungs, skin, hair and teeth (Athar et al., 2006). In the adult, SHH is 
also required for hair growth and is expressed in the hair follicle during the anagen 
(growth) phase (Chiang et al., 1999).
SHH is a 45kDa protein, which induces epidermal hyperplasia and keratinocyte 
proliferation when it is over-expressed. Importantly, SHH signalling is also 
activated in many neoplasms. Cells with mutations in PTCH or over-expression o f  
SHH cannot leave the S and G2/M phases o f  the cell cycle, so proliferation is 
sustained (Athar et al., 2006).
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Transport o f active hedgehog from the signalling cell to the responding cell occurs 
in three steps (Figure 1.9). First is the formation o f a soluble multimeric hedgehog 
complex, second is the release o f the lipid anchored protein from the signalling 
cell by the enzyme dispatched (Disp) and finally, Tout-velu-dependent synthesis 
o f heparin sulphate proteoglycan enables movement across the plasma membrane 
o f the responding cell (Burke et al., 1999; Zeng et al., 2001). The active hedgehog 
ligand is double lipid modified with a C-terminal cholesterol moiety and an N- 
terminal palmitate, which results in activation o f the signalling portion, after which 
the SHH-C terminal portion can diffuse away (Porter et al., 1996).
 *. P-SHH-NC
Dispatched
Multi meric Form 
Palmitoylation P-SHH-N C
Autoprocessing SHH-N C
SHH
SHH
Figure 1.9: Autoprocessing Reaction o f Sonic Hedgehog in a Signalling Cell. When 
SHH is released from the signalling cell by dispatched, it travels along the plasma 
membrane and interacts with proteins such as PTCH on a responding cell.
In the absence o f SHH, patched (PTCH), a 12-pass transmembrane protein located 
at the cell surface inhibits smoothened (SMO), a 7-pass transmembrane protein 
located in intracellular endosomes. Once pathway activation occurs, then SMO can 
move to the cell surface membrane and initiate signalling.
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When the SHH ligand binds to its receptor (PTCH), the receptor is internalised and 
destabilised causing activation o f  smoothened (SMO). SMO translocates to the 
plasma membrane and activates GL1 zinc finger transcription factors via other 
signalling proteins such as Suppressor o f  Fused (SUFU) causing their translocation 
to the nucleus (Figures 1.10 and 1.11).
Mammalian cell culture experiments showed that phosphorylation by Grk2 causes 
internalisation o f  SMO and this also involves Arrb2. GLI is maintained in its 
repressor form by direct binding o f  SUFU (suppressor o f  fused), a tumour 
suppressor (Pearse et al., 1999; Stone et al., 1999). GLI activation by 
phosphorylation enables GLI to regulate the expression o f  SHH target genes such 
as PTCH, SMO, GLI1, GLI2, FOXM1, FOXE1 and HIP (Huangfu et al., 2003; 
Daya-Grosjean and Couve-Privat, 2005).
There is a balance between the antagonism o f  SHH and PTCH. Their 
concentrations are altered with respect to each other because up-regulation o f  
PTCH expression causes PTCH protein at the cell membrane to sequester SHH 
and limit its spread beyond the cells in which it is produced, creating a negative 
feedback loop (Cohen, 2003). It is o f  note that where most cancers require a 
collection o f  mutated genes, sporadic BCCs can be induced by homozygous 
mutations in both alleles o f  either PTCH or SMO and extremely rarely, SUFU, 
which is downstream o f  SMO (Reifenberger et al., 2005).
1.3.2 Hedgehog Signalling Defects in Gorlins (BCN) Syndrome
Aberrant hedgehog signalling was first discovered to be the underlying cause o f  
BCC due to a study o f  Gorlin’s or Basal Cell Nevus (BCN) Syndrome (Hahn et 
al., 1996; Johnson et al., 1996).
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Endogenous ligand?
SMO
ILI
\ l / -------------
GLI R  1 HH target genes
Figure 1.10: Sonic Hedgehog Signalling Pathway in the Absence o f Sonic Hedgehog
(GLIR is the repressor form of GLI).
SUFU
PTCH
G p ro te in?
GLI A » HH targ e t g e n e s
I--------------
Figure 1.11: Sonic Hedgehog Signalling Pathway in the Presence o f Sonic Hedgehog
(GLI A is the active form of GLI).
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Gorlin’s Syndrome is an inherited disorder, where numerous tumours occur 
(including BCCs), along with other developmental defects. Linkage mapping 
narrowed down the gene underlying Gorlin’s Syndrome to the PTCH locus on 
chromosome 9 (9q22) and frequent loss o f  heterozygosity at 9q was observed in 
BCCs from Gorlin’s patients. Mutations in the PTCH gene were then found to be 
associated with sporadic BCCs (Gailani and Bale, 1997; Unden et al., 1996; Daya- 
Grosjean and Couve-Privat, 2005; Lupi, 2007). PTCH mutations were present in 
both hereditary and sporadic BCC with p53 mutations found in all sporadic and 
nearly half o f  hereditaiy tumours by one group o f  researchers (Ling et al., 2001). 
Mutations in p53 are generally correlated with tumour aggressiveness but findings 
in BCC vaiy and there are very few recent publications, so the role o f  p53 is still 
not clear (Ansarin et al., 2006). Gailani and co-workers (1996) agreed that 
inactivation o f  PTCH is probably a necessary step in BCC development. Northern 
blots and RNA in situ hybridization showed that PTCH was expressed at high 
levels in tumour cells but not in normal skin, suggesting that mutational 
inactivation o f  the gene leads to over-expression o f  a mutant transcript owing to 
the failure o f  a negative feedback mechanism (Gailani et al., 1996).
Mutations caused by UV light leading to BCCs may vary within the PTCH or 
SMO genes. Unden and colleagues (1996) found different types o f  mutations in 
one patient’s BCCs. They later used fine mapping to identify a region that might 
contain PTCH mutations to within 1Mb at 9q22.3 (Unden et al., 1996; Unden et 
al., 1997). These findings were confirmed and extended by Reifenberger and co­
workers (1998) who found that loss o f  heterozygosity due to various SMO 
mutations (second allele lost, the loss o f  the first allele was inherited) could also 
lead to BCCs. However, they later found that only 40% o f  BCC causative 
mutations in PTCH, SMO or SUFU had UV signatures (Reifenberger et al., 1998; 
Reifenberger et al., 2005). Another research group also found various UV  
signature mutations for PTCH and p53 in BCCs (Soehnge et al., 1997). Allelic loss 
was frequently found in sporadic BCCs, suggesting that factors other than UVB  
may be a cause. Only one third o f  BCCs demonstrating allelic loss also had a
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mutation likely to be caused by UVB in the remaining allele, inferring that other 
factors are probably involved (Gailani and Bale., 1997; Daya-Grosjean and Couve- 
Privat, 2005).
SHH signalling was shown to be hyper-activated in sporadically occurring BCCs 
that had high levels o f  GLI1 and PTCH mRNA in tumour cells (Dahmane et al., 
1997; Unden et al., 1997). Sonic hedgehog pathway activation can also cause BCC 
formation in mouse models and epithelial cell down-growth in organotypic 
cultures using HaCaT cells (Bigelow et al., 2005; Daya-Grosjean and Couve- 
Privat, 2005). Over-expression o f SHH in normal human keratinocytes was 
enough to induce BCC-like features in regenerated murine skin transgenic for long 
terminal repeat-driven SHH on immune-deficient mice (Oro et al., 1997). 
Furthermore, the lack o f  collective mutations could explain the lack o f  
aggressiveness, slow growth, and lack o f  metastases in BCCs (Fan et al., 1999).
GLI accumulation was observed in induced murine BCCs, but GLI destruction 
signals were also identified and removal o f these signals enabled increased tumour 
formation (Nilsson et al., 2000; Huntzicker et al., 2006). GLI2 over-expression in 
transgenic mice under the control o f a bovine K5 promoter (active in basal layer 
and hair follicle outer root sheath keratinocytes) led to multiple skin tumours, 
many resembling BCCs. There was ajso up-regulation o f  SHH target genes 
(Grachtchouk et al., 2000) and together these results showed that the expression o f  
GLI transcription factors due to active SHH signalling was required for BCC 
tumour formation.
PTCH and SMO mutations have also been shown to cause BCCs in xeroderma 
pigmentosum patients (Bodak et al., 1999; Couvet-Privat et al., 2002; Daya- 
Grosjean, 2000). These patients have a high rate o f  BCCs due to their inability to 
repair UV-associated DNA damage. Activating mutations in SHH (leading to 
activation o f  the SHH signalling pathway) may also cause these BCCs (Couve- 
Privat, 2004; Daya-Grosjean and Couve-Privat, 2005). However, it has been
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shown that activation o f  SHH occurs very rarely in sporadic tumours, while 
deactivation o f  PTCH is extremely common (Teh et al., 2005).
1.3.3 SHH Signalling in the Hair Follicle
The role o f  SHH pathway signalling is well established in the hair follicle, not just 
during morphogenesis but also in the adult. Hair follicle induction is independent 
o f  SHH, but SHH is essential for down-growth o f  epidermal cells and 
consequently for morphogenesis o f  the hair shaft (Hutchin et al., 2005). In adults, 
SHH is expressed in the matrix and the developing germ, and cyclopamine (SHH 
pathway inhibitor) blocks cyclic regeneration o f  hair (Blanpain and Fuchs, 2006; 
Silva-Vargas et al., 2005).
In GLI2_/‘ mice, hair follicle development was arrested, while upon GLI2 
activation in transgenic rescue experiments, hair follicles developed, showing that 
hair follicle down-growth requires GLI2, a SHH pathway effector. GLI2 was 
shown to be effective only when constitutively expressed in SHH ' skin, otherwise 
no hair follicles would develop (Mill et al., 2003). SHH'/_ and control embryos 
showed epidermal placodes and associated dermal condensates but further hair 
follicle development did not occur. In addition, PTCH and GLI1 expression were 
also reduced but interestingly late-stage follicle differentiation markers were 
detected in SHH /_ skin grafts, as well as cultured vibrissa explants treated with 
cyclopamine which would effectively block SHH signalling (Chiang et al. 1999). 
Furthermore, anti-hedgehog monoclonal antibody treatment caused a hairless 
phenotype in mice (Wang et al. 2000).
1.3.4 Origins of BCC
Many researchers believe that BCCs originate from hair follicles. The expression 
o f  hair follicle stem cell markers in human BCCs led to the idea that BCCs could 
be derived from the undifferentiated outer root sheath (ORS) cells o f  the hair 
follicle (Reis-Filho et al., 2002). SHH and PTCH mRNA accumulate in follicular, 
but not in interfollicular skin in normal mice, supporting the argument for BCCs
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originating in the hair follicle. Further support for this idea has come from 
examining SHH expression in hair placodes o f  embryonic skin and finding that 
SHH promotes interfollicular basal cell proliferation and hair follicle down-growth 
(Adolphe et al., 2004; St-Jacques et al., 1998).
It has been suggested that epithelial-mesenchymal interactions are required for the 
development o f  epithelial invaginations, as seen in hair follicles and BCCs (Hardy 
et al., 1992; Schmidt Ullrich and Paus., 2005). Mice conditionally over-expressing 
GLI2 gave rise to BCCs, but nearly all o f  these were derived from hair follicles 
and not interfollicular epidermis as judged by haematoxylin and eosin staining and 
K17 immunocytochemistry. In situ hybridisation for K15 (a marker o f  
undifferentiated follicular epithelium, including stem cells, in adult mice) showed 
high expression in early tumours located close to a hair follicle but decreased as 
the tumours grew larger. Once GLI2 expression was removed and tumour cells 
had regressed, an inductive mesenchyme led to hair follicle formation (Hutchin et 
al., 2005). This shows a close relationship between SHH signalling in both hair 
follicles and BCCs. PTCH, SMO, GLI 1-3 are all expressed in mesenchymal cells, 
and interactions involving the SHH pathway between the epithelium and the 
mesenchyme which are important for down-growth o f  the hair follicle, may also 
be necessary for BCC down-growth (Millar, 2002). In mice expressing GLI2, 
nearly all BCCs arose from hair follicles demonstrating that BCCs are likely to be 
caused by aberrant follicle organogenesis (Hutchin et al., 2005).
GLI2 also regulates the expression o f  cyclins D1 and D2 (required for cell cycle 
progression and interaction with tumour suppressor proteins), which may be 
involved in tumour progression (Mill, 2003). However, Silva-Vargas and co­
workers (2005) showed that interfollicular epidermal cells can acquire 
characteristics similar to those o f  bulge stem cells by using p-catenin and SHH 
expression gradients to induce hair follicle formation (Silva-Vargas et al., 2005).
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There are still discrepancies concerning which part o f  the hair follicle may be the 
origin o f  BCCs. Researchers have shown that BCCs may originate from 
undifferentiated cells o f  the outer root sheath. Hutchin and colleagues (2005) 
found that they can arise from follicular ORS epithelium in the proximal hair 
follicle, leading them to believe that ‘BCCs represent an aberrant form o f  follicle 
organogenesis’. They found that when conditionally expressing GLI2 in mice, 
nearly all BCCs arose from hair follicles (Hutchin et al., 2005). A separate group 
used GHADn (mutant GLI responsive promoter) transgenic mice to show that 
small BCC-like proliferations developed which appeared to come directly o ff the 
hair follicle (Huntzicker et al., 2006). Over-expression o f  SHH in the skin was 
found to result in epidermal hyperplasia by antagonising p21 (cyclin-dependent 
kinase inhibitor 1A) cell cycle arrest. This also resulted in the proliferation o f hair 
follicle like structures into BCC like growths (Fan and Khavari, 1999; Oro et al., 
1997). Also, pTCHneo67/+ (neo cassette heterozygote) mouse skin irradiated in early 
anagen (hair follicle down-growth phase), showed a higher rate o f  BCC induction 
compared to telogen hair follicles. Immunohistochemistry showed that these BCCs 
appeared to be derived from the follicular ORS (Mancuso et al., 2006). In a 
separate study, immunohistochemistry showed similar expression profiles between 
BCC and the follicular ORS compared to BCC and epidermis (including 
expression o f  basal differentiation markers K5 and K14 and no expression o f K8, 
K1 and K10) again hinting that BCCs may be derived from part o f  the hair follicle 
(Kruger et al., 1999).
However, there are several publications which are in conflict with the hair follicle 
origin hypothesis and suggest that BCCs may actually originate in the basal layer 
o f  the epidermis. Hedgehog-induced proliferation was found to be restricted to the 
epidermal basal cell compartment (Adolphe et al., 2004). Also, some 
immunohistochemistry data has shown that PTCH induced skin tumours originate 
from the basal cell compartment (Adolphe et al., 2006). In humans and mouse 
BCC models, ‘many tumours arose with no visible connection to the hair follicle’, 
suggesting that ectopic SHH target gene expression in interfollicular cells can
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induce hair follicle differentiation (Hu et al., 2003; Oro and Higgins, 2003). It was 
observed that initiating events in the epidermis can induce BCC features (using 
SHH expressing keratinocytes to regenerate human skin transgenic for long 
terminal repeat-driven SHH on immune deficient mice), without any inductive 
influence from mesenchymal cells and therefore hair follicle structures are not 
required for BCC development (Fan et al., 1997).
Some believe that BCCs may in fact originate from putative epidermal stem cells, 
SHH has been shown to have involvement in cell-fate specification and 
proliferation o f  stem cells. BCCs also grow slowly and share similarities in gene 
expression profile to stem cells along with continuous cell renewal (Parisi and Lin, 
1998; Tumbar et al., 2004). The action o f  HH as a stem cell factor in drosophila 
embryos suggested the importance o f SHH in human stem cells as well as in BCCs 
(Owens and Watt, 2003; Blanpain and Fuchs, 2006). It was also demonstrated that 
drosophila ovary stem cells cannot proliferate in the absence o f  HH signalling, 
inferring that HH is a stem cell factor (Zhang and Kalderon, 2001). Human 
tumours caused by SHH signalling may have resulted from the expansion o f  stem 
cell pools as it had been shown that SHH can regulate human putative epidermal 
stem cell proliferation. These epidermal stem cells underwent increased 
proliferation when grown in the presence o f SHH (conditioned media from SHH- 
N expressing cells) and proliferation was decreased in the presence o f  the SMO 
inhibitor, cyclopamine (Zhou et al., 2006). BCCs are thought by some to be 
derived particularly from the interfollicular basal cell layer o f  the epidermis 
(Adolphe et al., 2006; Youssef et al., 2010). Tumour cells in the epidermis would 
be lost by terminal differentiation if  they didn’t reside in the epidermis long term, 
so stem cells are a likely point o f origin (Owens and Watt, 2003).
BCCs and the lower hair follicle region have similar keratin expression (K5, K6 
and K14) as well as a2 and pi integrins. Epidermal cells with high levels o f  pi 
integrin can be passaged for a long time, an important “stem cell” property (Fuchs 
et al., 2008). If BCCs were derived from interfollicular basal stem cells, the
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undifferentiated phenotype o f  BCCs could be explained. It has been shown by 
expressing SMO selectively using K15, K17 and K19 promoters in subsets o f  
mouse epidermal keratinocytes in different skin compartments, that BCCs did not 
arise in hair follicle bulge cells, but in the majority (93% in this region) from 
interfollicular epidermis (Youssef et al., 2010). It may be expected that because 
stem cell associated keratins (K15 and K19) are expressed in BCCs and in the hair 
follicle ORS, then the hair follicle may indeed be a likely location for the origin o f  
BCCs. However, BCC formation was not induced by activation o f SMO in hair 
follicle bulge stem cells o f  mice, but BCCs were found to arise from long-term 
resident progenitor cells o f  the interfollicular epidermis and the upper 
infundibulum by clonal analysis (Youssef et al., 2010).
1.3.5 Mouse Mutations in SHH Pathway
Mouse models have contributed considerably to the understanding o f  SHH 
function in the hair follicle and in BCC. Skin o f  SHH'7' mice showed inhibition o f  
hair follicle morphogenesis, with no dermal papillae, almost no GLI1 present and 
reduced PTCH expression in primary hair germs (Chiang et al., 1999). This 
showed that activation o f the SHH signalling pathway was essential for hair 
follicle morphogenesis. A separate research group used SHH'7' mice to show that 
hair follicle development initiated correctly, but did not proceed normally in the 
absence o f  SHH. The follicular structures were abnormal and no hair was formed 
(St-Jacques et al., 1998). SHH'7' skin grafts on nude mice (lack T-cells) had 
hairless pigmented skin after 2-3 weeks, further supporting a role for SHH 
signalling in hair follicle morphogenesis. This group also found that skin grafts 
from SHH'7' embryos were abnormal and formation o f  the hair follicle arrested 
after hair bud formation, supporting the findings o f  Chiang and co-workers (1999). 
SHH present in the proximal tip is thought to be involved in down-growth o f  the 
hair follicle, and probably involved in epithelial-mesenchymal interactions with 
the underlying dermis. These publications showed that SHH is not required for 
placode formation or initiation o f  down-growth, but is essential for hair follicle 
formation. Therefore, it is likely that loss o f  SHH blocks essential epithelial-
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mesenchymal interactions which are involved in early hair follicle morphogenesis 
(St-Jacques et al., 1998).
C57BL/6 mice (postnatal day 19) showed activation o f SHH signalling in skin 
with concomitant increase in expression o f  SHH, PTCH and GLI1 (Sato et al., 
1999). Severe combined immunodeficiency (SCID) mice also showed abnormal 
BCC-like features when grafted with human keratinocytes expressing SHH (Fan 
and Khavari, 1999). Furthermore, BCCs were induced in mice over-expressing 
SHH (Dahmane et al., 1997) and features o f  basal cell nevus (Gorlin’s) syndrome 
have been observed in mice expressing SHH (Oro et al., 1997). Thus, these reports 
suggest that expression o f  SHH in skin leads to activation o f  the SHH pathway 
which can then induce the formation o f  BCCs.
Mice over-expressing wild type GLI2, under the control o f  a K5 promoter, 
developed BCCs, whereas mice over-expressing a mutant form, GLI2AN2 (GLI2 
without N-terminal domain) developed a range o f  skin tumours, even though the 
SHH pathway was activated in both types o f  mice. This showed that the N- 
terminal domain may have a specific function and an impact on the type o f tumour 
formed, possibly via interactions with G lil (Sheng et al., 2002).
Mouse models also had an important role in unearthing the importance o f  PTCH in 
embryogenesis and in adult skin. Mice null for the ligand PTCH died during 
embryogenesis, whilst mice heterozygous for PTCH had developmental defects 
and some developed medulloblastomas (Bai et al., 2002; Goodrich et al., 1997). 
To look at the effect o f  loss o f  PTCH in adult skin, conditional PTCH knockout 
mice were created. The inducible activity o f  Cre recombinase under the control o f  
a keratin 6 (K6) promoter was used to control the expression o f  PTCH using 
retinoic acid. Normally, K6 is expressed in the companion layer o f  the hair follicle 
and ORS, but with retinoic acid treatment, it is also expressed in interfollicular 
epidermis. These experiments showed that loss o f  PTCH function was sufficient 
for tumour progression, and the tumours formed were reminiscent o f  BCCs
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(Adolphe et al., 2006; Aszterbaum et al., 1999). Together these studies confirmed 
the importance o f  SHH signalling for tumour development and showed that PTCH 
deactivation alone enabled SHH pathway activation which resulted in BCC 
induction.
Transgenic murine skin over-expressing smoothened (SMO), a downstream SHH 
pathway protein, developed abnormalities similar to BCCs. In these experiments, 
SMO was under the control o f  a K5 promoter that directed expression (and 
therefore downstream SHH signalling) to the basal epidermis and hair follicle 
ORS (Xie, 1998). As deactivating PTCH mutations and activating SMO mutations 
cause BCCs, PTCH null and SMO over-expressing mice provide the most accurate 
models for BCC.
SUFU normally represses activation o f  GLI transcription factors, so SUFU 
inactivating mutations cause constitutive SHH pathway activation. SUFU'7' mouse 
embryos were found to die in utero at -E 9.5  with developmental defects, a similar 
age to PTCH'7' embryos. This was found to be due to potent ligand independent 
activation o f  the SHH pathway, which could not be inhibited by the SMO inhibitor 
cyclopamine or increased by the SMO agonist SAG. SUFU+7' mice developed 
similar features to Gorlins syndrome including an abnormal basal cell phenotype. 
This confirmed that SUFU inactivating mutations can lead to disorders caused by 
SHH pathway signalling. Although we know that SUFU mutations are extremely 
rare in BCC patients, they may be important in other cancers in which SHH 
signalling is involved (Svard et al., 2006).
1.3.6 SHH Signalling in Cell Culture Models
There are very few publications describing BCC cell lines, suggesting that these 
cells do not grow well in culture. Therefore, several keratinocyte cell culture 
models expressing components o f  the SHH pathway have been developed for in 
vitro use. For example, an organotypic culture model using immortalised
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keratinocyte cells over-expressing SHH has been developed. In this model, 
keratinocytes were grown on a collagen lattice containing fibroblasts at the air- 
liquid interface (culture medium contacts the cells from the underside). This 
allows keratinocytes to differentiate and stratify in air as well as invade the 
collagen gel below. This model was used to view the ‘tumour-like’ down-growth 
o f  SHH over-expressing cells (observed in sections stained with haematoxylin and 
eosin). Cross-sections o f  the cultures were cut on a cryostat and dried onto glass 
slides. Immunocytochemistry with specific antibodies were used to compare the 
expression o f  various proteins (e.g. Ki67, a proliferative marker) in SHH 
expressing cells and normal cells. Treatment with an EGFR activity inhibitor 
(AG 1478) reduced the invasive phenotype and reduced Ki67 staining compared to 
untreated cells, showing that the EGF signalling pathway may be involved in 
modulating SHH signalling which could lead to increased invasiveness. In support 
o f  this, addition o f  recombinant EGF increased infiltration o f  SHH expressing 
keratinocytes into the collagen lattice containing fibroblasts. Increased MMP-9 
(matrix metalloproteinase 9) expression was also observed (Bigelow et al, 2005). 
MMP-9 breaks down extracellular matrix and is therefore associated with an 
invasive cell phenotype. This model is simple and lacks many factors such as 
immune cells and a vascular system but has the key advantage that you can see 
whether inhibitors to the SHH pathway actually inhibit tumour invasiveness.
Other models include keratinocyte cell lines over-expressing GLI transcription 
factors. Kasper and colleagues (2006) treated GLI 1 over-expressing keratinocytes 
with recombinant EGF and found that EGF signalling modulated GLI1 target gene 
expression. This seems to support the finding o f  Bigelow and co-workers (2005) 
that SHH pathway activity is modulated by addition o f  recombinant EGF to SHH 
over-expressing organotypic cultures (Bigelow et al., 2005). Additionally, a 
separate publication demonstrated a migratory phenotype in N/TERT1 cells 
expressing both EGF and GLI1, and showed that GLI1 represses ERK activity 
even when EGFR is increased (Neill et al., 2008). HaCaT keratinocytes expressing 
GLI1 and GLI2A under the control o f  doxycycline showed that c-Jun expression
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was elevated (mRNA and protein) in GLI2A expressing cells but to a lesser extent 
in GLI1 expressing cells. The same was found for N/TERT1 keratinocytes and 
primary human foreskin keratinocytes expressing GLI2 under retroviral control. 
This was supported in BCC tissue by immunohistochemistry and qPCR, which 
showed that c-Jun levels were higher than found in normal skin and located 
throughout the tumour islands (where SHH pathway components were also found) 
but not in the stroma. These results showed that c-Jun was a direct target o f  GLI 
(Laner-Plamberger et al., 2009).
Another research group found that GLI1 and EGFR co-expression in rat kidney 
cells (RK3E) induced anchorage-independent growth associated with 
tumorigenesis, but this was not achieved when GLI1 or EGFR were expressed 
individually. The tumorigenic capability o f these genes when expressed in 
combination was also demonstrated when HaCaT keratinocytes expressing GLI1 
and EGFR under the control o f  doxycycline were transformed. The importance o f  
the MEK/ERK branch (EGF pathway) was confirmed when inhibition o f  
MEK/ERK activity by adding U 0126  reduced anchorage-independent growth. 
Wortmannin, a PI3K/AKT inhibitor, was also added but had no effect, inferring 
the PI3K/AKT branch (EGF pathway) was not involved (Schnidar et al., 2009).
The drawback o f  these cell models is that in vivo BCCs have an up-regulated SHH 
pathway due to deactivation o f  PTCH or activation o f  SMO and not due to 
increased SHH ligand or activation o f  GLI transcription factors (except for rare 
cases o f  SUFU deactivating mutations, where GLI cannot be repressed). This 
model therefore bypasses the protein interactions between SHH and GLI which 
may be important for BCC development.
1.3.7 SHH Signalling Pathway Mutations in Other Disorders
SHH signalling pathway mutations in SHH, PTCH, GLI2, GLI3 and SMO have 
been reported in a variety o f  other genetic disorders (Table 1.1) and there is 
evidence that SHH may be influenced by other signalling pathways.
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Table 1.1: Genetic Disorders Caused by Defective SHH Signalling.
Disorder Clinical Presentation Publication
Holopros-
encephaly
Failure o f  the front lobes o f  the 
brain to separate
Ming et al., 2002
Greig cephalo- 
poly-syndactyly
Rare autosomal disorder 
characterised by physical 
abnormalities o f  the head, face, 
fingers and toes
Vortkamp, 1991
Pallister-Hall
syndrome
Abnormal development o f  many 
parts o f the body
Biesecker, 1997
Medulloblastoma Most common brain tumour in 
children
Erez et al., 2002; Xie et 
al., 1997; Smyth et al., 
1999
Meningioma Common benign brain tumour Xie et al., 1997
Squamous Cell 
Carcinoma
Carcinoma o f skin, lips, mouth, 
oesophagus etc.
Ping et al., 2001; 
Ahmadian et al., 1998
Tricho­
epithelioma
Small benign nodules o f  the skin 
(derived from hair follicle)
Vorechovsky et al., 1997
Oesophageal
carcinoma
Malignancy o f the oesophagus Maes aw a et al., 1998
Foetal
rhabdomyoma
Derived from striated muscle DiSanto et al., 1992; 
Klijanienko et al., 1988
Rhabdomyo­
sarcoma
Malignant tumour derived from 
striated muscle
Beddis et al., 1983
Small cell lung 
cancer
Carcinoma o f larger airways, 
often metastatic
Watkins et al., 2003
Prostate cancer Cancer that develops in the 
prostate epithelium
Karhadkar et al., 2004
Breast cancer Cancer that develops in the breast, 
various types
Xie et al., 1997
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1.4 Epidermal Growth Factor (EGF)
Epidermal growth factor (EGF) is an important molecule that stimulates cell 
proliferation in embryonic development and in the adult, but it is also involved in 
the growth o f  tumours during invasion (Bigelow et al., 2005; Hausman, 2004).
1.4.1 EGF Signalling Pathway
EGF is a 53 amino acid polypeptide that binds to a specific transmembrane 
tyrosine kinase receptor (EGFR). These enzymes modify proteins by adding 
phosphate groups to either tyrosine, or in some cases serine/threonine residues 
(Normanno et al., 2005; Cooper and Hausman, 1998). EGFR is expressed in the 
basal layer and to a lesser extent in suprabasal cells o f  the epidermis (Bigelow et 
al., 2005; Hausman, 2004) and when EGFR is blocked, cells undergo apoptosis 
(Bigelow et al., 2005).
EGFR (also known as ErbBl) belongs to the ErbBl-4 family o f  receptors and the 
other family members (ErbB2-4), also known as HER2-4 in humans, have 
different ligands. EGFR is inactive as a monomeric transmembrane protein but 
binding o f  EGF ligand to the receptor (EGFR) on the cell surface induces 
conformational changes that promote protein-protein interactions leading to 
receptor dimerisation and activation (Figure 1.12). A large number o f  
phosphorylation events are involved in the EGF signalling cascade, leading to 
functional changes in target proteins. These include increasing enzyme activity, 
cellular location or association with other proteins in the signalling cascade. Once 
dimerised, EGFR polypeptide chains cross-phosphorylate one another at tyrosine 
residues within the catalytic domain to further increase protein kinase activity.
In addition, further phosphorylation o f  tyrosine residues outside o f  the catalytic 
domain, creates binding sites for additional proteins that then transmit intracellular 
signals downstream o f  the activated receptor. These proteins bind to the receptor 
phosphotyrosine residues via src homology 2 (SH2) domains (Figure 1.12) 
leading to activation o f  various signalling cascades including PIP2/IP3, MEK/ERK
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and P13K/AKT (Bigelow et al., 2005). The SH2 domain was originally identified 
as a conserved domain in the oncogene src but was subsequently found in many 
other signalling proteins with phosphotyrosine containing target domains 
(Filippakopoulos et al., 2009).
An important part o f  the EGF pathway involves phosphatidylinositol 4, 5- 
biphosphate (PIP2), inositol 1, 4, 5-triphosphate 3 (IP3) and diacylglycerol (DAG). 
PIP2 is bound to the inner plasma membrane and close to phospholipase C (PLC). 
When cells are stimulated by EGF, the G-protein linked receptor activates PLC 
which cleaves PIP2 into IP3 and DAG at the plasma membrane (Figure 1.12). 
DAG remains at the membrane and is a physiological activator o f  protein kinase C 
(PKC) while IP3 diffuses to the endoplasmic reticulum and opens Ca2+ channels to 
release Ca2+ from storage, which then goes to the plasma membrane to co-activate 
PKC. In addition, PIP2 can also be further phosphorylated at position 3 by PI3 
kinase (PI3K) to make PIP3. The pleckstrin homology domain o f  AKT binds to 
PIP3, recruiting AKT to the inner plasma membrane for phosphorylation and 
activation by another protein kinase, PDK1 (Cooper and Hausman, 1998; Henson 
et al., 2007). AKT then regulates the function o f  many downstream targets by 
phosphorylation on serine/threonine residues to promote cellular survival (Cooper 
and Hausman, 1998).
Another important arm o f  the EGFR pathway is the MEK/ERK cascade involving 
a family o f  serine/threonine protein kinases. Ras activates Raf which then activates 
MEK (MAP Kinase/ERK Kinase). MEK then activates members o f  the ERK 
family by phosphorylation at both threonine and tyrosine residues (has dual 
specificity). ERK then phosphorylates and activates various target protein kinases 
and transcription factors. Activation o f  the ERK signalling pathway is known to 
lead to cell proliferation, survival and differentiation (Cooper and Hausman, 1998; 
Henson et al., 2005).
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Fos, part o f the AP-1 transcription complex is activated by phosphorylation o f Elk- 
1 by ERK (Schnidar et al., 2009; Laner-Plamberger et al., 2009). c-Jun represents 
the other part o f the AP-1 complex and this is normally activated by JNK, on a 
separate branch o f the RAS pathway (Figure 1.12). It has been shown that 
MEK/ERK somehow interacts with c-Jun/AP-1 and that U 0126 (MEK inhibitor) 
can abolish c-Jun phosphorylation.
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Figure 1.12: EGF Signalling Pathway. Phosphorylation o f the EGF receptor leads to 
downstream signalling through PI3K/AKT and MEK/ERK pathways.
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1.4.2 EGF and Cancer
The EGF pathway has previously been shown to function in cancers other than 
BCC, including epithelial cancers o f  the prostate and breast. Activation o f  the 
EGF pathway is thought to make tumours more aggressive and more likely to 
metastasize, a function linked to a role in epithelial mesenchymal transition [EMT] 
(Hardy, 2010).
EMT occurs when epithelial cells lose their epithelial characteristics and express 
mesenchymal markers (keratinocytes become fibroblast-like). Indeed, in BCCs 
and SCCs, ErbBl (EGFR) ligands were found to increase in the adjacent “normal” 
epidermis (qPCR and immunohistochemistry data). However, downstream 
ERK 1/2 and AKT were found to be activated in normal epidermis adjacent to 
SCCs, but importantly this was not observed for BCCs (Rittie et al., 2007). This 
suggests a lack o f  activation o f  either the PI3K/AKT or MEK/ERK branches o f  the 
EGF pathway in BCCs. Significant elevation o f  EGFR ligands in papillomas and 
SCCs has also been supported (Kiguchi et al., 1998). Additionally, EGFR was 
found in proliferating layers o f skin cancers (both BCCs and SCCs) and one 
research group found expression in all cells o f  BCCs by immunohistochemistry 
(IHC) on frozen sections (Kikuchi et al., 1990; Lavrijsen et al., 1989). EGF 
pathway transcription complex (AP-1) components c-Jun and c-Fos were also 
shown to be increased in BCCs, suggesting that at least part o f  the EGF pathway is 
activated. Together, these results do not clearly show that the EGF pathway is 
activated in BCCs. As the EGF pathway is generally thought to be involved in cell 
survival and proliferation, the low levels o f  p-ERK and p-AKT found previously 
are consistent with the fact that BCCs are slow growing tumours that rarely 
metastasize.
However, there is evidence for an interaction between SHH and EGF signalling 
(particularly via MEK/ERK) at the level o f GLI transcription factors, causing an 
infiltrative BCC phenotype. HaCaT cells in organotypic culture that expressed 
SHH showed increased EGFR phosphorylation compared to cells that did not.
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Furthermore, cells expressing SHH also showed an ability to invade a collagen 
matrix and this invasion was prevented when EGFR signalling was inhibited 
(Bigelow et al., 2005). Gene expression profiling (qPCR) o f N/TERT1 
keratinocytes over-expressing GLI1 and stimulated with EGF, identified a subset 
o f  GLI1 target genes modulated via MEK/ERK signalling. The same research 
group showed that GLI and EGF are both required for induction o f cell cycle 
progression and that EGF signalling inhibited GLI1 controlled stem cell marker 
expression (Kasper et al., 2006). Another research group found p-ERK in the 
tumour margin o f  one BCC sample by immunohistochemistry, suggesting that 
EGF signalling may cause invasive characteristics in some tumour cells (Neill et 
al., 2008). Interestingly, increased levels o f  the transcription factor c-Jun were 
found in BCCs in vivo and in SHH over-expressing organotypic cultures. 
However, c-Jun expression can be controlled by GLI1 and GLI2, as well as by 
EGF signalling, so c-Jun may be important for transcription o f  augmented 
downstream genes (Laner-Plamberger et al., 2009; Bigelow et al., 2005; Schnidar 
et al., 2009).
If  there are interactions between the EGF and SHH signalling pathways, inhibitors 
o f  the EGF pathway might provide an effective treatment for BCC. Research has 
been carried out with topical formulations that inhibit MAPK and PI3K/AKT 
signal transduction pathways and these successfully limited cell proliferation in 
breast cancer (Davison et al., 2008a) so it may be worth trying this approach for 
BCCs.
c-Jun is thought to be up-regulated in BCCs, and constitutive activation o f  the AP- 
1 complex can lead to cell proliferation (Figure 1.13). It is not known how c-Jun 
might be activated in BCCs but crosstalk between the MEK/ERK arm o f the EGF 
pathway (which is possibly activated) and the MEKK1/JNK arm (activated by 
inflammatory cytokines and cell stress leading to apoptosis), may play a role. 
Reducing c-Jun levels with RNAi (interference RNA; inhibit gene expression by
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inactivating specific mRNAs) in cells with active GLI and EGFR signalling 
reduced transformation inferring a role for c-Jun (Schnidar et al., 2009).
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Figure 1.13: Possible Interactions between SHH and EGF Signalling Pathways.
Interactions between the MEK/ERK arm of the EGF pathway at the level o f GLI 
transcription factors (possibly via AP-1 complex) could lead to modulation o f SHH 
pathway target genes by a physical interaction between c-Jun and GLI2 (and to a lesser 
extent with GLI1). This would lead to a positive feedback loop with activated GLI up- 
regulating c-Jun. Combining c-Jun and GLI may lead to up-regulation o f EGFR and SHH 
target genes, which would increase cell migration and proliferation.
GLI target genes (S100A7 and IL-1R2) have their transcription modulated by a 
physical interaction between GLI2 and c-Jun (c-Jun promoter has a functional GLI 
binding site) (Laner-Plamberger et al., 2009). When c-Jun is knocked out with 
shRNA (small hairpin RNA, used to silence gene expression), expression o f these 
genes decrease, and primary c-Jun '' keratinocytes show reduced proliferation
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(Laner-Plamberger et al., 2009; Zenz et al., 2003). Both c-Fos and c-Jun are part o f  
the AP-1 transcription complex, so transcription may be inhibited by the MEK 
inhibitor PD98059 (also inhibits c-Fos). In addition, c-Jun is also thought to be a 
target o f  MEKK1/JNK (Franklin et al., 1992).
1.5 Development Rationale for Novel Topical Treatments
There is a clinical need for a formulation which can be used to treat more invasive 
BCC subtypes in order to reduce health service costs in the western world.
The general strategy is to look at expression o f  EGF proteins in BCC biopsies to 
decide whether there is a need to target the EGF pathway in addition to using a 
SMO inhibitor such as cyclopamine. In addition to this, a cell culture model o f  
BCC will be developed which can be used to test inhibitor efficacy prior to the 
development o f  a suitable formulation.
Many possible treatments are toxic and can cause severe side effects because the 
drugs are non-specific (act on more than one part o f  a signal transduction 
pathway). If formulations targeting EGF were given orally, they would have high 
toxicity due to this lack o f  specificity. BCCs are not metastatic, so a systemic drug 
reaching organs other than the skin is not necessary and so this toxicity can be 
decreased by topical administration. This reduces first pass metabolism (when the 
drug is metabolised by the liver, reducing the amount that reaches the systemic 
circulation), so less o f  the drug is needed for topical delivery thus reducing toxicity 
(Rang, 2003). This means that the drug can be administered at home rather than in 
hospital, saving health care costs.
1.5.1. EGF Signalling Pathway Inhibitors
There are two main types o f  EGF pathway inhibitor: monoclonal antibodies and 
protein kinase inhibitors (Henson and Gibson, 2006). Suramin and Trastuzumab 
(Herceptin) are monoclonal antibodies which inhibit the whole EGF pathway and 
they have been used to treat prostate cancer and breast cancer respectively (Boylan
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et al., 1998; Harries and Smith, 2002; Kalli et al., 2004). Small molecule inhibitors 
are more specific and include PX-866 (a PI3K inhibitor which has been effective 
on lung cancer cell lines; Henson and Gibson, 2006), PD98059 (MAPK 
phosphorylation inhibitor) and LY249002 (another PI3K inhibitor), which have 
been used in combination with tamoxifen to limit breast cancer cell growth 
(Davison et al., 2008a; Ellis, 2004).
1.5.2 EGF Antagonists (PD98059 and LY294002)
PD98059 and LY294002 are EGF antagonists which may be suitable for use in a 
topical formulation (Figure 1.14). Both inhibitors have previously been used in 
the treatment o f  other carcinomas in which EGF signalling is active. LY294002 is 
a derivative o f  the naturally occurring bioflavanoid quercetin, a PI3K inhibitor. It 
acts by competitively inhibiting the ATP binding site o f PI3K, thus preventing the 
transfer o f  the terminal phosphate o f  ATP to phosphoinositol. This then inhibits 
the formation o f  PIPs and activation o f AKT. PI3K affects oncogenes such as v-src 
and v-abl so its inhibition is likely to be useful for reduction o f  tumorigenesis 
(Vlahos et al., 1994). Wortmannin is a more potent inhibitor o f  PI3K but acts 
irreversibly, whereas the action o f  LY294002 is reversible.
PD98059 is a flavonoid that acts as a potent and selective inhibitor o f MEK 
phosphorylation by cRAF or MEK kinase. This leads to inhibition o f  MAPK 
phosphorylation, directly downstream o f  MEK (Alessi et al., 1995; Dudley et al., 
1995).
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Figure 1.14: Chemical Structures ofLY294002 (A) and PD980S9 (B).
1.5.3 Cyclopamine
Cyclopamine (Figure 1.15) is a teratogenic steroidal alkaloid derived from plants 
( Veratrum genus), which induces a cephalic defect (cyclopia) in vertebrate 
embiyos by preventing the division o f  the foetal brain into two lobes 
(holoprosencephaly), giving rise to its name based on Homer’s Cyclops from 
Greek Mythology (Taipale et al., 2000).
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Figure 1.15: Chemical Structure of Cyclopamine.
Its action was first discovered when sheep grazing on Veratrum californicum gave 
birth to lambs, suffering from cyclopia, on the 14th day o f  gestation. Similarities 
noticed between Fmtfrw/w-induced cephalic defects in lambs (including cyclopia) 
and holoprosencephaly-like abnormalities (Figure 1.16). These are associated with 
the loss o f  SHH pathway signalling which eventually led to the discovery that
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cyclopamine binds directly to the SMO heptahelical protein bundle. Cyclopamine 
inhibits SMO by influencing its protein conformation and thus blocking activation 
o f downstream genes in the sonic hedgehog pathway. This antagonistic action on 
SHH signalling has been shown to be SHH and PTCH independent (Chen et al., 
2002a; Chen et al., 2002b; Taipale et al., 2000).
Figure 1.16: Veratrum Californicum, Sonic Hedgehog Game Character and an 
example o f Cyclopia in Sheep.
Cyclopamine and related steroidal alkaloids have similar structures to cholesterol. 
However, steroidal alkaloids with a structure similar to cyclopamine are not all 
potent inhibitors o f SMO. There appear to be similarities between the functions of 
cholesterol and cyclopamine, which may use a common vesicular pathway for 
their actions. This is thought to be the case because PTCH and the Niemann-Pick 
Cl protein (a transmembrane molecular pump involved in cholesterol 
homeostasis), are structurally similar (Davies et al., 2000). In addition, compounds 
that block cholesterol transport by affecting the vesicular trafficking o f the 
Niemann-Pick C l protein, are also weak SHH antagonists. Furthermore, co­
localisation o f PTCH and Niemann-Pick C l protein was confirmed in vesicular 
compartments o f cells.
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1.5.4 Small Molecule SHH Pathway Inhibitors
There are a number o f small molecule inhibitors to components o f the SHH 
pathway, which may be useful for the treatment o f BCC or other cancers 
dependent on SHH signalling. Many have progressed to clinical trial (Table 1.2), 
but not all were available at the start of, or during, this study. The targets o f some 
of these inhibitors are shown in Figure 1.17.
(a) W ithout Hh (b) With Hh
Figure 1.17: Inhibitors o f the Basic Components in the Sonic Hedgehog Pathway. SHH
pathway (a) in the absence o f SHH and (b) in the presence o f SHH, and where the 
pathway would be de-activated by inhibitors (adapted from Scales and Sauvage, 2009).
Normally, in sporadic cases o f BCC, SHH inhibitors would not be useful since the 
pathway is constitutively activated in the absence o f SHH. However, in xeroderma 
pigmentosum patients, where BCCs can be caused by SHH mutations, they may be 
applicable. Most inhibitors to the SHH signalling pathway target SMO, but some 
also inhibit GLI transcription factors (Table 1.2). Inhibition o f GLI still leaves the
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pathway upstream active which has lead to the discovery o f  transcriptional 
modulation by non-canonical pathways (Jenkins, 2009).
Table 1.2: Small Molecule SHH Pathway Inhibitors in Development (adaptedfrom  
Toftgard and Tegund, 2010).
Compound Target Developmental Phase
Robotnikinin SHH Preclinical
Cyclopamine SMO Preclinical
KAAD-Cyclopamine SMO Preclinical
Jervine SMO Preclinical
IPI-609 SMO Preclinical
IPI-926 SMO Clinical phase I (advanced and/or  
m etastatic solid tum ours)
SANT1, 2, 3, and 4 SMO Preclinical
CUR-61414 SMO Clinical phase I (BCC), halted
H hA ntag691 /  H h Antag SMO Preclinical
GDC-0449 SMO Clinical phase I (advanced and/or  
m etastatic solid tumours, 
m edulloblastom a, pancreatic 
cancer)
Clinical phase II (advanced BCC, 
m etastatic colorectal cancer, 
ovarian carcinoma)
BM S-833923/XL139 Clinical phase I (advanced or 
m etastatic cancer)
GANT61 GLI Preclinical
HPI-1, 2, 3, and 4 GLI-A
function
Preclinical
1.6 Hypothesis
Inhibition o f  EGF signalling in combination with blocking SHH signalling restricts 
BCC growth.
1.6.1 Research Aims:
• To develop an in vitro cell model to test drug formulations.
• To probe EGF signalling in BCC in order to confirm the in vivo relevance 
o f  a formulation containing EGF inhibitors on all sub-types o f  BCC.
• Determine a suitable vehicle for drug deliveiy.
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Chapter 2
Sonic Hedgehog and Epidermal 
Growth Factor Signalling in 
Monolayer Cultures
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2.1 Introduction
In recent years, several research groups have been in agreement that epidermal 
growth factor (EGF) signalling cascades somehow modulate the Sonic Hedgehog 
(SHH) pathway, leading to augmented expression o f  a subset o f  target genes. It 
has been shown that the combined expression o f  EGF and SHH causes neural stem 
cell proliferation (Palma et al., 2005), which may be important in prostate 
carcinoma. More recently, however, publications have suggested that it is 
particularly the MEK/ERK portion o f  the EGF pathway which is augmenting SHH 
signalling at the level o f  GLI transcription factors (Schnidar et al., 2009).
Experiments using Glil-overexpressing N/TERT1 keratinocytes and qRT-PCR 
have shown that recombinant EGF augments the expression o f  a subset o f Gli- 
induced genes. Furthermore, five o f these genes (ARC, S100A7, IL1-R2, EGR-3 
and JAG-2) demonstrated large increases in the presence o f  recombinant EGF. In 
fact, S100A7 levels increased 2.3 fold with EGF alone, 9.8 fold with GLI1 alone 
and up to 1,300 fold with both GLI1 and EGF compared to untreated controls 
(Kasper et al., 2006). In order to confirm which parts o f  the EGF pathway are 
involved in the change o f GLI1 target gene expression, HaCaT keratinocytes 
expressing a doxycycline-regulated conditional allele o f  GLI 1 supplemented with 
recombinant EGF, were treated with a PI3K inhibitor (LY294002) or a MEK 1/2 
inhibitor (U0126). Data from qRT-PCR experiments showed that the MEK/ERK 
arm o f  the EGF pathway but not PI3K/AKT arm is involved in augmenting the 
SHH pathway (Kasper et al., 2006).
In SHH-overexpressing HaCaT keratinocytes, it has been shown that the addition 
o f  recombinant EGF allowed tumour invasion in organotypic cultures. The 
importance o f  the EGF pathway for invasion was also confirmed by showing that 
an EGFR inhibitor (AG 1478) reduced matrix infiltration. Higher levels o f  
phosphorylation o f  both the EGFR and RAF (MEK/ERK cascade o f  EGF 
pathway) were also observed in SHH expressing organotypic cultures. This is
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additional confirmation o f  the importance o f not only the EGF pathway but 
specifically the MEK/ERK arm (Bigelow et al., 2005).
EGF has also been shown to repress Glil-induced expression o f  stem cell 
characteristics (colony formation) and markers (such as EMT marker vimentin) in 
N/TERT1 cells. Cell-to-cell adhesion was increased in the presence o f GLI1 and 
E-cadherin localisation also changed from perinuclear to the plasma membrane in 
GLI1 expressing cells. In contrast to other published research, Neill and colleagues 
(2008) also found a decrease in EGFR and ERK activity associated with colony 
formation in GLI1 expressing cells. Furthermore, ERK was not increased in GLI1 
expressing cells even in the presence o f  exogenously increased EGFR (Neill et al., 
2008), which suggested a negative feedback loop between GLI1 and ERK. In 
agreement with other publications, they found no change in AKT activity.
Schnidar and co-workers (2009) showed that U 0126  (MEK 1/2 inhibitor) reduced 
anchorage independent growth and c-Jun/AP-1 induced gene expression while 
wortmannin (PI3K inhibitor) did not. They used HaCaT keratinocytes where GLI 1 
expression was under the control o f  doxycycline and this data supports a role for 
the MEK/ERK arm o f the EGF pathway (combined with GLI activation) in 
oncogenic transformation (Schnidar et al., 2009).
The same group also suggested a mechanism involving an AP-1 transcription 
factor (c-Jun) in this oncogenic transformation. The AP-1 complex can be 
activated by MEK/ERK which then augments the SHH pathway at the level o f  
GLIA (also termed GLIact) to induce GLI/EGF target gene expression and 
oncogenic transformation. This has been shown by in silico promoter analysis 
where GLI and AP-1 binding sites were both present in GLI/EGF target genes and 
this was not found in EGF-independent GLI target genes. Stimulation o f  EGFR 
signalling activates c-Jun/AP-1 via MEK/ERK, with c-Jun binding to the 
promoters o f  GLI/EGF target genes. In confirmation o f  this, inhibition o f
49
MEK/ERK prevents activation o f  c-Jun, reduces GLI/EGF target gene expression 
and also reduces transformation (Schnidar et al., 2009).
GLI1 and GLI2A-expressing HaCaT and N/TERT1 keratinocyte cell lines have 
been used to show that GLI 1 and GLI2A can regulate transcription o f  c-Jun. The 
proliferative potential o f  GLI was found to be reduced in the absence o f  c-Jun 
(Laner-Plamberger et al., 2009) and c-Jun has also been found in the nuclei o f  
BCC cells, suggesting that it is important for BCC development.
The publications described above showed some discrepancies, such as whether 
ERK is increased in BCC and whether c-Jun is a transcription factor downstream 
o f  MEK/ERK. The use o f  different cell lines (HaCaT and/or N/TERT1) that over­
express different parts o f the SHH pathway could explain the variable results 
obtained in some o f  these studies. However, they all seem to agree that MEK/ERK 
is involved in BCC development but the detailed mechanisms are still to be fully 
elucidated.
The main objective in our current research is to confirm the activity o f  both SHH 
and EGF pathways after addition o f  recombinant SHH and/or EGF to N/TERT1 
keratinocytes and to show pathway activation by measuring expression o f a subset 
o f  target genes (EGR-3, IL1R2, S100A7 and PTCH).
The ERK arm o f  the EGF pathway has been shown to augment SHH signalling 
and has been considered to be a good target for treating BCC alongside inhibitors 
o f  the SHH pathway. Monolayer keratinocyte cultures activated by the presence o f  
recombinant SHH and/or EGF were therefore considered a good starting point for 
testing these inhibitors.
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2.1.2 Aims
• To determine whether SHH and EGF signalling could be activated in 
N/TERT1 cells so that an in vitro model for BCC could be developed.
• To compare levels o f SHH target genes when SHH and EGF were both 
present to determine whether EGF has an effect on SHH signalling.
2.2 Methods
2.2.1 Cell Lines
Normal human somatic cells have a limited capacity to replicate in culture, and 
quickly become senescent. In general, this is due to short telomere length or DNA  
damage, which reduces the lifespan o f the cell. However, in principal, 
immortalisation allows cells to replicate for an unlimited number o f  passages. Two 
keratinocyte cell lines have been utilised for this project, N/TERT1 (from Dr 
James Rheinwald, Brigham and Women’s Hospital, Harvard Institute o f  Medicine, 
Boston, MA, USA) and HaCaT (from Prof. Petra Boukamp, German Cancer 
Research Center [DKFZ], Heidelberg, Germany).
Normal human epidermal keratinocytes were immortalised by stable hTERT 
expression and loss o f  P16INK4a to produce the N/TERT1 cell line. hTERT is the 
activity-limiting component o f telomerase, a holoenzyme with a template for 
telomere synthesis and a catalytic protein subunit with reverse transcriptase 
activity which prevents the loss o f  telomeres in cells. P16INK4a is involved in cell 
cycle control and would normally limit the lifespan o f  cells and loss o f  P16INK4a 
prevents the change from G1 to S growth phase. However, N/TERT1 cells retain 
responsiveness to growth control and differentiation signals and histologically 
appear similar to normal human keratinocytes in organotypic cultures or when 
grafted onto mice. Their survival in the absence o f  exogenous growth stimuli is 
enhanced compared to primary keratinocytes. Therefore, they provide a useful
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model to study gene expression changes in response to well-defined stimuli 
(Dickson et al., 2000).
HaCaT cells represent a spontaneously immortalised human keratinocyte cell line. 
The cells were originally obtained in 1988 from histologically normal skin distal to 
an excised melanoma. This cell line was named HaCaT because o f  the human 
adult skin keratinocyte origin and because cells were propagated in low Ca2+ 
medium and at an elevated temperature (Boukamp et al., 1988). Spontaneous 
immortalisation o f  human cells is quite rare, probably because the genome is more 
stable than for other animal cells, such as rodents. Early in the immortalisation 
process, HaCaT cells differentiated and stratified in high calcium conditions, but 
grew as a monolayer in low calcium. Further passages reduced the effects o f  low 
calcium levels and cells that survived increased temperature were able to grow 
autonomously in culture. Marker chromosomes resulted which were able to show 
that the cell line was monoclonal by karyotyping. This also showed that HaCaT 
cells were aneuploid but many cells in late passages were polyploid. It has been 
suggested that polyploidy may be the cause o f  autonomous growth in culture.
HaCaT cells have been shown to be non-tumorigenic and non-invasive. Like 
normal keratinocytes, they grow into a well-structured epidermis when 
transplanted onto mice, having the same keratin expression profile, exhibiting 
normal differentiation and retaining all these properties at higher passages. Cells 
immortalised by virus infection (e.g. Simian Virus-40), a commonly used 
technique, tend to have altered growth properties, distorted keratinisation and 
deficient differentiation (Boukamp et al., 1988).
2.2.1.1 Maintaining Cell Lines (N/TERT1 and HaCaT)
N/TERT1 cells were thawed at 37°C in a water bath, transferred to a 20ml 
Universal tube and 9 volumes o f  DMEM (calcium-free, glutamine-free) /Ham’s 
F12 (1:1, v/v) (Gibco, Invitrogen, Paisley, UK) containing 10% FBS (Lonza, 
Slough, UK) were slowly added. After careful mixing by pipette, the cells were
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pelleted by centrifuging at 1,200 rpm for 5 minutes at room temperature (RT) and 
the supernatant was discarded. The N/TERT1 cell pellet was resuspended in 20ml 
keratinocyte serum-free medium (K-SFM) containing bovine pituitary extract 
(25pg/ml), EGF (0.2ng/ml) and 0.3mM CaCh (Gibco, Invitrogen, Paisley, UK). 
The cells were carefully mixed and incubated at 37°C (5% CO2) in a T75 culture 
flask (Coming, Fisher Scientific, Loughborough, UK). The medium was changed 
every 2-3 days but as N/TERT1 cells did not grow that well in this medium, there 
were sub-cultured at low density (30% confluency).
To subculture N/TERT1 cells, the medium was aspirated and the cells were 
washed once with dPBS. Trypsin-EDTA (Gibco, Invitrogen, Paisley, UK) was 
added (5ml) and the cells incubated at 37°C (in 5% CO2) for approximately 10 
minutes or until the cells were no longer adherent. An equal volume (5ml) o f  
serum containing medium (DMEM/Ham’s F12 [1:1, v/v] containing 10% FBS) 
was added to the cells to inhibit the trypsin. The cell suspension was carefully 
mixed, transferred to a 50ml falcon tube and centrifuged at 1,200 rpm for 5 
minutes at RT. The supernatant was discarded, the cell pellet resuspended in 2- 
10ml K-SFM and cell number counted using a haemocytometer. Cells were then 
placed into new flasks (at approximately lx l0 5cells per T75) and K-SFM was 
added to make a total o f  20ml.
HaCaT cells were thawed at 37°C in a waterbath and 20ml DMEM (Lonza, 
Slough, UK) containing 2 mM L-glutamine and 10% FBS was slowly added and 
mixed by pipetting. The cells were then incubated at 37°C (5% CO2) in a T75 
culture flask and the medium changed every 2-3 days. HaCaT cells were 
subcultured at higher density (-80%  confluency). Medium was aspirated and the 
cells washed once with PBS before adding 5ml trypsin-EDTA. The cells were then 
incubated at 37°C (5% CO2) for approximately 10 minutes or until cells were no 
longer adherent. DMEM with 10% FBS (5ml) was added to inhibit tiypsin activity 
and after careful mixing, the cell suspension was transferred to a 50ml falcon tube. 
The cells were centrifuged at 1,200 rpm for 5 minutes at RT and the supernatant
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discarded. The pellet was resuspended in 2 -10ml DMEM with 10% FBS and the 
cell number counted using a haemocytometer. Cells were placed into new flasks 
(at approximately lxlO 5 cells per T75) and DMEM containing 10% FBS was 
added to a total o f  20ml. Cells were then incubated at 37°C (5% CO2) until 
confluent (5-7 days).
2.2.1.2 Growing N/TERT1 Keratinocytes to High Confluency
In order to grow N/TERT1 keratinocytes to a level above 30% confluency, a 
different medium was required. In this case, cells were cultured in a mixture o f  K- 
SFM and DF-K media (1:1, v/v). DF-K is calcium-free, glutamine-free 
DMEM/Ham’s F I2 mixture (1:1, v/v) containing 0.2ng/ml EGF, 25pg/ml bovine 
pituitary extract and 1.5mM L-glutamine (Gibco, Invitrogen, Paisley, UK). This 
medium was replaced every 2 days and N/TERT1 cells become fully confluent 5-7 
days after subculture.
2.2.1.3 Cryopreserving Keratinocytes for Storage
In order to keep cells over a long period o f time in liquid nitrogen, a specialised 
freezing mixture is required. N/TERT1 cells were stored in a mixture o f  DMEM 
and F12 (1:1, v/v) with 16% FBS and 20% DMSO which was premade and stored 
at -80°C. The components were thoroughly mixed, allowed to stand at 4°C for 2 
hours, filter-sterilised (at 0.2pm), 1ml aliquots placed into 2ml cryovials and 
stored at -80°C.
The N/TERT1 cells were prepared by aspirating the medium and washing the cells 
with dPBS (sterile phosphate buffered saline). Trypsin-EDTA (5ml) was added 
and the cells incubated at 37°C (5% CO2) for 5-12 minutes. An equal volume 
(5ml) o f DMEM-F12 [1:1, v/v] containing 10% FBS was then added and carefully 
mixed to inhibit the trypsin activity. The cells were pelleted by spinning at 1,200 
rpm for 5 minutes at RT and the medium was aspirated. Cells were then re­
suspended in 3-4ml K-SFM and counted using a haemocytometer.
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N/TERT1 cells were frozen at the recommended cell concentration (5 x l0 4 to 
2x105 cells per ampule) by adding 1ml o f the cells in K-SFM to a 1ml freezing 
mixture aliqout (1:1, v/v). The vials were wrapped in tissue, placed in a 
polystyrene tube box and frozen at -80°C. After 24 hours, the vials were 
transferred to liquid nitrogen for long term storage.
HaCaT cells were frozen by adding culture medium containing cells directly to 
filter-sterilised (at 0.2pm) FBS containing 10% DMSO. Again, this freezing 
mixture was premade and stored in 1ml aliquots at -80°C.
HaCaT cell cultures were prepared for freezing by aspirating the medium, washing 
the cells in dPBS and then adding 5ml trypsin-EDTA. The cells were incubated at 
37°C (5% CO2) for 5-12 minutes and then an equal volume (5ml) o f  DMEM 
containing 2mM L-glutamine and 10% FBS was added to inhibit the trypsin 
activity. The cells were pelleted by spinning at 1,200 rpm for 5 minutes at RT and 
the supernatant aspirated. The cells were resuspended in 3-4ml DMEM containing 
10% FBS, counted and adjusted to a concentration o f  3 x l0 6 cells per ml o f  
medium. The cells in medium (1ml) were then added to a cryovial containing 1ml 
o f  freezing mixture. The vials were wrapped in tissue, placed in a polystyrene tube 
box and frozen at -80°C. After 24 hours, the vials were transferred to liquid 
nitrogen for long term storage.
2.2.1.4 Confirming EGF Pathway Activation
In order to cany out further experiments using recombinant EGF, it was important 
to confirm that the EGF pathway could be activated in N/TERT1 and HaCaT 
keratinocytes.
N/TERT1 cells were plated at approximately 6 x l0 5cells/dish in four 10cm dishes 
with 10ml K-SFM containing growth supplements (bovine pituitary extract 
[25pg/ml], EGF [0.2ng/ml] and 0.3mM CaCh per dish). The cells were incubated 
at 37°C (5% CO2) for 36 hours, the K-SFM aspirated, the cells washed three times
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with dPBS and 10ml K-SFM without EGF or bovine pituitary extract was added to 
each dish. The cells were incubated at 37°C (5% CO2) for 24 hours and then 
exposed to lOng/ml EGF (Gibco, Invitrogen, Paisley, UK) for 5, 10 or 20 minutes 
(3 separate dishes). Extraction buffer (0.8ml) was applied to each dish and the 
cells were scraped into 1.5ml eppendorf tubes, then boiled for 5mins and stored at 
-20°C for western blot analysis. The extraction buffer contained 1ml 0.5M Tris 
(Fisher Scientific, Loughborough, UK), 0.8ml glycerol (Sigma-Aldrich Company 
Ltd, Gillingham, UK), 1.6ml 10% SDS (Fisher Scientific, Loughborough, UK), 
0.08ml 1M dithiothreitol (Sigma-Aldrich Company Ltd, Gillingham, UK) and 
0.2ml bromophenol blue (Sigma-Aldrich Company Ltd, Gillingham, UK).
HaCaT cells were also plated (at approximately 6 x l0 5cells/dish) in four 10cm 
dishes with 10ml DMEM containing 10% FBS and incubated at 37°C (5% CO2) 
for 36 hours. The medium was aspirated, cells washed three times with dPBS and 
then 10ml DMEM (no FBS) was added to each dish. The cells were incubated at 
37°C (5% CO2) for 24 hours and then exposed to lOng/ml EGF (Gibco, 
Invitrogen, Paisley, UK) for 5, 10 or 20 minutes (3 separate dishes). Extraction 
buffer (0.8ml) was applied to each dish and the cells were scraped into 1.5ml 
eppendorf tubes, then boiled for 5 minutes and stored at -20°C for western blot 
analysis.
2.2.1.5 EGF and SHH Pathway Induction in N/TERT1 Cell Line 
N/TERT1 cells were plated at approximately 6 x l0 5 cells per 10cm dish in 10ml K- 
SFM plus growth supplements: bovine pituitary extract (25pg/ml), EGF 
(0.2ng/ml) and 0.3mM CaCI2 . The cells were incubated at 37°C (5% CO2) for 36 
hours and then the K-SFM was aspirated, the cells were washed three times with 
dPBS and 10ml K-SFM without EGF or bovine pituitary extract was added to each 
dish. The cells were incubated at 37°C (5% CO2) for 24 hours and then exposed to 
EGF (lOng/ml) and/or SHH (lOng/ml), (mouse recombinant proteins from E. Coli: 
Sigma-Aldrich Company Ltd, Gillingham, UK) in the presence or absence o f the 
agonists, LY294002 (20pM) and/or PD98059 (20pM), for 24 hours. SDS sample
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buffer (0.8ml) was applied to each dish and the cells were scraped into 1.5ml 
eppendorf tubes, then boiled for 5 minutes and stored at -20°C for western blot 
analysis. Alternatively, 0.9ml Trizol was applied to each dish and the cells were 
scraped into 1.5ml eppendorf tubes and stored at -80°C for RNA extraction.
2.2.1.6 Cell Viability Assay
This assay records luminescence signals from viable cells based on the quantity o f  
ATP present, thus showing if  there is an increase or decrease in cell viability when 
N/TERT1 keratinocytes were treated with inhibitors to the EGF pathway. 
N/TERT1 keratinocytes were plated in a 96 well plate at a density o f  approx 440 
cells/well in lOOpl K-SFM containing growth supplements. The cells were 
incubated at 37°C (5% CO2) for 24 hours to approximately 30% confluent. The K- 
SFM was then aspirated and replaced with IOOjllI K-SFM per well plus the 
treatments shown in Table 2.1 (4 replicates per treatment).
Table 2.1: Treatments usedfor N/TERT1 Keratinocyte Cell Viability Assay.
Treatment Quantities
Control 20 j l i1 K-SFM
Inhibitor diluent 15nl D M SO + 5pl K-SFM
PI3K inhibitor 20pM LY294002 in 15pl DMSO + 5pl K-SFM
MEK inhibitor 20pM PD98059 in 15ul DMSO + 5pl K-SFM
PI3K + MEK inhibitors 20pM LY294002+20pM PD98059 in 15pl DMSO + 
5pi K-SFM
After 24 hours, an aliquot o f fresh Cell Titer-Glo (CTG) reagent (Promega UK 
Ltd, Southampton, UK) was made by mixing 10ml substrate and 10ml buffer from 
the kit. The medium was removed from the 96 well plate, cells were washed three 
times in dPBS and then lOOpl K-SFM was added to each well. The plate was 
allowed to equilibrate for 30 minutes at RT before the addition o f  lOOpl CTG 
reagent, to each well. The plate contents were mixed on an orbital shaker to induce 
cell lysis and then the plate was allowed to incubate at RT for 10 minutes to 
stabilise the signal. Luminescence was measured on a Tropix TR717 microplate 
luminometer using an integration time o f  0.5 seconds.
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2.2.2. Molecular Biology
2.2.2.1 RNA Extraction
Total RNA was extracted from skin or cultured cells using Trizol reagent (Gibco, 
Invitrogen, Paisley, UK). Briefly, 0.9ml trizol was added to cryostat cut (0.7pm) 
slices o f  normal human skin or to a 10cm plate o f  confluent cells and the contents 
were scraped into a 1.5ml eppendorf tube and vortexed for 5 minutes. An aliquot 
(0.25ml) o f  chloroform (Fisher Scientific, Loughborough, UK) was added, the 
solution was shaken for 15 seconds and then left to stand for 2-15 minutes. This 
was centrifuged at 12,000 rpm for 10 minutes at 4°C. The top aqueous layer was 
removed and transferred to a clean 1.5ml tube and 0.6ml isopropanol added, mixed 
and left to stand for 10 minutes. The mixture was centrifuged at 12,000 rpm for 4 
minutes at 4°C and the supernatant discarded. The pellet was washed with 1ml 
75% ethanol (Fisher Scientific, Loughborough, UK) and centrifuged at 7,500 rpm 
for 5 minutes at 4°C. The ethanol was discarded and the pellet air dried until it 
became translucent. The pellet was resuspended in 15-30pl nuclease-free water 
(Sigma-Aldrich Company Ltd, Gillingham, UK), and an aliquot (3-4pi) removed 
to measure the RNA concentration by spectrophotometry (absorbance at 260 nm).
2.2.2.2 Reverse Transcription-Polymerase Chain Reaction (RT-PCR)
Reverse transcription was carried out to make cDNA from total RNA previously 
extracted from cells. RNA (lp g), Oligo dT (n=15) primer ( lp l at 500pg/ml) 
(Promega Uk Ltd, Southampton, UK) and enough dFLO to make up to 6pl were 
mixed in a 0.2ml eppendorf tube and placed in thermal cycler (PTC-200 Peltier 
Thermal Cycler, GRI) for 10 minutes at 70°C. Reverse transcriptase (1 pi at lOU/pl 
from Promega UK Ltd, Southampton, UK), RNAse inhibitor ( lp l at 40U/pl from 
Promega UK Ltd, Southampton, UK) and 12pl reaction master mix were added 
and the tube returned to the cycler for 30 min at 42°C, followed by 70°C for 10 
minutes. The reaction master mix contained 4pl 5x RT buffer (Promega UK Ltd, 
Southampton, UK), 4pl dNTP mix (lOnM each from Roche Applied Science, 
Mannheim, Germany) and 4pl dFLO.
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PCR primers were designed to include intron/exon boundaries where possible (size 
increase indicates genomic DNA contamination), to have 50-60% guanine (G) and 
cytosine (C) content, preferably end on a G or C and be approximately 21 base 
pairs in length. Also, both primers should have an annealing temperature within 
5°C o f each other according to the equation: 4(G+C)+2(A+T)-5°C (where A and T 
are Adenine and Thymine and G and C are Guanine and Cytosine respectfully). 
Finally, primers were located on the cDNA 200bp to 1.5 Kb apart so the amplicon 
produced by PCR was clearly visible on an agarose gel.
Primers were prepared at a concentration o f  O.lpg/pl and the master mix was 
prepared using Qiagen HotStarTaq Plus kit reagents: 2.5pl lOx CL buffer (Coral 
Load buffer, pH 8.7 containing 15mM MgCh, KC1 and (NH ^SC^, gel loading 
reagent, red dye and orange dye), 0.5pi lOmM dNTPs, lp l cDNA (lpg/pl), 
18.72pl dH20 and finally 0.25pi 5U/pl Taq polymerase (Promega UK Ltd, 
Southampton, UK). The appropriate forward and reverse primers ( lp g  o f  each in 
lp l, see Table 2.2) were added to each tube, making a total reaction volume o f  
25pl. All tubes (including a water control) were put in the thermal cycler for 5 
minutes at 95 °C (enzyme activation step) and then left for 35-40 cycles (94°C 
denaturing, 59°C annealing and 72°C synthesis). Finally, the reaction was 
incubated at 72°C for 10 minutes to extend all remaining products to full length. 
PCRs were optimised by varying the annealing temperature by 1-2 degrees, and by 
varying the M gCb concentration (1.5mM to 5mM) per reaction. The conditions 
which gave the strongest amplicon o f  the correct size with least non-specific bands 
were chosen.
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Table 2.2: PCR Custom Primers (from Sigma-Aldrich Ltd, Gillingham, UK).
Gene NCBI 
Accession #
Type Prim er Sequence (5’ to 3’) Size
(bp)
SMO NM 005631 F TGC TGT GTG CCG TAT ACA TGC 1045
SMO NM 005631 R AAG TCG TAG AAG TGG CAG CTG
PTCH NM 000264 F TTA CTC ATG CTC GCC TAT GCC 998
PTCH NM 000264 R CTG GTT TCC CGA GGT ACA ATG
SHH NM 000193 F AGA TGT CTG CTG CTA GTC CTC 1043
SHH NM 000193 R AGC ACC CGG TTG ATG AGA ATG
GLI1 NM 005269 F TCA ACT CGC GAT GCA CAT CTC 1333
GLI1 NM 005269 R GTA TAG GCA GAG CTG ATG CTG
APRT NM 000485 F GCT GCG TGC TCA TCC GAA AG 277
APRT NM 000485 R CCT TAA GCG AGG TCA GCT CC
2.2.2.3 Quantitative PCR (qPCR)
This is a quantitative method o f  PCR, which enabled comparison o f  fold-change in 
gene expression between cells cultured under different conditions (e.g. in the 
presence or absence o f  recombinant EGF and/or SHH). Primers were designed as 
for conventional PCR except that the amplicons were smaller (ideally 100-250bp 
in size) to increase amplification efficiency (see Table 2.3 for qPCR primer 
sequences and amplicon sizes).
Reactions were run in a 96 well plate containing 6\i\ dH20, 12.5p,l Brilliant SYBR  
Green qPCR Mastermix (Agilent Technologies, West Lothian, UK), 1.25p.l 
forward primer (F), 1.25pl reverse primer (R) and finally 4pl (0.5, 1, or 1.5pg) 
cDNA per sample well. The primers (Custom Oligos, Sigma-Aldrich Company 
Ltd, Gillingham, UK) were made up to correct concentration (pg/pl) as per the 
optimisation procedure results. Reactions were run at 58°C using the ACt method 
on an MXP3000 thermal cycler with MX Pro software. Although the ideal 
annealing temperatures varied between primer pairs, a compromise had to be made 
to allow the house-keeping gene to be run at the same time. Since all annealing 
temperatures were within 5°C, it was possible to optimise all PCR reactions at 
58°C.
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Table 2.3: QPCR Custom Primers (from Sigma-Aldrich Ltd, Gillingham, UK).
Gene NCBI Accession 
#
Type Sequence (5’ to 3’) Size (bp)
PTCH NM 000264 F GAT GCA GAA TTC TGA AGT 
CGAC
114
PTCH NM 000264 R GAG AAA GTT CTA CAC CAT 
GCA G
EGR-3 NM 004430 F CAG GAT TAC CAC TCG GCC 
AAG
183
EGR-3 NM 004430 R GAA TGC CTT GAT GGT CTC 
CAG
IL1R2 NM 173343 F CAA GAG AGG ATT TGC ACA 
TGG
172
IL1R2 NM 173343 R CAC CGT CTG TGC ATC CAT 
ATT
S100A7 NM 002963 F CTG CTG ACG ATG ATG AAG 
GAG
177
S100A7 NM 002963 R GCT CTG CTT GTG GTA GTC 
TGT
ACTB NM 001101 F AGA AAA TCT GGC ACC ACA 
CCT
174
ACTB NM 001101 R ATA GCA CAG CCT GGA TAG 
CAA
TF2H NM 022011 F AAG TTC GAC TTG GAA TGA 
TGC G
97
TF2H NM 022011 R ATG ACA CGT CAG TCT ATT 
AGG CTT
ARP NM 001003 F AGC CGG TGT AAA TGT TGA 
GC
81
ARP NM 001003 R CAG ATG AGG CTC CCA ATG 
TT
APRT NM 009698 F GCT GCG TGC TCA TCC GAA 
AG
247
APRT NM 009698 R CCT TAA GCG AGG TCA GCT 
CC
Various cDNA and primer concentrations for each gene were run as a series o f  
different combinations to find the optimal concentration for the reaction (Table 
2.4). Further optimisation was carried out as necessary. Low Ct (threshold cycle) 
values were preferable. The Ct is the earliest detectable point above background 
levels and was calculated by the MX Pro software. A Ct at a low cycle number is 
only achievable with high levels o f  cDNA and if there is a large amount o f  the
61
gene o f  interest in the cells. Thus, lower Ct values were more easily achievable for 
housekeeping genes such as ACTB than for EGR-3, IL1-R2, S100A7 or PTCH.
Once the cDNA and primer concentrations required to achieve the lowest Ct value 
for each gene were determined, another qPCR reaction was run using a cDNA  
dilution series (neat (0.5, 1 or 1.5pg), 1:10, 1:100 and 1:1000) and the cycle 
number for each dilution was plotted against the fluorescence to create an 
amplification curve. Amplification curves for this dilution series should give four 
equally spaced plots (one for each dilution). The Ct values (determined by the MX 
Pro software) on this graph were taken for each curve and plotted again against the 
dilution (Ct against the log quantity o f  the sample) to give a standard curve. From 
this R2, slope and efficiency values were derived by the MX Pro software. For 
good optimisation, the R2 value should be as close to 1 as possible, the slope 
should be between -3.2 and -3.5 and the efficiency should be between 90 and 
110%.
Table 2.4: cDNA and Primer Concentrations for QPCR Optimisation.
cDNA (gg) Primers (gg/pl.)
1.5 0.15
1.5 0.1
1.5 0.05
1 0.15
1 0.1
1 0.05
0.5 0.15
0.5 0.1
0.5 0.05
At the end o f  the qPCR, a melting or dissociation curve was made by heating the 
reaction to denature the dsDNA (double stranded DNA), SYBR green 
fluorescence is strong when bound to dsDNA but is very low when unbound, so 
melting the dsDNA should result in one smooth curve for all replicates
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(fluorescence plotted against temperature) if  only one product was formed in the 
reaction (no contamination and no primer dimers).
After optimisation the qPCR reactions were carried out under the optimised 
conditions for each set o f  primers to find fold changes in gene expression when 
N/TERT1 cells were grown in the presence or absence o f  SHH and/or EGF and 
also presence or absence o f inhibitors (LY294002 or PD98059). The fold change 
with each treatment was plotted as bar charts by the MX Pro software for analysis.
2.2.2.4 Statistical Analysis.
Statistical analysis was done using INSTAT by Ordinary ANOVA, Parametric, 
Tukey test. This statistical test was used because it is a single step comparison o f  
whether or not the means o f all possible pairs in unrelated groups are significantly 
different from one another.
2.2.2.5 Gel Electrophoresis
PCR reactions (lOp.1) containing coral load buffer (see section 2.2.2.2) were run on 
a 1% agarose gel to compare the expression o f  genes qualitatively. A lOObp ladder 
(5jnl; New England Biolabs, Hitchin, UK) was also run alongside to estimate the 
correct amplicon size.
Agarose gels (1%) were prepared in a VWR AGT-1 horizontal gel tank with a UV 
transparent base. Briefly, 0.5g agarose (Sigma-Aldrich Company Ltd, Gillingham, 
UK) was dissolved in 50ml 2x TAE buffer containing 0.01% v/v ethidium 
bromide (5pl stock added). The stock TAE buffer (50x) contained 242g Tris 
(Fisher Scientific, Loughborough, UK), 57.1ml acetic acid (Fisher Scientific, 
Loughborough, UK) and 100ml 0.5M EDTA, adjusted to pH8 (Sigma-Aldrich 
Company Ltd, Gillingham, UK). Gels were made from 50ml o f  agarose in TAE 
and generally contained 20 wells. The gel was immersed in approximately 50ml o f  
2x TAE electrophoresis buffer and run at 50V for approximately 1 hour. The gel
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tank (UV transparent) was placed on a 365nm transilluminator and digital images 
acquired using Alphalmager HP digital camera and software.
2.2.2.6 DNA Purification using Qiagen PCR Purification Kit
DNA amplified by PCR was purified prior to sequencing using a purification kit 
(Qiagen, Crawley, UK). Five volumes o f  buffer PB were added to one volume o f  
PCR sample and mixed. A spin column was placed into a 2ml collection tube and 
the sample was applied to the column and centrifuged at 13,000 rpm for 60 
seconds at RT. The flow-through in the collection tube was discarded and the 
column placed back in the tube. Buffer PE (0.75ml) was added to column and 
centrifuged at 13,000 rpm for 60 seconds at RT to wash the DNA. Again, the flow­
through was discarded, the column put back in the tube and centrifuged at 13,000 
rpm for 1 minute at RT. The column was then placed in a clean 1.5ml tube and 
50pl buffer EB added to the centre o f  the membrane to elute the DNA. This was 
centrifuged at 13,000 rpm for 1 minute at RT.
2.2.2.7 DNA Sequencing
Sequencing was carried out to confirm that the PCR had amplified the correct 
products and the insert had been cloned in the correct orientation. The reaction mix 
contained 2pl DNA, lp l forward primer (F) (see Table 2.1), 2pl 5x sequencing 
buffer (Amersham Biosciences, GE Healthcare Life Sciences, Little Chalfont, 
UK), 2pl big dye reagent mix (Applied Biosystems, Foster City, CA, USA) and 
3 pi dH20. Reactions were placed in a thermal cycler for one cycle (96°C 1 min, 
96°C 10s, 50°C 5s, 60°C 4 min) and then 25 cycles without the initial step (96°C 
10s, 50°C 5s, 60°C 4 min). After cycling, 25pl ice cold 95% ethanol (Fisher 
Scientific, Loughborough, UK) and lp l 3M sodium acetate (Sigma-Aldrich 
Company Ltd, Gillingham, UK) were added to the reaction mix. This was kept on 
dry ice for 10 minutes and then the tube was centrifuged at 15,000 rpm for 25-30 
minutes at 4°C and the supernatant removed. An aliquot (180pl) o f  75% ethanol 
was added, the tube centrifuged at 4°C for 2 minutes and the ethanol removed.
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This procedure was repeated with another 180pl aliquot o f  75% ethanol and the 
tube centrifuged for 2 minutes at 4°C and the supernatant removed. The pellet was 
air dried for 10-15 minutes and stored at -20°C until ready for automated 
sequencing. This was provided by Central Biotechnology Services (CBS) in the 
School o f  Medicine (Andrew Francis and Keith Hart in, Henry Wellcome 
Building, School o f  Medicine, Cardiff University). Fluorograms and sequencing 
data (text) was sent by e-mail and viewed using free software (FinchTV v 1.4.0 
from Geospiza Inc).
2.2.3 Cloning
2.2.3.1 PCR Amplification o f  SHH cDNA
Primer sequences for the two separate portions o f  SHH cDNA (named SHH 5’ and 
SHH 3 ’) are shown in Table 2.5. RNA was extracted from normal skin (see 
section 2.2.2.1) and RT-PCR was carried out using various primer combinations 
and an annealing temperature o f 59°C. PCR reactions were run on 1% agarose gels 
(2.2.2.4) and viewed on a UV light box (stained with ethidium bromide).
Table 2.5: PCR Custom Primers (from Sigma-Aldrich Company Ltd, Gillingham, UK)
Gene NCBI 
Accession #
Type Sequence (5’ to 3’) Size
(bp)
SHH 5’ NM 000193 F GATGCTGCTGCTGGCGAGAT 830
SHH 5’ NM 000193 R TTGTGCGGCGCCACAAAGAG
SHH 3’ NM 000193 F CTCACTTTCCTGGACCGCGA 655
SHH 3’ NM 000193 R CTTCAGGTGGACTTGACCGC
2.2.3.2 Ligation into Cloning Vector:
PCR products from the 5 ’ and 3 ’ ends o f SHH were ligated separately into a 
cloning vector using a pGEM-T easy kit (Promega UK Ltd, Southampton, UK). 
An aliquot (5pi) o f  each PCR reaction product was mixed with lp l vector 
(50ng/pl), lp l T4 ligase (3U/pl) and 5pl 2x rapid ligation buffer (pGEM-T easy 
kit) and then incubated at 4°C overnight.
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2.2.3.3 Transformation:
The vials containing the ligation reaction were centrifuged briefly and placed on 
ice. An aliquot (50pl) o f chemically competent bacteria (One Shot Top 10 from 
Invitrogen, Paisley, UK) were thawed on ice. Two 3 pi aliquots o f each ligation 
reaction were pipetted into separate sterile tubes and 25pi o f the competent cell 
mix was added to each, mixed and incubated on ice for 30 minutes. The bacteria 
were then transformed by heat shock at 42°C for 30 seconds and then put back on 
ice. An aliquot (250pl) o f  pre-warmed S.O.C medium (Invitrogen, Paisley, UK) 
was added to each and the vials were place in a shaking incubator at 37°C for 1 
hour (shake at 300 rpm) to allow time for expression o f the ampicillin resistance 
gene before plating. An aliquot (lOOpl) o f  each transformation mix was spread on 
a separate LB agar plate containing ampicillin (1:1000 50mg/ml stock), IPTG (4pl 
0.2% IPTG (Isopropyl (3-D-1 -thiogalactopyranoside) and 40pl X-Gal (dissolved in 
dimethylformamide at 20mg/ml) for blue/white selection (Fluka Analytical, 
Sigma-Aldrich Company Ltd, Gillingham, UK). The plates were inverted and 
incubated at 37°C overnight. A white colony was removed from each plate and 
spread down half a new LB agar plate containing ampicillin (1:1000 o f  50mg/ml 
stock) and a second colony was spread on the other half o f  the plate. The plates 
were incubated at 37°C overnight. A single colony was removed from each half 
plate and placed in separate tubes containing 5ml liquid broth with 5pl 50mg/ml 
ampicillin. The tubes were incubated overnight at 37°C while shaking at 300 rpm.
2.2.3.4 Bacterial DNA Isolation by Miniprep:
A 1.5ml aliquot o f  each bacterial culture was centrifuged at 8,000rpm for 2 
minutes at RT and the supernatant was discarded. Three buffers were used from a 
Qiagen Miniprep Kit (Qiagen, Crawley, UK). PI buffer (lOOpl) was added and 
mixed, then P2 buffer (lOOpl) and finally P3 buffer (lOOpl). The solution was then 
centrifuged at 13,000 rpm for 15 minutes at RT. The supernatant was transferred 
to a fresh tube and 900pl 100% ethanol (Fisher Scientific, Loughborough, UK) 
was added and mixed. The tubes were spun at 13,000 rpm for 15 minutes at RT, 
the supernatant discarded and the DNA pellet was washed with 70% ethanol
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(500pl). The tubes were centrifuged again at 13,000 rpm for 2 minutes at RT and 
the supernatant removed. The DNA pellet was air dried and resuspended in 50pl 
TE buffer.
2.2.3.5 Restriction Digests:
Each DNA sample ( lp l)  was digested with 0.5-1 pi o f an appropriate restriction 
endonuclease (20,000/ml) (New England Biolabs, Hitchin, UK) in 2.5pl buffer (as 
appropriate) and enough dfhO to make up to a total reaction mix o f 25pl. Where 
appropriate (depending on the restriction endonuclease used), 0.5pl BSA (10 
mg/ml, from N ew  England Biolabs, Hitchin, UK) was added. This mixture was 
incubated for 1.5 hrs at 37°C and the digestion products run on a 1% agarose gel.
Double restriction digests required addition o f  0.5-1 pi o f  a second restriction 
endonuclease (New England Biolabs, Hitchin, UK), a buffer appropriate for both 
enzymes and an appropriate reduction in dH20. If the double digest failed, then 
each cut must be done separately with a clean up and DNA precipitation between 
the two reactions.
2.2.3.6 Gel Extraction of Restriction Fragments using Qiagen Gel Extraction 
Kit.
DNA fragments were excised from an agarose gel with a clean scalpel and the gel 
slice weighed in a 1.5ml eppendorf tube. Three volumes o f  QG buffer were added 
to each gel slice (300pl per lOOpg). The gel slice was incubated at 50°C for 10 
minutes and then one volume o f isopropanol was added and the sample mixed. 
This mixture was applied to a spin column in a 2ml tube and centrifuged at 13,000 
rpm for 1 minute at RT. The initial flow-through was discarded, and a further 
0.5ml o f  QG buffer was added to the spin column which was then centrifuged at 
13,000 rpm for 1 minute at RT. Then, 0.75ml o f  PE buffer was added to the spin 
column to wash o ff the QG buffer and the tubes centrifuged again at 13,000 rpm 
for 1 minute at RT. The flow-through was discarded and the tube was centrifuged 
at 13,000 rpm for another minute at RT. The spin column was then placed into a
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clean 1.5ml tube and the DNA eluted by adding 30jxl dbhO to the column 
membrane and centrifuging at 13,000 rpm for 1 minute at RT.
The two portions (5’ and 3 ’) o f SHH cDNA were then ligated together to create a 
full length version. At the start o f  this project SHH cDNA was not commercially 
available.
2.2.3.7 Subcloning:
The SHH cDNA was ligated into a pcDNA3 expression vector (Invitrogen, 
Paisley, UK), which has a neomycin resistance gene for the selection o f  
successfully transfected cells. G418 (Geneticin from Invitrogen, Paisley, UK), an 
aminoglycoside antibiotic blocks polypeptide synthesis in all cells by inhibiting 
80S ribosomal function so the cells do not survive. The neomycin resistance gene 
in cells that were successfully transfected with pcDNA3, deactivates G418 by 
phosphorylation, enabling these cells to survive. Thus, a cell line that is stably 
transfected can be selected.
pcDNA3 vector ( lp l)  was linearised by digestion (see section 2.2.3.5) with EcoRI 
( lp l, 20,000U/ml) in enzyme buffer (2.5pl) and dH20 (21.5pl). This was 
incubated for 1.5 hours at 37°C after which lp l CIP (10,000U/ml) (calf intestinal 
alkaline phosphatase from New England BioLabs, Hitchin, UK) was added to 
remove phosphate groups from the cleaved ends o f plasmid. The tube was 
incubated at 37°C for a further hour. The linearised pcDNA3 vector was then gel 
purified (see section 2.2.3.6) to remove any uncut vector. The two sections o f SHH 
cDNA which were previously cloned in pGEM-T vectors (1.5pl o f  each) were 
linearised with EcoRI and XmnI restriction enzymes (see 2.2.3.5) and ligated into 
the linearised pcDNA3 expression vector (lp l) by incubating at 4°C overnight (see 
section 2.2.3.2) with lp l T4 ligase (3U/pl) and 5pl 2x rapid ligation buffer (pGEM 
T-easy kit). To ensure they were in a 5 ’ to 3 ’ orientation, EcoRI digests were 
carried out (see 2.2.3.5) followed by sequencing.
68
2.2.3.8 Endofree Plasmid Maxi Kit
An Endofree Plasmid Maxi Kit (Qiagen, Crawley, UK) was used to purify 
endotoxin-free plasmid DNA. A single colony picked from a freshly streaked plate 
was used to make a starter culture by inoculating 3ml LB (Luria Bertani) medium 
containing 6pl ampicillin (50mg/ml) and shaking (300 rpm) in an orbital incubator 
at 37°C for 12 hours. The 250pl starter culture was placed in a 500ml conical flask 
containing 250ml LB medium and incubated in an orbital incubator at 37°C 
overnight at 300 rpm. The bacterial cells were harvested by centrifugation at 7,000 
rpm for 15 minutes at 4°C and then purified using a modified alkaline lysis 
procedure. The plasmid DNA was added to Qiagen anion-exchange resin and a 
medium-salt wash was performed to remove impurities. The plasmid DNA was 
eluted with a high salt buffer, the DNA concentrated by isopropanol precipitation 
and washed in 70% ethanol (made with endotoxin free water). The pellet was then 
resuspended in 300[il endotoxin free TE and the DNA concentration measured by 
spectrophotometry (absorbance at 260nm) before making an appropriate stock 
dilution for transfection (lpg/pl). The construct was checked by re-digestion with 
EcoRI restriction endonuclease (see 2.2.3.5) followed by sequencing.
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2.2.3.9 Electroporation (Amaxa Kit)
Culture medium was aspirated from a T75 flask o f  N/TERT1 cells grown to 80% 
confluency (see section 2.2.1.2). The cells were washed once with dPBS and then 
harvested with trypsin-EDTA. Trypsinization was stopped by adding an equal 
volume o f DMEM-F12 medium containing 10% FBS. Cells were counted using a 
haemocytometer and medium containing 2.5x106 cells was centrifuged at 1,200 
rpm for 10 minutes at RT. The supernatant was aspirated completely and the pellet 
resuspended in 100|xl nucleofector solution from the electroporation kit (Amaxa V 
from Lonza, Slough, UK) which contained 5pg o f  Tet-on advanced plasmid DNA  
(Takara Bio Europe/Clontech, Saint-Germain-en-Laye, France). The sample was 
transferred into a cuvette which was placed into the Nucleofector II (Lonza, 
Slough, UK). The U-20 program was run, which had been optimised for HaCaT 
keratinocytes (this programme was selected as both HaCaT and N/TERT1 are 
keratinocyte cell lines and time constraints did not allow separate optimisation for 
N/TERT1 cells). After electroporation, warm K-SFM medium containing 
supplements (500pl) was added to each cuvette and carefully mixed. This mixture 
was then added to two 10cm plates containing 10ml pre-warmed K-SFM medium 
(including supplements) and carefully mixed to allow even distribution o f cells.
The medium was changed after 24 hours to K-SFM plus 400pg/ml G418 per plate 
to kill all non-stable transfected cells. Medium containing G418 was then changed 
every 4 days until colonies o f stable transfected cells emerged.
2.2.3.10 N/TERT1 Transfection with MIRUS TransIT®-LTl Reagent
Cells were plated at a density o f  2 x l0 5 cells per well 24 hours prior to transfection 
in a 6 well plate containing 2ml K-SFM per well. Immediately prior to 
transfection, the serum free medium was removed and replaced with 2ml warm 
DMEM-F12 plus 10% FBS 0.2ng/ml EGF, 25|tig/ml bovine pituitary extract and 
1.5mM L-glutamine. TransIT®-LTl transfection reagent (72pl) was added to 
1500pl pre-warmed serum free medium in a sterile 5ml tube and mixed by gentle 
pipetting. After incubating at RT for 20 minutes, 14.16p.l o f  Tet-On advanced
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vector DNA (0.5pg/pl) (Takara Bio Ltd/Clontech, Saint-Germain-en-Laye, 
France) containing SHH DNA was added and mixed by gentle pipetting. This was 
then incubated at RT for 15-30 minutes. The TransIT®-LTl reagent/DNA 
complex mixture was added dropwise to each well (264.4pl/well) o f the 6 well 
plate and again mixed by gentle pipetting. Cells were then incubated for 24 hours 
at 37°C in 5% CO2 . The success rate o f  transfection was monitored by repeating 
the transfection using a control pmaxGFP vector (Amaxa, Lonza, Slough, UK) 
which contains green fluorescent protein from the Planktonic copepod Pontellina 
plumata. An aliquot (19.2pl at 0.5pg/pl) was added in the place o f Tet-On 
advanced vector containing SHH. This pmaxGFP vector makes successfully 
transfected cells fluoresce green when exposed to blue light and cells were counted 
under an inverted microscope using a GFP filter to assess the percentage o f cells 
that had been successfully transfected.
2.2.4. Polyacrylamide Gel Electrophoresis and Western Blotting
2.2.4.1 Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
SDS-PAGE was carried out using the XCell Surelock mini-cell (Invitrogen, 
Paisley, UK). Proteins were separated on an SDS gel by electrophoresis and 
transferred to a membrane for western blotting using the XCell II Blot module. 
Immunochemistry was performed to detect the presence o f  proteins and to 
compare expression and phosphorylation levels in cells under different culture 
conditions.
Cells from each well o f  a 6-well plate (2.2.1.4) were suspended in 0.9ml SDS 
sample buffer containing 4.12ml H2O, 1ml 0.5M Tris, 0.8ml glycerol, 1.6ml 10% 
SDS, 0.08ml 1M DTT and 0.2ml bromophenol blue and boiled for 5 minutes. 
Enough mixture for two 10% separating gels was made (containing 0.1ml 10% 
SDS, 2.5ml 1.5M Tris, 3.3ml 30% acrylamide gel solution (Sigma-Aldrich 
Company Ltd, Gillingham, UK), 75pi APS (ammonium persulphate from
Fisher Scientific, Loughborough, UK) and 7.5pl N ,N ,N ’,N ’-
tetramethylethylenediamine (TEMED from Sigma-Aldrich Company Ltd,
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Gillingham, UK) and 4.1ml H2O. This was pipetted into cassettes and overlaid with 
water. Once set, the water was removed and a 4% stacking gel (50pl 10% SDS, 
1.25ml 0.5M Tris, 0.65ml 30% acrylamide gel solution, 3.05ml H2O, 50pl 10% 
APS and lOpl TEMED) was added above the separating gel. A 12 prong comb 
was placed into the top o f  the cassette and after the gel had set (about 5 minutes), 
the comb was carefully removed and the wells washed with dt^O. The cassettes 
were placed into the apparatus and lx  running buffer (30g Tris, 144g glycine 
(Sigma-Aldrich Company Ltd, Gillingham, UK), lOg SDS per litre o f H2O) was 
poured into the apparatus, ensuring that the wells were full o f  buffer. The protein 
extracts (lOpl) were loaded into the wells (volumes should give equal quantities o f  
protein in each well for comparison) and molecular weight standards loaded on the 
gel (usually the end lanes). Three markers were used in combination: lOpl 
Precision Plus protein marker (Bio-rad, Hemel Hempstead, UK) or 5 pi low 
molecular weight marker (Promega UK Ltd, Southampton, UK) together with 2pl 
Magicmark (Invitrogen, Paisley, UK). The outer and inner chambers were filled 
with running buffer and 125V at a starting current o f 25mA per gel applied until 
the tracker dye reached the bottom o f  the separating gel. Cassettes were opened 
and the gel was stained with 0.25% Coomassie brilliant blue R250 (Sigma-Aldrich 
Company Ltd, Gillingham, UK) in 40% methanol (Fisher Scientific, 
Loughborough, UK) and 10% acetic acid (Fisher Scientific, Loughborough, UK) 
for one hour. The gel was then destained for 30 minutes in 40% methanol and 10% 
acetic acid. Duplicate gels were important as one was used for staining o f  the 
protein to check for even loading while the other gel remained unfixed and was 
used for western blotting.
2.2.4.2 Western Blotting
Immobilon membrane (PDVF Millipore) was immersed in methanol and then 
vigorously shaken in water to hydrate. Whatman paper and pads were soaked in 
western blot buffer (14.4g glycine, 3g Tris and 100ml methanol per litre dH20). 
Two pads were placed in the bottom o f the western blot module, then a 
gel/membrane sandwich was assembled (Whatman paper, gel, Immobilon
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membrane, Whatman paper) and placed on top o f  the pads. The module was then 
filled with further pads and the top locked. Buffer was added to the blotting 
module and the tank filled with dthO  to keep the gel cool during transfer. Transfer 
continued for 1-2 hours at 25v with a starting current o f  approximately 100mA.
2.2.4.3 Protein Detection by Immunochemistry
Western blots on Immobilon membrane were rehydrated with methanol and 
washed in water, then placed in 5% skimmed milk (Marvel, Tesco, UK) in Tris- 
buffered saline with 0.1% Tween 20 (TBST from Sigma-Aldrich Company Ltd, 
Gillingham, UK) for 1 hour to block antigenic sites. Marvel was replaced with 
10ml 5% marvel containing primary antibody (see Table 2.6 for dilutions o f  
antibodies used) for 1 hour, then washed for five times for 5 minutes in TBST. 
Another 10ml Marvel containing the secondary antibody (see Table 2.6 for 
details) was added, left to incubate for 1 hour and then the membrane was washed 
in TBST (again five times 5 minutes).
The membrane was laid on Saran wrap in the dark room and covered with ECL 
reagent for 5 minutes. The reagent was made by combining 1ml solution 1 (1ml 
250mM stock luminol (Sigma-Aldrich Company Ltd, Gillingham, UK) in DMSO, 
0.44ml 90mM coumaric acid stock (Sigma-Aldrich Company Ltd, Gillingham, 
UK) in DMSO, 10ml Tris, pH 8.5 plus dH20 to a total o f  100ml) and 1ml solution 
2 (64pl 30% H2O2 and 10ml Tris, pH8.5 plus dH20 to a total o f  100ml). The 
reagent was poured off, the membrane wrapped in Saran film and placed in a 
cassette together with sensitive X-ray film (Amersham Biosciences, GE 
Healthcare Life Sciences, Little Chalfont, UK). This was left for 2 to 10 minutes 
(longest incubation carried out first) and then the X-ray film was placed in Kodak 
D-19 developer, water and finally Kodak Processing Chemical Fixer (Sigma- 
Aldrich Ltd, Gillingham, UK).
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Table 2.6: Primary and Secondary Antibodies for Western Blotting.
Antigen C at# Company Species WB
Dilution
Storage
ERK 9102 Cell Signalling 
Technology Inc, 
Danvers, MA, USA
Rabbit 1:1000 -20°C
P-ERK 9106S Cell Signalling 
Technology Inc, 
Danvers, MA, USA
Mouse 1:1000 -20°C
Keratin 14 LL002 Gift from Prof E.B. 
Lane
Mouse 1:100 4°C
PTCH Sc1194 Santa Cruz 
Biotechnology Inc, 
Santa Cruz, CA, USA
Goat 1:100-
1:1000
4°C
SMO Sc6152 Santa Cruz 
Biotechnology Inc, 
Santa Cruz, CA, USA
Rabbit 1:100-
1:1000
4°C
Glil Sc13943 Santa Cruz 
Biotechnology Inc, 
Santa Cruz, CA, USA
Goat 1:100-
1:1000
4°C
SHH Sc6149 Santa Cruz 
Biotechnology Inc, 
Santa Cruz, CA, USA
Goat 1:100-
1:1000
4°C
Anti-Mouse
IgG-HRP
P0161 Dako UK Ltd, Ely, UK Rabbit 1:500 4°C
Anti-Rabbit 
IgG - HRP
P0127 Dako UK Ltd, Ely, UK Swine 1:500 4°C
Anti-Goat 
IgGs - HRP
A5420 Sigma-Aldrich 
Company Ltd, 
Gillingham, UK
Rabbit 1:40000 4°C
75
2.3 Results
2.3.1 SHH Signalling and Activation of the EGF Pathway.
Initially, we had to confirm that the key components o f  the SHH pathway were 
present in N/TERT1 and HaCaT keratinocyte cell lines. RT-PCR showed that 
SMO and PTCH were expressed in both N/TERT1 and HaCaT cells, although in 
HaCaT, there were miscellaneous bands in addition to a strong band o f  the correct 
size for PTCH (Figure 2.2). The product size was incorrect for SHH so it was 
concluded that this result was spurious and that no SHH was present in either cell 
line (HaCaT nor N/TERT1). Finally, GLI1 was expressed in HaCaT cells but not 
in N/TERT1 cells. GLI1 expression was relatively low suggesting there is little or 
no signalling before the addition o f commercial recombinant SHH. The absence o f  
SHH and GLI1 in N/TERT was unexpected but proved useful as PCR could be 
used to detect expression o f  SHH pathway target genes when N/TERT 1 cells were 
grown in the presence o f  recombinant SHH (see Table 2.7 for list o f  target genes 
examined). This subset o f  target genes have been specifically chosen due to the 
known increased expression in N/TERT 1 keratinocytes treated with recombinant 
EGF where GLI1 levels can be high (Kasper et al., 2006).
Ideally, western blot analysis should have been used to confirm the expression o f  
SHH pathway components. However, antibodies to these proteins (SHH, PTCH, 
SMO and GLI1) were not reliable (see Table 2.6) and could not be optimised.
In order to confirm that the EGF pathway was active after treatment o f  N/TERT 1 
keratinocytes with recombinant EGF, total protein was extracted from the treated 
cells at three time-points after treatment: 5, 10 and 20 minutes and cells with no 
EGF were used as a control. The protein extracts were separated by SDS-PAGE 
and western blots performed.
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Figure 2.2: SHH Pathway Components in Ps/TERTl and HaCaT Keratinocytes.
Ethidium bromide gel showing expression o f SHH signalling pathway components: SMO, 
PTCH, SHH and GLI1 in N/TERT1 (yellow) and HaCaT (blue) keratinocyte cells, with 
APRT control and lOObp molecular weight marker. lOpl o f each PCR product in coral 
load buffer was applied to each well.
Table 2.7: Change (foldmRNA induction) in SHH Target Genes (EGR-3, S100A7, IL-1R2 
and PTCH) in N/TERT 1 cells expressing GUI and/or EGF compared to Untreated 
Controls (data from Kasper et al., 2006).
EGF G U I EGF/GLI1
EGR-3 7.7 1.2 652.6
S100A7 2.3 9.8 1351.1
IL1-R2 2.4 9.9 999.5
PTCH -2.1 29.9 19.7
K14 is the same at all time points, which shows equal loading o f the wells because 
K14 levels should always be the same in cells o f the same type. There was little 
change in ERK1, except for a slight increase in N/TERT1 cells. ERK2 in 
N/TERT1 cells appeared to increase over time, with slightly lower ERK1/2 bands 
at the zero time point. ERK1/2 phosphorylated (N/TERT 1) was very low in 
absence o f EGF but dramatically increased in the presence o f EGF and remained
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the same for those time points. ERK1/2 in HaCaT cells remained the same at all 
time points. ERK1/2 phosphorylated in HaCaT cells was absent at the zero time 
point where EGF is absent. However, it was increased in the presence o f EGF at 
all time points. The p-ERKl band was missing at 10 and 20 minutes (Figure 2.3). 
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Figure 2.3: EGF Signalling Pathway Components in N/TERII and HaCaT 
Keratinocytes. Western blots o f ERK1/2 expression and phosphorylation in N/TERT1 (a) 
and HaCaT cells (b) at different time points after the addition o f EGF to the culture 
medium with a Magicmark protein marker. K14 control indicated equal protein sample 
loading (lOpl per well).
2.3.2. Cell Viability Tests
Baseline luminescence was extremely small in the absence o f N/TERT 1 cells 
indicating that the values achieved in the presence o f cells were a genuine measure 
o f viability (Table 2.8). The luminescence in the absence o f diluents and inhibitors 
represents the control. DMSO reduced the luminescence by about 5% but there 
was no additional effect in the presence of LY294002, this was similar to when 
DMSO was applied alone. PD98059 had a much greater effect, causing a 23% 
reduction in luminescence. The effect o f PD98059 on luminescence was increased 
in the presence o f LY294002.
44 Kb 
42 Kb
44Kb 
42 Kb
52Kb
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Table 2.8: N/TERT1 Cell Viability In the Presence o f EGF Pathway Inhibitors 
L Y294002 and/or PD98059. Cell viability decreased slightly in the presence o f  DMSO 
diluents or LY294002. However, there was a larger decrease in cell viability (23% 
reduction in luminescence) in the presence o f PD98059. Data expressed as the mean o f 4 
cell culture well replicates for each treatment. RLU = Relative Light Unit
Control (no 
DMSO, no 
inhibitors)
DMSO
(no
inhibitor
control)
20pM
LY294002
20pM
PD98059
20pM 
LY29400 
2 +
20pM
PD98059
Luminescence
(RLU)
489542 464784 473072 377220 314754
% Reduction 
Luminescence
0 5.06 3.36 22.94 35.70
Reduction -24,758 -16,470 -112,322 -174,788
2.3.3 N/TERT1 Cells treated with Recombinant SHH, EGF and EGF  
Pathway Inhibitors (PD98059 and LY294002).
Although the key components (PTCH and SMO) o f  the SHH pathway were 
present in N/TERT1 and HaCaT cell lines, it was important to confirm that the 
pathway could be activated.
The N/TERT 1 cells were grown and treated with recombinant SHH and/or EGF 
and then treated with LY294002 and/or PD98059 as described in the methods. 
Expression o f  K14 (control), EGR-3, PTCH and S100A7 was examined by RT- 
PCR (Figure 2.3). The data shown in Figure 2.3 was also analysed using Image J 
density gradient software (http://rsbweb.nih.gov/ij/) and the results were 
normalised against the K14 control data. This software was also used to compare 
reproducibility in the duplicate experiments shown. This programme measured the 
density over the area o f  bands on a DNA gel, which were then used to calculate
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the relative band density compared to the control (K14) and the data was then 
displayed in graphic form using Microsoft Excel (see Figures 2.4 to 2.6).
K14 levels are equal in all circumstances (Figure 2.3 and 2.4). PTCH was 
increased with SHH but this increase was blocked by EGF. PTCH was also 
increased with LY294002, but this increase was blocked by SHH and reduced by 
EGF. However, PTCH levels in the presence o f  PD98059 with LY294002 were 
similar to the control, with both arms o f  the EGF pathway inhibited.
EGR-3 was slightly increased in the presence o f  SHH but there was a greater 
increase in the presence o f  EGF. LY294002 completely blocked EGR-3 
expression, whereas PD98059 had no effect on the control but blocked EGR-3 in 
the presence o f  SHH or EGF. LY294002 and PD98059 combined completely 
blocked EGR-3 except when both SHH and EGF were present.
S100A7 was low in the control but increased in the presence o f  SHH or EGF. 
LY294002 caused the S100A7 control to increase. SHH or EGF increased S100A7 
further but the level was reduced when both were present. PD98059 had little 
effect on S100A7 and knocked down the effect o f LY294002 when both were 
applied. These change differed slightly between the two samples for each gene.
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Figure 2.4: RT-PCR o f SHH Target Genes (PTCH, EGR-3 and S100A7) and K14 
Control in N/TERT1 Cells. Stimulation with EGF and/or SHH for 24 hours in the 
presence and absence of EGF signalling inhibitors (LY294002 and/or PD98059). 
Duplicate experiments are shown.
There is variation between the two experiments (yellow is the first and blue is the 
second experiment). PTCH was increased with SHH, whereas EGF alone had no 
effect. However, EGF blocked the increase in PTCH caused by SHH (Figure 
2.4a). LY294002 blocked PTCH expression in the presence o f SHH and/or EGF, 
but PTCH was increased in the control cells (Figure 2.4b). PD98059 reduced 
PTCH expression slightly, blocked the SHH induced increase in PTCH, but had 
little effect on EGF modulation o f PTCH (Figure 2.4c). PD98059 and LY294002 
interfere with one another so PTCH levels in the presence o f SHH were higher and 
almost returned to the levels seen in the absence of inhibitors (Figure 2.4d).
_ + + _ _ + + _ _ + + -  + + _ 
-  -  + + _ + + - -  + + +
K14 PTCH EGR-3 S100A7
- - + + - . +  + - - + + - - + +
K14 PTCH EGR-3 S100A7
81
(a) PTCH (no inNMora)
10000
9000
8000
7000
6000
5000
4000
3000
2000
10000 1 r I
SHH+EGF EGF
(c)
SHH and/or E GF treatments
PTCH (P09S059)
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0 Jd
(b) PTCH (LY214*02)
10000
9000
8000
7000
6000
5000
4000
3000
2000
10000 rC L
(d)
SHH and/or EGF treatment*
PTCH (LY294002 and Pd98«5»)
10000
9000
8000
7000
6000
5000
4000
3000
2000
1000
0 J Z t L
SHH and/or EGF treatments SHH and/or EGF treatment*
Figure 2.5: Relative expression o f PTCH in N/TERT 1 Keratinocytes treated with 
Recombinant SHH and/or EGF in the Presence or Absence o f Inhibitors (LY294002 
and/or PD98059). Graphs show PTCH expression in two PCR experiments: blue bars 
represent one experiment (top part of Figure 2.3) while the yellow bars represent the 
other (bottom part o f  Figure 2.3).
EGR-3 was increased in the presence o f SHH or EGF, but this effect was neither 
additive nor synergistic (Figure 2.5a). LY294002 totally blocked EGR-3 
expression and inhibited the effect o f SHH or EGF (Figure 2.5b). However, 
PD98059 had little effect in the absence o f SHH or EGF but totally blocked EGR- 
3 expression in their presence (Figure 2.5c). This block was relieved in the 
presence o f SHH and EGF together when both inhibitors were used (Figure 2.5d).
These results suggest that there may be some SHH pathway activity and the small 
increase in expression in the presence o f both SHH and EGF may be evidence o f a 
mild synergistic effect but nowhere near as large as described by Kasper et al 
(2006).
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Figure 2.6: Relative Expression o f EGR-3 in N/TERT 1 Keratinocytes treated with 
Recombinant SHH and/or EGF in the Presence or Absence o f Inhibitors (LY294002 
and/or PD98059). Graphs show EGF-3 expression in two PCR experiments: blue bars 
represent one experiment (top part o f Figure 2.3) while the yellow bars represent the 
other (bottom part o f Figure 2.3).
S100A7 was increased by SHH or EGF, but together they only caused a small 
increase in S100A7 which was not additive (Figure 2.6a). LY294002 increased 
S100A7 expression slightly in the absence and to a greater extent in the presence 
o f SHH or EGF but there was little effect when both SHH and EGF were present 
(Figure 2.6b). PD98059 increased S100A7 but SHH had no additional effect, 
whereas EGF did increase S100A7 slightly, but this was lost when both were 
applied together (Figure 2.6c). The positive effect o f LY294002 was lost in the 
presence o f PD98059 (Figure 2.6d).
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Figure 2.7: Relative Expression o f S100A7 in N/TERT 1 Keratinocytes treated with 
Recombinant SHH and/or EGF in the Presence or Absence o f Inhibitors (LY294002 
and/or PD98059). Graphs show S100A7 expression in two PCR experiments: blue bars 
represent one experiment (top part o f Figure 2.3) while the yellow bars represent the 
other (bottom part o f Figure 2.3).
2.3.3.1 Quantitative PCR (qPCR)
Conventional PCR did not identify the large changes in expression o f GLI1 and 
EGF target genes observed by Kasper et al. (2006) but some small differences 
were apparent. These would be difficult to evaluate by conventional RT-PCR, so 
quantitative analysis was performed by qPCR to measure the fold change in gene 
expression.
The expression o f three GLI/EGF target genes (EGR-3, IL-1R2 and S100A7) and 
(one SHH target gene PTCH) was assessed in N/TERT 1 cultures by qPCR 
following primer optimisation. Cells were stimulated with recombinant SHH 
and/or EGF and then treated with either a PI3K inhibitor (LY294002) or a MEK 
inhibitor (PD98059). Each experiment was done in the presence and absence of
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inducers (SHH or EGF) and in the presence and absence o f  inhibitors (LY294002 
or PD98059) together with control data. In this way, any effect o f the inhibitors on 
gene expression could be assessed.
2.3.3.1.1 Selection o f a Suitable Housekeeping Gene
Three housekeeping genes were selected and primer pairs were optimised for 
qPCR: transcription factor IIH (TF2H), actin related protein (ARP) and adenine 
phosphoribosyl transferase (APRT). Expression o f these three genes was then 
measured during stimulation o f N/TERT 1 cells by SHH and/or EGF and any effect 
o f  the inhibitors (LY294002 and PD98059) assessed.
In all three cases, the housekeeping genes showed a major reduction in expression 
(up to 10,000 fold) when cells were treated with both inhibitors together (Figure 
2.7). Based on these results, it became clear that by inhibiting both sides o f the 
EGF pathway, expression o f many genes in the N/TERT 1 cell line are affected. 
This is a consideration with regards to the potential toxicity o f  the proposed 
formulation. The combined LY294002/PD98059 treatment was therefore not 
continued in further experiments.
Table 2.9 shows the combinations o f  recombinant SHH and/or EGF or no 
recombinant proteins applied to N/TERT 1 keratinocytes. There are four replicates 
for these combinations where N/TERT 1 cells were grown in the absence o f  
inhibitors or the presence o f PI3K inhibitor LY294002 and/or MEK inhibitor 
PD98059 in addition to the SHH and/or EGF recombinant proteins. Due to the 
complexity o f qPCR amplification plots for these experiments, a key is included in 
this table to make it clearer what each plot represents.
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Table 2.9: Combinations of recombinant SHH, EGF and signal transduction pathway
inhibitors used to treat keratinocytes.
Inhibitors Plate
no.
SHH EGF Key to amplification plots
No Inhibitors 1 - - Brown square (solid)
2 + - Blue circle (solid)
3 + + Brown triangle (open)
4 - + Turquoise diamond (open)
LY294002 5 - - Orange triangle inverted (solid)
6 + - Grey diamond (solid)
7 + + Yellow star
8 - + Purple square (open)
PD98059 9 - - Green inverted triangle (open)
10 + - Green triangle (solid)
11 + + Orange star
12 - + Grey circle (solid)
LY294002+PD98059 13 - - Purple diamond (solid)
14 + - Olive square (solid)
15 + + Blue-green triangle (solid)
16 - + Orange star
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Figure 2.8: QPCR Data fo r  Housekeeping Gene Expression in N/TERT 1 Keratinocytes.
Amplification plots for TF2H, ARP and APRT showing expression in cultured cells in the 
presence o f LY294002 and/or PD98059. In all three cases, expression was dramatically 
decreased in the presence o f both inhibitors (LY294002 and PD98059, shown in purple, 
olive green, cyan and orange, see Table 2.9 for key).
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Optimisation o f ACTB ((3-actin) primers also showed outlying curves in the 
amplification plots when LY294002 and PD98059 were both present. However, 
when these treatments were not included all the Ct (cycle threshold) values were 
clustered together and the p-actin gene maintained stable expression (Figure 2.8). 
The alternative housekeeping genes would have also been useful where 
experiments using both inhibitors in combination were not included, however 
ACTB was chosen because the amplification plots were close together giving very 
similar Ct values at a low number of cycles.
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Figure 2.9: QPCR Data for ACTB (Housekeeping Gene) Expression in N/TERT I 
Keratinocytes. Amplification plots after optimisation o f cDNA from SHH and/or EGF 
stimulated N/TERT 1 keratinocytes treated with inhibitors (LY294002 or PD98059). ACTB 
expression remained stable in N/TERT I keratinocytes under these treatment regimes.
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2.3.3.1.2. ACTB (P-actin) Optimisation
QPCR is used to measure DNA amplification because it can give more accurate 
results than end point PCR, which may continue and give results which are past 
the exponential phase o f the reaction. In qPCR, the fluorescence caused by binding 
o f  Sybr Green is measured throughout the reaction. Fluorescence increases by 
1000 fold When Sybr Green binds double stranded DNA. Measurements are used 
at the threshold cycle (Ct), which is the cycle at which fluorescence is determined 
to be statistically significant above the background. It is more accurate to measure 
the Ct value because this is the exponential phase o f the qPCR rather than the 
endpoint o f  a PCR cycle and endpoint values can be influenced by limiting 
reagents, cycling parameter differences or reaction components. Lower Ct values 
are preferable because primer dimers are more likely to occur at later timepoints, 
but high Ct values can be caused by low levels o f  DNA. QPCR optimisation 
means that it is possible to check for primer dimers, chose the conditions required 
for a low Ct value and make sure the experiment will be as accurate as possible 
using a housekeeping gene which maintains the same Ct value under all 
conditions.
The lowest Ct value for ACTB primers was obtained with lp g  cDNA and 1.5 pg 
ACTB primers, therefore, further optimisation around these values was continued. 
The dissociation or melting curve for the ACTB primers (Figure 2.9a) shows that 
when the amplification products o f QPCR were heated, there was only one melting 
point. This means that there was one product and therefore no primer dimers 
interfering with the results. The amplification plot for ACTB shows that at serial 
cDNA dilutions o f  1, 1:10, 1:100 and l:1000pg/pl, the plots were evenly spaced 
(Figure 2.9b). The Ct values taken from the amplification plots with the serial 
dilutions were then plotted against the cDNA concentrations used to make the 
standard curve, which should have an efficiency as close to 100% as possible and 
an R2 value as close to 1 as possible for the most accurate qPCR experiments. The 
standard curve for ACTB was very good, staying within the recommended range
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and thus qPCR carried out under the optimised conditions should give very 
accurate results (Figure 2.9c).
The levels o f each gene (EGR-3, IL1-R2, PTCH1 and S100A7, see Table 2.2 for 
primer sequences) when N/TERT1 cells had been treated with SHH, EGF and 
inhibitors (Table 2.9) were normalised to the levels of housekeeping gene ACTB, 
which always remains constant. The effect o f SHH, EGF, LY294002 and 
PD98059 treatments could then be compared graphically.
(a) Dissociation Curve b) Amplification Plot
(c) Standard Curve
Figure 2.10: Optimisation o f ACTB primers with cDNA from  N/TERT1 keratinocytes.
(A) dissociation curve for ACTB primers with N/TERT1 cDNA; (B) Dilution series of 
N/TERT 1 cDNA neat (l.5pg) cDNA (blue), 1:10 dilution cDNA (red), 1:100 dilution 
cDNA (green) and 1:1000 dilution cDNA (grey) with ACTB primers (C) Standard curve 
for N/TERT 1 cDNA dilution series with ACTB primers.
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p-actin is abundant in keratinocytes because it is a cytoskeletal protein and so a 
relatively low Ct value can be obtained by optimisation o f  the qPCR reaction. 
However, EGR-3, IL1-R2, S100A7 and PTCH are present in much lower amounts 
and so this makes it much harder to optimise those primers for qPCR because very 
large amounts o f  cDNA would be required.
2.3.3.1.3 EGR-3 optimisation for N/TERT1 keratinocytes.
2pg cDNA and lp g  EGR-3 primers gave the lowest Ct value so these 
concentrations were used for further qPCR o f  this gene. The dissociation curve 
showed a small extra curve (blue line), which may be caused by some 
contamination or primer dimerisation, but the rest o f the lines follow one curve so 
have no contamination or primer dimers (Figure 2.10a). The amplification plots 
show that the dilutions did not have equal spacing between them (Figure 2.10b) 
and although the R2 value was 0.995, the slope and efficiency could not be 
optimised to within the suggested limits o f  between -3.2 and -3.5 slope and 
between 90-110% efficiency, although optimisation was repeated several times 
(Figure 2.10c). This may lead to reduced accuracy in the results for expression o f  
this gene.
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Figure 2.11: Optimisation o f EGR-3 Primers and N/TERT 1 Keratinocyte cDNA. (a)
Dissociation curve for N/TERT 1 cDNA with EGR-3 primers, (b) Amplification plot of 
dilution series o f N/TERT1 cDNA neat (1.5pg) cDNA (blue), 1:10 dilution cDNA (red), 
1:100 dilution cDNA (green) and 1:1000 dilution cDNA (grey) and EGR-3 primers, (c) 
Standard curve for N/TERT 1 cDNA dilution with EGR-3 primers.
2.3.3.1.4 Effect o f SHH/EGF on EGR-3 expression in N/TERT1 keratinocytes.
Having optimised the EGR-3 and ACTB housekeeping gene primers, qPCR was 
run with the N/TERT 1 cDNA to compare EGR-3 expression under different 
conditions (for treatments with SHH/EGF and/or inhibitors see Table 2.9). There 
were two control conditions used, the first was from untreated N/TERT 1 cells and 
the second was not treated with SHH or EGF but was one or both inhibitors were 
applied (Figure 2.11b and c)
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EGR-3 levels did not significantly change in the presence o f  SHH and/or EGF 
when no inhibitors were present (Figure 2.11a). The PI3K inhibitor (LY294002) 
increased EGR-3 levels in response to SHH (-2  fold, p=0.05) or EGF (~1.5 fold, 
NS) compared to both controls. However, in combination SHH and EGF action 
was blocked (EGR-3 levels in the presence o f  SHH were significantly greater than 
SHH and EGF in combination, p=<0.001). The control in the presence o f  
LY294002 (PI3K inhibitor) caused reduced expression (0.5 fold EGR-3 
expression) compared to the control where no inhibitors were present (1 fold EGR- 
3 expression) but this was not significant. MEK inhibitor PD98059, reduced EGR- 
3 expression in the control and in the presence o f SHH and/or EGF (p=<0.001 for 
all) compared to the control where no inhibitors were present (Figure 2.11).
The large-fold increase in EGR-3 seen by Kasper et al. (2006) when cells are 
treated with both GLI1 and EGF is not reproduced in the current work with 
presence o f both recombinant SHH and recombinant EGF in N/TERT 1 medium. 
The 7.7 fold increase in EGR-3 expression in the presence o f  EGF alone which 
was shown by Kasper et al. (2006) was also not shown in the qPCR results o f  the 
current work (Figure. 2.11 A).
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Figure 2.12: Relative Fold Change (qPCR) in EGR-3 Levels in N/TERT I Cells treated 
with SHH and/or EGF in the Presence or Absence o f Inhibitors (PD98059 or 
LY294002). Relative fo ld  change in EGR-3 levels determined by qPCR in the absence (a) 
and presence o f two inhibitors, LY294002 (b) and PD98059 (c). Each bar represents data 
in the absence o f SHH and EGF (control), presence of either SHH or EGF or both. 
Statistical analysis was done by Ordinary ANOVA, Tukey test. * P=<0.05, ** P=<0.005, 
*** p=<o.001. Data expressed as a mean +/- SD for n=3 experiments with 3 replicates 
for each experiment.
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2.3.3.1.5 IL1R2 optimisation.
2pg cDNA and 0.5pg IL1R2 primers gave the lowest Ct value for qPCR so these 
concentrations were used for further qPCR of this gene. Optimisation provided a 
dissociation curve which showed a small peak in front o f the large clean peak for 
the melting o f the amplification products, which means there may have been a 
primer dimer or contamination in the qPCR reaction (Figure 2.12a). The dilution 
series reactions showed that the final curve (1:1000 dilution) had a very late Ct 
value which meant it didn’t even fit on the graph (Figure 2.12b). However, the 
first three Ct values for the dilution series were plotted against the dilution the 
slope and efficiency fell within the suggested guidelines (Figure 2.12c), which 
would mean that the accuracy o f qPCR experiments for this gene was high.
(a) Dissociation Curve (b) Amplification Plot
Figure 2.13: Optimisation o f 1L-1R2 Primers and N/TERT 1 Keratinocyte cDNA. (A)
Dissociation curve for N/TERT1 cDNA with IL-1R2 primers (B) Dilution series of 
N/TERT1 cDNA: neat (1.5pg) cDNA (blue), 1:10 dilution cDNA (red), 1:100 dilution 
cDNA (green) and 1:1000 dilution cDNA (grey) with IL-1R2 primers (C) Standard curve 
for N/TERT 1 cDNA dilution series with IL-1R2 primers.
(c) Standard Curve
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Slope = -3.37 
Eff = 98%
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2.3.3.1.6 Effect o f SHH/EGF on IL1R2 expression
SHH caused no significant increase in IL1R2 levels. EGF caused a 5 fold increase 
(p=<0.001), but the effect o f EGF on IL1R2 was inhibited slightly by SHH 
(p=<0.001 when compared to the control) (Figure 2.13a).
PI3K inhibitor LY294002 led to no change in IL1R2 levels for the control or in the 
presence o f  SHH compared to the control where no inhibitors were present. EGF 
caused a 2 fold increase (p=<0.005) and there was an additive increase (~3 fold) 
when both SHH and EGF in were applied (p=<0.001). IL1R2 levels in the 
presence o f SHH and EGF are significantly greater than in the presence o f  SHH 
(p=<0.001) or EGF (p=<0.005) individually (Figure 2.12b).
MEK inhibitor PD98059 did not effect the IL1R2 levels in the controls. SHH did 
not effect IL1R2 either. EGF increased IL1R2 3 fold (p=<0.005) which was 
maintained in the presence o f SHH (p=<0.005). This was also significantly 
increased compared to in the presence o f  SHH (p=<0.001) (Figure 2.13c).
As with EGR-3, IL1R2 expression did not show the large fold increase seen by 
Kasper et al. (2006) when SHH and EGF in combination was used to treat the 
cells.
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Figure 2.14: Relative Fold Change (qPCR) in IL-1R2 Levels in N/TERT1 Cells treated 
with SHH and/or EGF in the Presence or Absence o f Inhibitors (PD98059 or 
LY294002). Relative fold change in IL1-R2 levels determined by qPCR in the absence (a) 
and presence o f two inhibitors, LY294002 (b) and PD98059 (c). Each bar represents data 
in the absence o f SHH and EGF (control), presence of either SHH or EGF or both. 
Statistical analysis was done by Ordinary ANOVA, Tukey test. * P=<0.05, ** P=<0.005, 
*** P=<0.001. Data expressed as a mean +/- SD for n=3 experiments with 3 replicates 
for each experiment.
2.3.3.1.7 S100A7 optimisation.
2pg cDNA and 1.5pig S100A7 primers gave the earliest Ct values so these 
concentrations were used for further qPCR of this gene (Figure 2.15b). 
Optimisation provided a clean dissociation curve which shows no primer dimers or 
contamination in the qPCR reaction (Figure 2.15a). However, the qPCR with a 
dilution series did not give curves at equal intervals reactions and the Ct values 
were still not early enough for a very efficient qPCR, probably due to the low 
levels of S100A7 in these cells (Figure 2.15b). Optimisation did not enable slope
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and efficiency to fall within the suggested guidelines even after repeating 
optimisation several times (Figure 2.15c), which may reduce accuracy o f QPCR 
experiments for this gene, again poor qPCR may be due to the low levels of 
S100A7 present.
(a) Dissociation Curve (b) Amplification Plot
(c) Standard Curve
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Figure 2.15: Optimisation o f S100A7 Primers and N/TERT1 Keratinocyte cDNA. (A)
Dissociation curve for N/TERT1 cDNA with S100A7 primers. (B) Dilution series of 
N/TERT 1 cDNA using 1.5/ug cDNA (blue), 1:10 dilution (red), 1:100 dilution(green) and 
1:1000 dilution (grey) with S100A7 primers. (C) Standard curve for N/TERT1 cDNA 
dilution series and SI00A 7 primers.
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2.3.3.1.8 Effect of SHH/EGF on S100A7 expression in N/TERT1 
keratinocytes.
SHH increased S100A7 expression 4 fold (NS) and EGF increased S100A7 12 
fold when compared to the control (p=<0.001). However, SHH blocked the effect 
o f  EGF (Figure 2.15A).
LY294002 (PI3K inhibitor) increased S100A7 1 fold (p=0.05). SHH had little 
effect, but EGF slightly increased S100A7 (p=0.05) and in combination with SHH 
there was an additive increase in S100A7 (p=0.001), which was also significantly 
larger than in the presence o f  either SHH (p=0.001) or EGF (p=0.005) (Figure 
2.15B).
PD98059 (MEK inhibitor) increased S100A7 4 fold (p=0.001). The addition o f  
SHH had little effect, EGF increased S100A7 4 fold and with SHH and EGF in 
combination the increase was 5 fold (NS; Figure 2.15C).
2.3.3.1.9 PTCH Optimisation
The 2pg cDNA and lpg PTCH primers gave the earliest Ct value so these 
concentrations were used for further qPCR optimisation for this gene. PTCH 
primer optimisation gave dissociation curves with a small peak ahead o f  the main 
large clean melting curve for each o f the treatments (SHH and/or EGF and/or 
inhibitors) which means there may have been primer dimers or contamination in 
the qPCR reaction (Figure 2.16a). The amplification plots gave equally spaced Ct 
values and therefore good slope and efficiency levels were derived from the 
standard curve (Figures 2.16b and c). These should give accurate results PTCH 
levels by qPCR.
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Figure 2.16: Relative Fold Change (qPCR) in S100A 7 Levels in N/TERTl Cells treated 
with SHH and/or EGF in the Presence or Absence o f Inhibitors (PD98059 or 
LY294002). Relative fold change in S100A7 levels determined by qPCR in the absence (a) 
and presence o f two inhibitors, LY294002 (b) and PD98059 (c). Each bar represents data 
in the absence o f SHH and EGF (control), presence of either SHH or EGF or both. 
Statistical analysis was done by Ordinary ANOVA, Tukey test. * P=<0.05, ** P=<0.005, 
*** p= < o .001. Data expressed as a mean +/- SD for n=3 experiments with 3 replicates 
for each experiment.
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Figure 2.17: Optimisation o f  PTC H  prim ers on N /TE R T1 keratinocytes. (A)
Dissociation curve for N/TERT 1 cDNA with PTCH primers. (B) Dilution series o f  
N/TERT1 cDNA using 1.5fig cDNA (blue), 1:10 dilution (red), 1:100 dilution(green) and 
1:1000 dilution (grey) with PTCH primers. (C) Standard curve for N/TERT1 cDNA 
dilution series and PTCH primers.
2.3.3.1.10 Effect of SHH/EGF on expression of PTCH in N/TERT1 
keratinocytes.
SHH and/or EGF caused little change in PTCH levels (NS). However, PI3K 
inhibitor LY294002 decreased PTCH 0.2 fold, SHH had little effect and EGF 
decreased PTCH 0.4 fold, this effect was additive when both were present in 
combination with a 0.2 fold decrease in PTCH (NS). MEK inhibitor PD98059 
caused a 0.4 fold increase in PTCH, SHH and EGF had little effect but when 
present in combination there was a 0.2 fold decrease in PTCH levels.
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Figure 2.18: Relative Fold Change (qPCR) in PTCH Levels in N/TERT1 Cells treated 
with SHH and/or EGF in the Presence or Absence o f Inhibitors (PD98059 or 
LY294002). Relative fold change in PTCH levels determined by qPCR in the absence (a) 
and presence o f two inhibitors, LY294002 (b) and PD98059 (c). Each bar represents data 
in the absence o f SHH and EGF (control), presence o f either SHH or EGF or both. 
Statistical analysis was done by Ordinary AN OVA, Tukey test. * P=<0.05, ** P =<0.005, 
*** p=<o.001. Data expressed as a mean +/- SD for n=3 experiments with 3 replicates 
for each experiment.
Figure 2.17A shows no increase in gene expression in the presence o f SHH 
comparable to GLI overexpression (see Table 2.5) (Kasper et al. 2006). This 
seems to suggest a lack of activation of the SHH pathway by addition of 
recombinant SHH to N/TERT1 cells, as PTCH is a target gene upregulated in the 
event of SHH pathway activation that is important in negative feedback of the 
pathway.
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There was also no significant inhibition o f PTCH by EGF observed in GLI over­
expressing cells. Consistent with this LY294002 or PD98059 also have little effect 
on PTCH expression (Figure 2.17 B, C). Thus not confirming the conventional 
PCR data (see Figures 2.4,2.5).
The results for QPCR were not as expected. Not one o f the genes shows the large 
fold increases in gene expression for cells treated with both recombinant SHH and 
EGF in combination compared to SHH or EGF treatments individually, which was 
reported with GLI1 and EGF by Kasper et al. (2006). The unexpected results 
obtained by conventional PCR when N/TERT1 cells were treated with EGF 
pathway inhibitors, LY294002 and PD98059 including a decrease in PTCH and 
EGR-3 in the presence o f PD98059 or LY294002 were not confirmed by QPCR 
analysis.
2.3.4 Cloning
As the SHH gene is GC rich, it proved difficult to amplify a full length copy so the 
cDNA was amplified in two overlapping sections. The 5’ section was 830bp in 
length and the 3 ’ section was 655bp. They were cloned separately in the pGEM-T 
easy cloning vector. The overlapping region contained an XmnI site that cuts SHH 
only once and allows the two sections to be ligated together to create the full 
length cDNA (Figure 2.1 in methods).
The two separate pieces o f the SHH cDNA were released from the pGEM-T easy 
vector with a double digest (XmnI and EcoRI). However, since there is an XmnI 
site in the pGem-T easy vector, this digest resulted in three bands (Figure 2.19). 
Ideally the pGEM-T easy vector would have been cut on its own to prove that it 
has an XmnI site and therefore is cut into two pieces. After this digest pGEM-T 
easy should also have been run on the same gel as the two SHH sections to show 
that the two upper bands in the first and second lanes are definitely pGEM-T easy 
vector. The products were sequenced to check that there were no polymorphisms
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and XmnI sites at the beginning and end o f the SHH sections can be seen in 
Figures 2.20 and 2.21.
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Figure 2.19: Xmnl/EcoRl Double Digests fo r Sub-cloning into pcDi\A3. Xmnl/EcoRI 
restriction digest o f pGEM-T Easy DNA clones o f the 3 ’ section o f SHH (A) and the 5 ’ 
section o f the SHH cDNA (B) and EcoRI linearised pcDNA3 (C). The required SHH 
cDNA sections of655bp and 830bp are highlighted by the red boxes.
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Figure 2.20: XmnI site present near the beginning o f sequence for the bottom half of 
SHH sequenced with T7 primer. XmnI site is highlighted in blue.
104
« i - l - I  i I l - n - 1  t i
C G G C G C C  A A G A A G G T C T T  C T A C G T  G A T C G A  
720 730 740
Figure 2.21: XmnI site was present near the end of the bottom section o f SHH sequence 
with a SHH2F primer. XmnI site is highlighted in blue, however, the DNA levels appear 
low.
The two sections were then ligated together and then ligated into the EcoRI site 
(within multiple cloning site) o f the pcDNA3 eukaryotic expression vector. 
Restriction digestion was also used to confirm the successful ligation of the full 
length SHH cDNA in to the expression vector (Figure 2.22). Sequencing 
confirmed which clones were successful in achieving the top section of SHH 
ligated to the bottom section at the XmnI site rather than two top sections or two 
bottom sections ligated together (correct orientation) (Figure 2.23). The 
sequencing was also used to confirm that no polymorphisms had been introduced 
into the sequence during transformation. A portion of SHH sequence and pcDNA3 
sequence are shown in Figure 2.24.
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Figure 2.22: Full Length SHH cDNA Cloned into the pcDNA3 Plasmid. DNA was
isolated from each o f the six clones (1-6) and cut with EcoRl. The pcDNA3 vector 
(5446bp) is present in all lanes but ligated SHH DNA (1485bp) is only present in samples 
3, 4 and 6 (highlighted by red box).
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Figure 2.23: Top and bottom sections ligated in the correct orientation as shown by 
sequencing data. XmnI sites successfully ligated together (highlighted in blue) The top 
section o f SHH is on the right o f the XmnI site, the bottom section on the left. The quality 
of the trace is poor possibly due to low DNA levels.
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Figure 2.24: EcoRI and SHH sequences.
Good quality sequence data.
Figure 2.25: EcoRI sequence leads onto SHH sequence (2F primer). Full length SHH 
successfully transfected into pcDNA3 expression vector (sequence highlighted yellow) at 
EcoRI site (sequence highlighted blue).
Although SHH was cloned successfully, attempts to transfect N/TERT1 cells were 
unsuccessful due to time limitations and cell culture infections. Two methods o f 
transfection were tried during the course of this study using a Tet-on vector 
including electroporation and Mirus transfection reagent. A GFP control vector 
was used to assess transfection efficiency. The electroporation conditions used 
were those recommended for the HaCaT cell line (not optimised to N/TERT1 
because both are keratinocytes and also due to time constraints) and therefore not 
necessarily ideal. After G418 selection no cells survived to form colonies. 
Therefore the Mirus method was attempted since this had been used successfully 
by others using N/TERT-1. Low levels o f GFP (Figure 2.26) were observed but on 
subculturing, changes in cell morphology occurred suggested the cells had been 
stressed so selection was not continued.
Due to the problems encountered and the time-consuming double selection 
required for the creating a Tet-on stable cell line SHH was cloned as described into 
pcDNA3. However, before creating an over-expressing cell line, further 
optimisation o f transfection o f N/TERT-1 with different reagents or 
electroporation conditions would be required.
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Figure 2.26: N/TERT1 cells Transfected with GFP Vector using Mirus Agent. (A)
N/TERT1 cells showed normal morphology at ~70-80% confluency [IOx magnification] 
(B) Low number o f N/TERT1 cells expressing GFP indicates poor transfection efficiency 
[lOx magnification with green filter].
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2.4 Discussion
Kasper et al. (2006) found particularly large increases in the expression o f a subset 
o f  SHH target genes (EGR-3, S100A7, IL1-R2) in N/TERT1 keratinocytes with 
doxycycline-induced overexpression o f GLI1, and the addition o f recombinant 
EGF (see Table 2.7). PTCH transcription was also up-regulated by GLI1 so up- 
regulation by SHH pathway activation alone would be expected (Daya-Grosjean 
and Couve-Privat, 2005). These genes were therefore used as markers for 
SHH/EGF pathway activation. If recombinant SHH and EGF applied to the 
N/TERT1 cells in combination showed a large increase in these target genes then 
inhibitors to SHH and EGF signalling may be useful for treating BCC.
Decreased cell viability in the presence o f PD98059 may have caused altered gene 
expression as death signalling pathways, which include parts o f  the EGF signalling 
pathway would have been activated in the cells (Jin and El-Deiry., 2005). 
However, cDNA quantities were carefully measured and equalised prior to PCR, 
so reduced cell numbers would not have affected the quantity o f  DNA actually 
used in the study. It would also have been a good idea to carry out these cell 
viability tests in the presence o f the recombinant SHH and EGF which were added 
to the cells.
Activity o f  the EGF pathway was confirmed only for the MEK/ERK branch, but it 
would also have been useful to confirm activity o f  the PI3K/AKT by looking at 
AKT phosphorylation after EGF addition by western blotting prior to use o f  the 
PI3K inhibitor LY294002 in this study.
The response to PD98059 and LY294002 in the conventional PCR experiments 
showed complete inhibition o f  PTCH and EGR-3 in the presence o f  SHH, this 
appears to be unrelated to EGF signalling. Since these are not confirmed by qPCR 
they should be interpreted with caution. These PCRs had to be carried out at 35-40 
cycles to be visable, a point at which PCRs are not quantitative. In addition it is
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impossible to know, using conventional methods, whether these reactions are 
efficient at all concentrations o f  the target gene as can be observed from the 
amplification plots obtained in QPCR. For example in Figure 2.8 an amplification 
plot for one sample for TF2H started o ff at the same CT but then failed to reach a 
similar end point.
Using Image J analysis o f the band density o f the PCR gels, similar data for target 
gene expression (PTCH, EGR-3 and S100A7) was obtained in the duplicate 
experiments (see Figures 2.4, 2.5 and 2.6). In all cases, the second experiment 
gave higher levels o f  expression, although the same amount o f  DNA was used. 
However, these results did not give the large fold increases in target gene 
expression (EGR-3 and S100A7) observed by Kasper et al (2006). This may be 
due to the fact that they used N/TERT1 cells expressing GLI1 and then treated 
with EGF, rather than trying to induce GLI1 with recombinant SHH as done in the 
current experiments. Thus, the results are not likely to be anomalous.
Although conventional PCR suggested some activity in response to SHH due to 
increased PTCH, EGR-3 and S100A7, the more accurate real time method (which 
enables you to avoid reaching a plateau when amplifying genes so a comparison 
between different treatments is more reliable) showed no significant increase in 
expression o f  any o f  these genes. The augmentation o f GLI target gene expression 
by EGF observed by Kasper et al (2006) were not observed in N/TERT1 cells 
treated with recombinant SHH and EGF in combination.
As expected, PTCH had the highest expression in the presence o f  SHH, but was 
reduced in the presence o f  EGF. However, this was not entirely inconsistent with 
Kasper et al (2006) where EGF inhibited PTCH expression (see Table 2.7).
There is some evidence for stimulation o f EGR-3 in the presence o f both SHH and 
EGF (Figures 2.3 and 2.5). S100A7 showed increased expression in the presence 
o f SHH and EGF either alone or together (Figures 2.3 and 2.6). However, these
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results do not show the same large fold increases in expression for these genes that 
were described by Kasper et al (2006) in the presence o f EGF and up-regulated 
GLI1 (see Table 2.5). The results for PTCH, EGR-3 and S100A7 in the presence 
o f  inhibitors are also hard to rationalise because PTCH expression appeared to 
decrease in the presence o f either PD98059 or LY294002 (Figure 2.4 and 2.5), 
but showed no change when cells were treated with both LY294002 and PD98059 
in combination. This work was repeated twice with the same result (Figures 2.4 to 
2.6).
The lack o f  SHH signalling found in N/TERT1 cells lines could be explained 
because SHH signalling does not occur in adult epidermal cells except for during 
the anagen (down-growth) phase o f the hair follicle. This means that the lack o f  
GLI1, a SHH pathway transcription factor also comes as no surprise. However, 
addition o f  recombinant SHH to these cell lines would be expected to activate the 
pathway and testing GLI1 levels after SHH addition by RT-PCR or western 
blotting would have been useful to confirm successful activation. A lack o f  
availability o f  useful GLI1 antibodies meant this could not be carried out 
successfully for this study. Western blotting for the SHH, PTCH, SMO and GLI 1 
proteins would also have been useful to confirm the RT-PCR results, but the same 
problems with antibodies prevented this being a useful option.
RT-PCR results seemed to show some activation o f SHH signalling, with up- 
regulation o f  PTCH upon SHH addition to the cell medium. The reduction in 
PTCH levels by EGF inhibitors PD98059 (MEK inhibitor) and LY294002 (PI3K 
inhibitor) when applied individually may show that EGF does increase SHH target 
gene expression. Addition o f  both inhibitors simultaneously to the cell medium 
seemed to cancel out any effect each had individually. This probably means that 
another part o f  the EGF pathway was instead activated in the absence o f  
MEK/ERK and PI3K/AKT or that the inhibitors actually lost their efficacy in 
combination. If this is the case it could be problematic for a topical formulation 
containing both inhibitors.
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Further evidence o f  SHH pathway activation was shown using RT-PCR by the 
small increases in EGR-3 and S100A7 in the presence o f recombinant SHH or 
EGF. However, there was not the additive effect in expression when both SHH 
and EGF were added to the medium which was found by Kasper and colleagues 
when they added recombinant EGF to GLI1 expressing cells (Kasper et al. 2006).
The effect o f  PD98059 and LY294002 were unexpected because if the EGF 
pathway really does modulate SHH signalling by increasing target gene 
expression, a decrease in S100A7 (one such target gene) would be expected when 
inhibitors to the EGF pathway are present. This would particularly be expected in 
the presence o f  PD98059 because it has been suggested in publications that the 
MEK/ERK branch o f the EGF pathway is involved in augmenting SHH target 
genes (Schnidar et al., 2009). It is interesting that the presence o f  LY294002, a 
PI3K inhibitor has seemingly increased S100A7 expression. This seems to show 
that in this case LY294002 is not inhibiting a signalling pathway which increases 
S100A7 expression, but may in fact be inhibiting a separate signalling pathway 
which would otherwise inhibit S100A7.
In the case o f  the S100A7, expression increased in response to EGF and was 
inhibited by both PD98059 and LY294002. However, what is surprising is the 
inhibition o f  the EGF response by SHH. There was no significant inhibition o f  
PTCH by EGF as seen previously which was consistent with no significant 
changes in PTCH levels in response to the inhibitors. The general decrease in 
EGR-3 expression in the presence o f PD98059 in comparison to no inhibitors 
present agrees with the conventional method o f PCR which showed very little if  
any expression in the presence o f  LY294002 and PD98059 (Figure 2.5).
There are a number o f  possible explanations why there is a little response to SHH. 
Firstly, SHH and GLI1 components o f the SHH pathway were absent from 
N/TERT1 and HaCaT keratinocytes. Other components whose presence was not
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confirmed by PCR, such as SUFU, may have also been deficient. Western analysis 
was not helpful in confirming the expression o f proteins in the SHH pathway due 
to poor antibodies. Other SHH signalling genes such as SUFU may have been 
interesting to look at in order to confirm that the pathway could be activated. The 
absence o f  GLI1 in N/TERT1 and HaCaT keratinocytes may mean that target 
genes could not be transcribed. However, one might expect an increase in GLI1 in 
the event o f  pathway activation.
Secondly, it may have been due to the recombinant SHH (20kDa N-terminal 
domain) which was added to cell culture medium because this was made in E.coli 
and therefore does not have the post translational modifications necessary for 
increased activity (palmitoylation and cholesterol attachment) (Incardona and 
Eaton, 2000; Pepinsky et al., 1998). In order to overcome this SHH was cloned to 
make recombinant SHH in cell culture medium (conditioned medium) or for 
making an N/TERT1 overexpressing cell line for comparison with the SHH 
expressing HaCaT cell line used previously (Bigelow et al., 2005). Due to time 
constraints it has not been possible to determine if  this was the reason for the lack 
o f  response. However, the recombinant SHH used had been batch tested for 
activity in C3H10Y1/2 fibroblast cells by the supplier (Sigma Aldrich Company 
Ltd, Gillingham, UK). Ideally these C3H10Y1/2 cells should have been used in 
this study as a positive control, for SHH activity and stability over the time course 
o f  the experiment, however due to financial constraints this was not possible. In 
addition a dose response curve should have been carried out for expression o f a 
GLI-responsive gene to determine the ED50 (effective dose or the amount o f drug 
that produces a therapeutic response in 50% o f the subjects taking it) for N/TERT1 
cells which may be different to C3H10Y1/2 cells. Another useful experiment 
would have been to use immunocytochemistry to view the localisation o f  GLI in 
the nucleus on treatment o f  cells with the recombinant SHH. However, 
commercially available antibodies to GLI1 are rarely effective. This may be useful 
to cany out in the future as new GLI1 antibodies are becoming commercially 
available.
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Thirdly, it could also be explained by a negative feedback loop, not relevant in 
GLI1 over-expressing cells. Normally SHH signalling up-regulates PTCH, thus 
inhibiting SMO, leading to a requirement for higher levels o f  SHH to keep the 
pathway activated. But no increase in PTCH expression was seen so this suggests 
a lack o f  activation o f  the SHH pathway signalling by SHH. Another possibility is 
that GLI3 inhibits GLI1 and GLI2 transcription.
Also, a paracrine effect may be important for SHH activation, where fibroblasts 
need to be present in order for the pathway to be activated effectively in 
keratinocytes. Using organotypic culture models Bigelow et al. (2005) 
successfully achieved tumour down-growth into the model dermis in response to 
SHH (Bigelow et al., 2005). This suggests that it is possible that a paracrine effect 
is needed for the formation o f BCC/SHH signalling.
The primary cilium, an antenna-like structure in the cell membrane, may also be 
required. It is currently thought that the primary cilium acts as a site where all the 
major components o f the SHH pathway can be gathered together to allow 
interaction to occur. PTCH is present in the cilia in the absence o f  SHH and on 
SHH addition is deactivated and moves out o f  the cilium into the cell. Smoothened 
then enters the cilium enabling downstream pathway activation. It is not known 
whether the primary cilium is present in N/TERT1 keratinocytes, this should be 
explored further based on recent publications suggesting their requirement for 
SHH signalling.
The timings used may not have been the most appropriate for maximal gene 
expression. RNA extraction was carried out 24 hours after addition o f  recombinant 
SHH and EGF because Kasper et al. added recombinant EGF to their cells 
(NTERTls expressing GLI1 under the control o f doxycycline) 24 hours prior to 
RNA extraction (Kasper et al., 2006). It seemed most appropriate to conduct a 
comparable experiment with recombinant SHH rather than expressing GLI1.
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However, although Kasper et al. did successfully find augmentation with 
recombinant EGF after 24 hours, GLI1 was constitutively active. Here the 
negative feedback loop might have produced enough PTCH to inhibit SHH 
signalling in 24 hours thus bringing levels o f Gli responsive genes to unstimulated 
levels (including PTCH). Another option would have been to show activation of  
the SHH pathway using western blotting to show increased protein expression o f  
PTCH. Unfortunately, as explained above, the PTCH antibodies available are not 
reliable and do not give clear results.
A possible problem with the attempted activation o f SHH signalling at the level o f  
the SHH ligand in a BCC model is that the signalling pathway is activated by 
PTCH or SMO mutations in BCCs.
Another potential problem is that EGFR is internalised rapidly on ligand binding, 
so it may be that EGF signalling activates transcription factors at a greater speed 
than SHH signalling. Laner-Planberger and co-workers showed that c-Jun 
interacted more strongly with GLI2 so Gli2 may need to accumulate (GLI2 
upregulates GLI1) before EGF addition, which would eventually lead to the 
activation o f  c-Jun. Using constitutive activation o f SHH signalling would have 
solved this problem because EGF could be added at any time and there would 
already be plenty o f GLI transcription factors present. Alternatively if  SHH had 
been added to the medium prior to EGF a synergistic effect between these 
pathways may have been observed. Various time points could be tested to find the 
time point for optimal GLI 1/2 signalling, where target gene expression could be 
used as a marker for activation. Care would need to be taken to select an 
appropriate gene, as there are early and late response genes (Dessaud et al. 2007). 
Ideally further time would be spent creating the constitutively expressing SHH 
N/TERT1 keratinocyte cell line as sustained SHH pathway signalling is required 
to form BCCs.
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Cloning o f  SHH was time consuming and although eventually successful there 
was not time to successfully transfect N/TERT1 cells with the SHH containing 
vector. In order to repeat the QPCR experiments on SHH expressing N/TERT1 
keratinocytes the Mirus transfection method could be continued in future and cell 
selection completed. Alternatively, a transient transfection could be carried out on 
the N/TERT1 cell line. However, recombinant SHH addition to the culture 
medium may after all have the same effect as SHH expressing cells because SHH 
protein is released from the SHH expressing cell and then acts as a ligand to 
activate the signalling pathway in adjacent cells.
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Chapter 3
Sonic Hedgehog and Epidermal 
Growth Factor Signalling in Co­
cultures of Keratinocytes and 
Fibroblasts
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3.1. Introduction
Recent publications have implicated that paracrine signalling and the requirement 
for the presence o f  a primary cilium is required to achieve SHH pathway 
activation (Walter et al., 2010; Eggenschwiler and Anderson., 2007; Haycraft et 
al., 2005; Clement et al., 2009; Wong et al., 2009). These extra requirements may 
explain the low level o f SHH signalling activity observed in monolayer cultures 
(see Chapter 2) and perhaps the influence o f other factors on SHH signalling 
requires further consideration.
For example, it is thought that SHH is involved in pancreatic tumour development 
and progression (Walter et al., 2010; Bailey et al., 2009; Liu et al., 2007). Over­
expression o f  SHH ligand occurs in 70% o f  primary pancreatic adenocarcinomas, 
while the PTCH and SMO mutations seen in BCC, have not been observed 
(Thayer et al., 2003; Liu et al., 2007, Tian et al., 2009). SHH is not expressed in 
the normal adult pancreas, but primary and metastatic pancreatic cancer cell lines 
were found to express components o f  the SHH pathway (expression o f SHH, 
PTCH and SMO has been reported in up to 70% o f pancreatic ductal carcinomas). 
Implanting either SHH expressing primary cells or a pancreatic cancer cell line 
expressing SHH into mice results in increased tumour size and number o f  
metastases compared to cells that do not express SHH (Bailey et al., 2009). This 
shows that the more aggressive pancreatic tumours have a requirement for SHH 
expression.
Work with an epithelial pancreatic cell line (T-HPNE) reinforced this finding. 
These cells were transformed with retro-viral vectors that provide oncogenic 
insults to mimic the progression model o f  pancreatic cancer. In this model, 
inhibition o f  SHH signalling reduced tumour growth, lymphangiogenesis and 
metastasis (Bailey et al., 2009) confirming that active SHH supported tumour 
growth. The importance o f  SHH was confirmed by global gene expression analysis 
using an Affymetrix exon microarray o f  primary pancreatic carcinoma cells versus 
non-neoplastic pancreatic cells which indicated SMO over-expression in
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pancreatic cancer cells. Immunohistochemistry on primary human pancreatic 
cancer tissue not only further substantiated this finding but also suggested a 
paracrine effect by demonstrating SMO expression in human pancreatic 
adenocarcinoma stromal fibroblasts.
3.1.1 Paracrine signalling
Paracrine signalling is essential for mediating SHH pathway activity in 
development, and such epithelial-mesenchymal interactions are essential for skin 
development. SHH signalling is also heavily involved during hair follicle 
development being necessary for the cross-talk between the dermal papilla and 
epithelial components (Lacina et al., 2007; Yauch et al., 2008).
Paracrine signalling via the SHH pathway has also been identified in various 
epithelial cancers. It has been suggested that stromal cells may be stimulated by 
SHH expressing tumour cells (Walter et al., 2010; Feldman et al., 2007). 
Additionally, cancer-associated fibroblasts were shown to stimulate pancreatic 
tumour cells and SHH over-expression in mice during development resulted in 
pancreatic cancer precursor lesions (Thayer et al., 2003; Morton et al., 2007).
Xenografts (grafts from one species to another) o f human tumours highly 
expressing SHH were implanted onto mice and it was found that the stromal cells 
next to the tumour had increased GLI1, indicating the SHH pathway had been 
activated in a paracrine manner. It was also demonstrated that SHH activity in the 
stromal microenvironment can provide a growth advantage to tumour cells. It was 
found that BCC fibroblasts influence the growth and differentiation pattern of  
normal keratinocytes, pushing them towards a malignant phenotype (Lacina et al., 
2007). These interactions may be due to the influence o f soluble growth factors or 
the collagen extracellular matrix on keratinocytes. Other xenograft mouse models 
that have been used for pancreatic cancer also showed a paracrine requirement for 
the SHH pathway, as tumour cells produced SHH ligand that activated the SHH 
pathway in the stroma (Tian et al., 2008). These authors also confirmed that
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paracrine but not autocrine SHH signalling occurs in pancreatic carcinomas. This 
was demonstrated by expressing the SMOM2 allele o f SMO and a PTCH-LacZ 
reporter allele in the pancreas to activate canonical SHH signalling in a cell- 
autonomous manner. The results showed that canonical SHH signalling did not 
occur in pancreatic epithelium in an autocrine manner. Furthermore, qRT-PCR 
experiments on laser capture micro-dissected human and mouse tumour samples 
confirmed the presence o f SHH signalling in tumour stroma (Tian et al., 2009).
Another publication co-culture o f a pancreatic cancer cell line with 10T1/2 cells 
(multipotent mouse embryo cell line stably transfected with a GLI reporter 
construct) resulted in the induction o f GLI reporter activity and this correlated with 
the level o f ligand produced by the tumour cells. This demonstrated that SHH 
produced by tumour cells could act on the stromal compartment again suggesting 
paracrine signalling (Yauch et al., 2008).
The same researchers examined signalling in vivo by xenografting pancreatic cells 
expressing SHH onto PTCHl-LacZ-Rag2'/' mice and found anti-P-galactosidase 
stained stromal cells adjacent to tumour cells indicating paracrine signalling 
(Yauch et al., 2008). The same group also showed that xenografting human 
tumour biopsies onto nude mice led to the replacement o f  human-derived stroma 
by mouse stroma.
However, the situation in prostate cancer cell lines is still unclear and it is 
uncertain if  SHH signalling is autocrine and/or paracrine. Work with three cell 
lines (LNCaP, PC3 and 22RV1) transfected with activated GLI2 showed SHH 
target gene activation, but this did not occur when the same cells were transfected 
with activated SMO. Also, cyclopamine (SMO inhibitor) did not affect the 
expression o f  target genes, but did limit cell proliferation. Therefore, autocrine 
SHH signalling does not seem to regulate tumour growth in these cells (Zhang., 
2007). However, analysis o f gene expression in benign and malignant prostate 
tissue did show that SHH signalling molecules in the stroma surrounding a
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prostate tumour did accelerate growth, mimicking SHH signalling in the 
mesenchyme during prostate development (Shaw et al., 2009).
3.1.2 Primary Cilia
There are two types o f mammalian cilia, motile and non-motile. Motile cilia can 
be found lining the trachea where they beat to clear dirt and mucus from the 
airway. Non-motile (primary) cilia generally function as sensory organelles. They 
protrude from cells into the extracellular space and many can have specialised 
functions (e.g. in the outer segments o f photoreceptors) but some do remain 
unspecialised.
Cilia have a basal body which is formed by transitional fibres, a terminal plate 
(these physically prevent entrance o f proteins into the cilia) and triplet 
microtubules which become the doublet microtubules (9+0 arrangement in 
primary cilia but 9+2 in motile cilia) in the long microtubular axenome (Figure
3.1). Generally, the cilia membrane is continuous with the plasma membrane 
(Singla and Reiter, 2006).
Ciliary
membrane
C i l i u m
Doublet
microtubule
Plasma
membrane
Transition
fibers
Terminal plate
Triplet
microtubules
Figure 3.1: Structure o f a Primary Cilium. The membrane is continuous with the plasma 
membrane and contains an array o f microtubules (Singla and Reiter, 2006).
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Cilia are formed when cells enter growth arrest and are then shed just before cells 
enter mitosis. There are three main stages of primary cilia development (Figure
3.2). First a golgi vesicle attaches to the mother centriole, enabling the centriole to 
extend and become the basal body forming the axoneme. Secondly, nearby 
vesicles join to form the cilia membrane which surrounds the axoneme. Thirdly, 
the axoneme covered in membrane reaches the cell surface, where the cilia and 
plasma membranes fuse to become continuous allowing the cilium to elongate 
further (Pedersen et al., 2008).
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Figure 3.2: Development of the Primary Cilium (adapted from Pedersen et al., 2008).
Primary cilia defects lead to a variety of disorders or ‘ciliopathies’ usually caused 
by an inability of the centrioles to form the primary cilia or to migrate prior to 
ciliogenesis. Polycystic kidney disease is an example of a ciliopathy and this is 
caused by unregulated cilia function due to loss of cilia length control. This leads 
to a misalignment o f hepatic bile duct and renal tubule cells resulting in cyst 
growth that can lead to loss of kidney function (Bonnet et al., 2009).
Recently, it has been shown that the primary cilium must be present on cells for 
SHH signalling to occur. In the absence o f SHH, PTCH remains at the base of the 
cilium and SMO is inhibited. GLI2 and GLI3 are moved up and down the cilia via 
intraflagellar transport (IFT), and they are cleaved into repressor forms by the
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centrosome-proximal proteasome so they cannot activate gene transcription. When 
present, SHH binds to PTCH and this translocates PTCH out o f the cilium and 
SMO is no longer inhibited. SMO then moves into the cilium tip and interacts with 
SUFU, GLI and other proteins localised here to activate the SHH signalling 
pathway. These interactions prevent cleavage of GLI2 and GLI3, which are 
translocated to the cilium base and on to the nucleus by IFT proteins (see Figure
3.3). GLI is then able to stimulate target gene transcription in the nucleus by 
binding to GLI-promoters in various target genes (Eggenschwiler and Anderson., 
2007).
IFT proteins, which move up and down the cilium continuously are required for 
GLI activity and in their absence, modulation o f SHH/GLI target genes are 
blocked (Haycraft et al., 2005; Clement et al., 2009; Wong et al., 2009). In
Figure 3.3: SHH Pathway Signalling in the Primary Cilium. In the presence o f SHH 
(ligand), PTCH translocates out o f the cilium, releasing SMO from inhibition, enabling its 
movement to the cilium tip where it interacts with SUFU and GLI transcription factors, 
allowing GLI transportation to the cell nucleus.
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support o f this, mice homozygous for 
IFT88 (an intraflagella transport 
protein) survived until after birth, but 
a targeted null allele o f mouse 
IFT88/polaris (intrafl age liar transport 
component) caused lethality at mid­
gestation and mutant embryos 
displayed randomised left-right 
symmetry (under the control o f the 
SHH pathway in mammalian 
development) associated with loss of 
cilia (Murcia et al., 2000).
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Interestingly, cilia are not required for SHH signalling in Drosophila, as shown by 
mutations which block cilia formation (Han et al., 2003). However, it is not clear 
at this time how many other signal transduction pathways in humans may require 
cilia, although there is evidence that cilia are also involved in Wnt and PDGFRa 
signalling (Eggenschwiler and Anderson., 2007).
Generally, one primary (non-motile) cilium is present on almost every interphase 
or non-dividing cell in the body (Satir and Christensen, 2007), but they are rarely 
present on immortalised cells (Strugnell et al., 1996). Primary cilia were induced 
in a 3T3-L1 cell line by growing cells to high confluency and growth arresting 
them by serum starvation (Zhu et al., 2009). It is thought that cilia are more easily 
induced in polarised cells and when the cells are confluent and growth arrested 
(Satir and Christensen, 2007). As shown by Bonnet and co-workers, polarisation 
o f cells appears to be important in the normal development o f  primary cilia 
(Bonnet et al., 2009). Thus, primary cilia on polarised cells can act as location 
markers and enable cell to orient themselves in relation to their surroundings (e.g. 
in the epidermal basal layer, cells are columnar in a vertical direction).
It was not known whether the cell lines used in this study (N/TERT1, HaCaT or 
HCA2) had primary cilia or not. The current studies with SHH and EGF included 
a growth arrest stage (24 hour culture minus FBS/BPE prior to SHH/EGF 
addition), which is thought to enable cilia formation. However, work had been 
carried out whilst the cells were still sub-confluent and therefore capable o f  
proliferating on addition o f EGF and it is not certain that primary cilia were 
present under these conditions, and if not, what conditions would be required to 
induce them. It had been previously shown that co-cultures at the air-liquid 
interface (keratinocytes not covered in culture medium but fed by medium from 
below) improved cell differentiation (Dickson et al., 2000). Images o f  
differentiated epidermis formed with HaCaT or N/TERT1 cells grown on a 
fibroblast containing collagen gel showed well organised, columnar basal cells 
(Bigelow et al., 2005; Dickson et al., 2000). An alternative method utilises a filter
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insert so the medium level can be reduced once cells have adhered, to allow 
stratification at the air-liquid interface. In this method, fibroblasts may be grown in 
the well beneath to introduce additional paracrine effects.
Antibodies to cilia components such as acetylated-a-tubulin or IFT88 have been 
used to demonstrate the presence o f cilia (immunofluorescence and confocal 
microscopy). Recently, it has been shown that cilia are present in the epidermis, 
dermis and hair follicles as well as BCCs. This method has also been used to show 
that cilia are present on hair follicle cells throughout their development and that 
structural proteins in cilia co-localise with SHH pathway proteins (Wilson et al., 
2009; Wong, 2009; Clement et al., 2009; Lehman et al., 2009). Transmission 
electron microscopy (TEM) has also been used to show ciliation o f  mesenchymal 
and ectodermal cells in the mouse limb bud and in pre-cystic collecting tubule 
cells o f the kidney (Haycraft et al., 2005; Bonnet et al., 2009).
In conclusion, these studies suggest that fibroblasts may be needed to facilitate 
SHH pathway activation in keratinocytes by paracrine signalling and the presence 
o f  cilia may also be an important factor in enabling activation o f SHH signalling.
3.1.3 Aims
• To determine whether SHH pathway signalling can be activated in co­
cultures which allow epithelial-mesenchymal interactions.
• To determine by confocal microscopy and/or scanning electron 
microscopy, whether cilia are present on these cell lines under various 
culture conditions.
3.2 Methods
3.2.1 Cell lines
HCA2 fibroblasts (obtained from Professor David Kipling, Cardiff University, 
UK) are normal human diploid neonatal foreskin fibroblasts immortalised by the 
hTERT portion o f telomerase. These have been shown to maintain normal
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fibroblast characteristics with a long lifespan whilst maintaining more uniform 
populations than primary fibroblasts. Generally, primary cell change significantly 
with time and form variable populations which do not give reproducible 
experimental results (Bond et al., 1999; McSharry et al., 2001).
3.2.2 Maintaining cell lines
HCA2 fibroblasts were removed from liquid nitrogen and thawed at 37°C. The 
cells were transferred to a 50ml falcon tube and 20ml DMEM containing 10% 
FBS and 2mM L-glutamine (Gibco, Invitrogen, Paisley, UK) was carefully added 
and mixed. The cells in medium were transferred to a T75 culture flask (Coming, 
Fisher Scientific, Loughborough, UK) and incubated at 37°C in the presence o f 5% 
CO2 . The medium was changed every 2-3 days and cells were subcultured when 
they reached 70-80% confluence. Subculture was achieved by aspirating the 
medium, washing the cells with 5ml dPBS, adding 5ml trypsin-EDTA (Gibco, 
Invitrogen, Paisley, UK) and incubating at 37°C with 5% CO2 for approximately 5- 
12 minutes (or until cells were no longer adherent). An aliquot (5ml) o f DMEM 
containing 10% FBS was then added to deactivate the trypsin-EDTA and the cell 
suspension was removed from the flask.. An aliquot o f  2ml was added to a T75 
flask containing 18ml DMEM with 10% FBS and the cells were then incubated at 
37°C in the presence o f 5% CO2 .
3.2.3 Cryo-preserving HCA2 for storage
A freezing mixture was prepared with 90% FBS and 10% DMSO, filter-sterilised 
(0.2pm) and stored in 1ml aliquots (in 2ml cryovials) at -80°C.
Medium was aspirated from a T75 flask when cells were 75-80% confluent. The 
cells were washed in 5ml dPBS and then treated with 5ml Trypsin-EDTA 
(incubate at 37°C in 5% CO2 for 5-12 minutes). The trypsin was inhibited by
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adding 5ml DMEM/F12 (1:1, vol:vol) containing 10% FBS and 2mM L-glutamine 
and the cells pelleted by centrifugation (1,200 rpm for 5 minutes at RT). The 
supernatant was aspirated and the cells re-suspended in 3-4ml DMEM/F12 (1:1, 
vokvol) with 10% FBS and 2mM L-glutamine. Cells were counted by 
haemocytometer, adjusted to lxlO 5 cells per 1ml and added to cryovials containing 
lml o f freezing mixture. The vials were wrapped in tissue, placed in a polystyrene 
tube box and frozen at -80°C overnight. They were transferred to liquid nitrogen 
for long term storage.
3.2.4 Co-culture of HaCaT and HCA2 cell lines
HaCaT cells at 80% confluence in a T75 flask, were released by incubating in 5ml 
trypsin-EDTA at 37°C with 5% CO2 for 5-12 minutes (or until no longer 
adherent). Trypsin-EDTA was deactivated by addition o f 5ml DMEM containing 
10% FBS and 2mM L-glutamine and 300pl o f the mixture was removed and 
applied to each o f four 0.4pm filter inserts (Greiner Bio-One Ltd, Stonehouse, 
UK) in a 6 well plate. This was repeated for a second 6 well plate. HCA2 
fibroblasts (80% confluent) were released from a T75 flask with trysin-EDTA and 
added to the wells beneath the filter inserts o f one plate while the second plate had 
no fibroblasts added. 2ml DMEM containing 10% FBS and 2mM L-glutamine was 
added to each filter insert and the wells o f both plates. The cells were incubated for 
36 hours at 37°C with 5% CO2 . Growth medium was aspirated and the cells 
washed three times with dPBS, then 2ml DMEM with 2mM L-glutamine (but no 
FBS) was added to cells in each compartment. Cells were incubated at 37°C with 
5% CO2 to induce growth arrest. Keratinocytes and fibroblasts in both plates were 
incubated at 37°C in 5% CO2 for 24 hours in the presence o f  either lOng 
recombinant SHH, lOng recombinant EGF, or both. Control cultures had no 
recombinant proteins added. The medium was aspirated, the cells washed three 
times with dPBS and RNA was extracted using Trizol (section 2.2.2.1),
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3.2.5 Stratified Co-culture
The co-culture described in section 3.2.4 was also repeated in a modified form. In 
this case, 24 hours after plating, HaCaT cells were allowed to grow at the air- 
liquid interface by reducing the level o f medium (DMEM with 10% FBS and 
2mM L-glutamine) to the underside o f  the filter insert (to feed cells from below) 
and then incubating at 37°C with 5% CO2 for 5 days (replacing the medium every 
1-2 days) to allow stratification prior to inducing growth arrest (achieved in the 
same way as in section 3.2.4).
3.2.6 Samples for Scanning Electron Microscopy (SEM)
Scanning electron microscopy (SEM) was carried out by Chris Von Ruhland 
(Department o f Medical Genetics, School o f  Medicine, Cardiff University). Co­
cultures o f HaCaT keratinocytes and HCA2 fibroblasts were prepared as before 
(see section 3.2.5) but with slight modification. HaCaT keratinocytes (150p,l) from 
a 10ml subculture (5ml DMEM containing 10% FBS and 5ml trypsin added to a 
30% confluent T75) were added to a 12 well plate containing filter inserts. The 
same number and volume of HCA2 fibroblasts were plated in 6 o f the wells below 
the inserts. Another 2 wells remained submerged in the medium without growth at 
the air-liquid interface (see section 3.2.4) and 2 wells were grown at the air-liquid 
interface for 10 days (see section 3.2.5) to allow further stratification.
In addition, 300pl o f HaCaT from a confluent T75 flask resuspended in lOmls 
were also added to each o f two 3.3cm plates each containing 3 coverslips for 
examination o f  monolayer cultures (after 7 days o f growth for the co-cultures). 
2ml DMEM containing 10% FBS and 2Mm L-glutamine was added to each 3.3cm 
plate. The medium was aspirated and replaced with fresh medium after two days.
Co-cultured cells were serum starved after 10 days o f  growth at the air-liquid 
interface while monolayer cultures were serum starved after 36 hours. The 
medium was removed from the cells grown on coverslips or in filter inserts and 
they were washed with dPBS (3 times) and then fixed with 1% glutaraldehyde in
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lOOmM phosphate buffer for 1 hour. HaCaT cells gown on cover slips were 
washed with H2O for 10 minutes (twice), then 10 minutes each in 50%, 70% and 
90% ethanol, followed by 10 minutes in 100% ethanol (twice). The cover slips 
were rinsed three times in hexamethyldisilazane for 10 minutes each (Nation, 
1983) then allowed to air dry. The coverslips were attached to a 32mm diameter 
SEM stub with self adhesive carbon discs (TAAB Laboratories Equipment Ltd, 
BERKshire, UK). The cells were then coated with gold in an EMscope vacuum 
coater (EMScope, Ashford, UK) and examined in a JEOL 840A SEM at 5kV (Jeol 
UK Ltd, Welwyn Gardens City, UK.).
3.2.7 Samples for Confocal Microscopy
Confocal microscopy was carried out by Dr Chris George (Wales Heart Research 
Institute, School o f Medicine, Cardiff University). HaCaT keratinocytes were 
subcultured from a 30% confluent T75 flask by addition o f 5ml trypsin-EDTA and 
incubated at 37°C in 5% CO2 for 10 minutes, before addition o f 5ml DMEM plus 
10% FBS to deactivate the trypsin. An aliquot (300pl) o f HaCaT cells was 
removed and pipetted into three separate plates (3.3cm diameter) each containing 3 
glass coverslips. 2ml DMEM containing 10% FBS and 2mM L-glutamine was 
added to each plate and mixed. The plates were incubated at 37°C in 5% CO2 for 
36 hours, after which, the medium was aspirated, the cells washed in dPBS (3 
times), and serum-free DMEM plus 2mM L-glutamine was added (2ml/plate) and 
left for 24hours. The medium was aspirated, the cells were washed in dPBS (3 
times) and ice-cold acetone-methanol (1:1 vol/vol) was applied for 5 minutes. 
Acetone-methanol was aspirated and cells were washed with dH20 (3 times). 
Mouse acetylated a-tubulin antibody (T6074; Sigma-Aldrich Company Ltd, 
Gillingham, UK) in PBS (1:50 dilution) was applied for 1 hour. The cells were 
washed three times in dH20 and donkey anti-mouse alexa 488 (Sigma-Aldrich 
Company Ltd, Gillingham, UK) in PBS (1:500) was applied for 30 minutes. 
Sections were mounted in hydromount plus 2.5% DABCO (Sigma-Aldrich 
Company Ltd, Gillingham, UK) to prevent photo-bleaching. Cover slips were
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carefully placed onto microscope slide and digital images obtained using a Leica 
SP5 resonant scanning confocal microscope.
3.2.8 Real Time PCR (qPCR)
Real time PCR (qPCR) was carried out as previously described in Chapter 2 (see 
Section 2.2.2.3).
3.3 Results
3.3.1 Quantitative (Real Time) PCR on Cultured Keratinocytes
While HaCaT cells do not reflect the behaviour o f  normal keratinocytes as well as 
N/TERT1 cells (due to polyploidy), they are a commonly used keratinocyte cell 
line because they maintain “normal” epidermal differentiation in monolayer 
culture (Boukamp et al., 1988). HaCaT were chosen over N/TERT1 keratinocytes 
because they can be grown in the same culture medium as HCA2 fibroblasts, and 
HaCaT cells express more GLI1 than N/TERT1 (see Figure 2.2), which may lead 
to increased SHH pathway activation. The experiments depend on co-culture o f  
keratinocytes with HCA2 fibroblasts in the same wells, so they must both grow in 
the same medium. N/TERT1 cells must be cultured in serum-free medium which 
does not favour the growth o f  HCA2 cells. This meant that primer optimisation 
(see Table 2.4) had to be repeated since gene expression may be different in 
HaCaT cells.
3.3.1.1 O ptim ising ACTB (p-actin) Primers on HaCaT Cell cDNA
ACTB (p-actin) primer optimisation was done with cDNA from control HaCaT 
cells which had not been treated with SHH or EGF (0.5, 1 and 1.5pg per reaction). 
ACTB primers were tested at three different levels: 0.05pg/pl, O.lpg/pl and 
0.15pg/pl. The reaction which gave the lowest Ct (cycle threshold) value was 
taken as the preferred combination o f  cDNA and primer (1.5pg cDNA and 
0.15(xg/pl ACTB primers in this case) because this is the earliest detectable point
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o f product above background levels. A low Ct level was obtained for ACTB 
primers and HaCaT cDNA as (3-actin was an abundant cytoskeletal protein in these 
cells. The dissociation curves showed that the primers gave good results (Figure 
3.4a) indicating that the reactions were not contaminated and the primers did not 
dimerize during the reaction. Serial dilutions o f cDNA were made (neat, 1:10, 
1:100, 1:1,000) and the qPCR fluorescence values plotted against the number of 
cycles for each dilution. For ACTB, the amplification plots were equally spaced 
(Figure 3.4b). The Ct values for each dilution were plotted against the dilution 
value to derive a standard curve, which showed a good R2 value, slope and 
efficiency so the qPCR results appeared to be very accurate (Figure 3.4c).
(c) Standard Curve
R2 = 0.998 
Slope = -3.17 
Eff= 106.6%
(a) Dissociation Curve (b) Amplification Plot
Figure 3.4: Optimisation o f ACTB Primers and HaCaT Keratinocyte cDNA. (a)
Dissociation curve for HaCaT cDNA with ACTB primers, (b) Dilution series o f HaCaT 
cDNA using 1.5pg cDNA (red), 1:10 dilution (green), 1:100 dilution (grey) and 1:1,000 
dilution (blue) with ACTB primers, (c) Standard curve for HaCaT cDNA dilution with 
ACTB primers.
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3.3.1.2 Optimising EGR-3 primers
The primer and cDNA concentrations were optimised as detailed in Chapter 2, 
Table 2.2.
Control cDNA from HaCaT cells which were not treated with SHH or EGF was 
used for the optimisation (0.5, 1 and 1.5pg cDNA per reaction with four different 
primer amounts (0.5pg, lpg, 1.5pg and 2pg). The reaction which gave the lowest 
Ct value used ( lp g  cDNA and lp g  EGR-3 primers) was used for all subsequent 
experiments. However, these Ct values were still relatively high and this is 
probably due to the low level o f  EGR-3 in these cells.
The dissociation curves (Figure 3.5a) showed a slight second peak and a slight 
shift in the main peak suggesting that there is more than one product and possibly 
some primer dimers. The qPCR reactions were repeated using serial dilutions o f  
cDNA (neat, 1:10, 1:100, 1:1000) and the resulting fluorescence was plotted 
against the cycle number. The three dilutions showed equal spacing between the 
curves but one dilution was consistently out due to low EGR-3 levels (Figure 
3.5b). This resulted in a standard curve with poor values for the slope and 
efficiency (slope should be between -3.2 and -3.5 and efficiency should be 90- 
110%). After repeating the optimisation with EGR-3 primers several times, good 
values for the slope and efficiency could not be achieved when all the serial 
dilutions were included, so the 1:1000 dilution was removed. This then produced a 
standard curve with good R2 and slope values, but the efficiency was still slightly 
above recommended levels and might cause inaccuracies in the qPCR results.
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(a) Dissociation Curve (b) Amplification Plots
(c) Standard Curve
R2= 1 
Slope =-3  
Eff = 118%
Cytte*
Figure 3.5: Optimisation o f EGR-3 Primers and HaCaT Keratinocyte cDNA. (a)
Dissociation curve for HaCaT cDNA with EGR-3 primers, (b) Dilution series o f HaCaT 
cDNA using lpg cDNA (blue), 1:10 dilution (red), 1:100 dilution (green) and a 1:1000 
dilution (grey) and EGR-3 primers, (c) Standard curve for HaCaT cDNA dilution with 
EGR-3 primers.
3.3.1.3 Optimising PTCH primers
The primer and cDNA concentrations were also optimised as detailed in Chapter 
2, Table 2.2. The lowest Ct values were obtained with lp g  PTCH primers with 
2pg cDNA. There were no extra peaks in the dissociation curve showing that only 
one product was produced and there was no evidence for any primer dimers or 
contamination (Figure 3.6a). However, again the 1:1000 dilution was too low to 
achieve a good Ct value (ideally Ct should be at below 24 cycles) even after 
repeating the reactions several times, probably due low levels o f PTCH expression 
in HaCaT cells (Figure 3.6b). The standard curve was plotted without the data for 
the 1:1000 dilution and reasonable values were obtained, with a good R2 value but
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slope and efficiency values slightly outside the guidelines (Figure 3.6c). Thus, the 
low levels o f PTCH could lead to inaccurate data using these primer and cDNA 
concentrations.
(a) Dissociation Curve ;i
(c) Standard Curve
(b) Amplification Plots
R 2 =  0 .99  
Slope = -2.2 
Eff = 182%
5
0-01 01 I
Mi* Quant*y
Figure 3.6: Optimisation o f PTCH Primers and HaCaT Keratinocyte cDISA. (a)
Dissociation curve for HaCaT cDNA with PTCH primers, (b) Dilution series o f HaCaT 
cDNA using Ipg cDNA (blue), 1:10 dilution (red), 1:100 dilution (green) and a 1:1000 
dilution (grey) and PTCH primers, (c) Standard curve for HaCaT cDNA dilution with 
PTCH primers.
3.3.1.3 Optimising IL-1R2 primers
Primer and cDNA concentrations were also optimised for IL-1R2 as detailed in 
Chapter 2, Table 2.2. The lowest Ct values were obtained with 1.5pg IL-1R2 
primers and 1.5pg cDNA (Figure 3.7). The dissociation curves showed a slight 
second peak in front o f the main peak suggesting that more than one product 
existed, possibly due to primer dimers (Figure 3.7a). The amplification plots show 
that the Ct values for each dilution were very late, again due to low level of IL-
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1R2 expression in HaCaT cells. Thus, the qPCR results were the best possible with 
these cells but could still not be fully optimised even after several attempts 
(Figure 3.7b). The 1:1000 dilution came too late to fit on the plot and as a 
consequence the standard curve was drawn only with Ct values from the first three 
dilutions in the series. This provided R2, slope and efficiency values that were 
reasonable so these conditions should give reliable qPCR results (Figure 3.7c).
(a) Dissociation Curve (b) Amplification Plots
....... : ■' f t  /f  i  i  M .
(c) Standard Curve
R2 = 0.99 
Slope = -3.37 
Eff = 97.9%
Figure 3.7: Optimisation o f ILIR2 Primers and HaCaT Keratinocyte cDNA. (a)
Dissociation curve for HaCaT cDNA with ILIR2 primers, (b) Dilution series of HaCaT 
cDNA using 1.5pg cDNA (red), 1:10 dilution (green), 1:100 dilution (blue) and a 1:1000 
dilution (grey) and IL1R2 primers, (c) Standard curve for HaCaT cDNA dilution with 
1L1R2 primers.
3.3.1.5 Optimising S100A7 primers
The primer and cDNA concentrations were optimised for S100A7 using the same 
techniques (see Chapter 2, Table 2.2). The lowest Ct values were obtained with 
1 pg S100A7 primers and 2pg cDNA. The dissociation curve for these primers was 
very good, with only a small extra peak for one sample (Figure 3.8a), showing
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that there was no contamination or primer dimers present. The amplification plots 
were equally spaced and the Ct values were reasonable (between 25 and 34 
cycles). Lower Ct values (between 20 and 30) were not achieved even after the 
optimisation was repeated several times (Figure 3.8b). The standard curve values 
were within the recommended guidelines (Figure 3.8c). These primers appeared to 
be well optimised and should therefore provide accurate data from qPCR 
reactions.
(a) D is so c ia t io n  C urve
(c)  S ta n d a r d  C urve
R2 = 0.995 
Slope = -3.3 
Eff= 99.4%
Figure 3.8: Optimisation o f S100A7 Primers and HaCaT Keratinocyte cDNA. (a)
Dissociation curve for HaCaT cDNA with S100A7 primers, (b) Dilution series with 
HaCaT cDNA: neat (1.5/ug) cDNA (blue), 1:10 dilution cDNA (red), 1:100 dilution cDNA 
(green) and a 1:1000 dilution cDNA (grey) and S100A7 primers, (c) Standard curve for 
HaCaT cDNA dilution series with S100A7primers.
3.3.1.6 SHH and EGF Signalling in Fibroblast: Keratinocyte Co-cultures.
HaCaT keratinocytes were cultured in a filter insert in the presence or absence of 
HCA2 fibroblasts. This allowed diffusion o f growth factors between the HaCaT
(b) Amplification P lots
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keratinocyte and HCA2 fibroblast cell lines which facilitates paracrine interactions 
(Figure 3.9).
HaCaT
HCA2
Figure 3.9: Co-culture o f HaCaT Keratinocytes and HCA2 Fibroblasts, (a) HaCaT 
keratinocytes and HCA2 fibroblasts are both cultured in the same well but separated by a 
filter insert, (b) Photograph o f an insert in the well o f a tissue culture plate (adapted from 
Greiner Bio-One, Stonehouse, UK).
HaCaT keratinocytes were allowed to reach 80-100% confluency, and then treated 
with either recombinant SHH, recombinant EGF, both or neither. Keratinocyte 
RNA was extracted from the cells in each filter insert and the activity of SHH 
signalling was assessed by measuring expression levels o f SHH-responsive genes 
(EGR-3, IL-1R2, S100A7 and PTCH) by RT-qPCR.
EGR-3 expression decreased slightly (0.2 fold) in the presence o f SHH and more 
(0.6 fold) in the presence of EGF. In combination, the decrease (0.4 fold) was 
intermediate (Figure 3.10a). In the presence of HCA2 fibroblasts, EGR-3 
expression increased 0.4 fold with SHH but decreased by 0.6 fold with EGF. 
When both were present, the EGF seemed to prevent the increase observed with 
SHH alone.
SHH increased IL-1R2 expression by 15 fold while EGF increased this by 140 
fold in the absence o f HCA2 fibroblasts (Figure 3.10b). When both SHH and EGF 
were present in the cell culture medium, the values were similar to EGF alone. In 
the presence o f HCA2 fibroblasts, SHH has little or no effect but even higher 
levels o f IL-1R2 were induced by EGF (210 fold) whether SHH was present or 
not.
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There was little change in S100A7 expression when cells were treated with SHH 
alone (Figure 3.10c) but EGF reduced S100A7 levels about 10 fold (from 0.9 to 
0.1). A similar reduction was seen in the presence o f both SHH and EGF. The 
results obtained in the presence o f  HCA2 fibroblasts were similar.
The PTCH data was similar to EGF-3 and SHH appeared to have no effect on 
PTCH expression in the absence o f HCA2 fibroblasts (Figure 3.10d). Again, EGF 
reduced PTCH levels compared to the control (no recombinant proteins), however 
EGF reduced PTCH by about 5 fold but SHH ameliorated this effect slightly. In 
the presence o f HCA2 fibroblasts, SHH increased PTCH expression from 1 to 1.4 
fold while EGF decreased PTCH levels 3 fold and inhibited the effect o f  SHH 
when both were applied.
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Figure 3.10: Effects o f  Keratinocyte Co-culture with Fibroblasts on SHH Target Gene 
Expression. Results show the effect o f co-culture of HaCaT keratinocytes with HCA2 
fibroblasts on expression o f (a) EGR-3, (b) IL-1R2, (c) S100A7 and (d) PTCH. Dark blue 
boxes represent experiments carried out in the absence and light blue presence o f HCA2 
cells. Data expressed as a mean +/- SD for n=2 experiments.
Thus, EGR-3, S100A7 and PTCH expression levels do not increase in the presence 
o f SHH when fibroblasts are not present. However, expression is decreased in the 
presence o f EGF. When fibroblasts were present, similar changes were apparent 
but there was only a slight increase in EGF-3 and PTCH when SHH was added. It
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would be interesting to find out the reason for the unexpected down-regulation o f  
these genes in the presence o f EGF.
However, the response o f IL-1R2 differed. The increased expression in the 
presence o f EGF was more pronounced in the presence o f  fibroblasts. It seems that 
paracrine signalling may be enhancing the effect o f  EGF signalling already 
observed in the absence o f fibroblasts. The up-regulation o f  IL-1R2 was more 
extensive than seen earlier (see Figure 2.14), where IL-1R2 expression was also 
increased with EGF but to a lesser extent. However, these experiments were done 
on two different cell lines (HaCaT and NTERT-1) which may explain the different 
levels o f expression. It would be interesting to repeat the LY294002 and PD98059 
inhibitor experiment (Figure 2.14b, c) to determine if  PI3K and AKT are also 
controlling the expression o f this gene in HaCaT cells.
The presence o f HCA2 cells did not have a large effect on the expression o f  any o f  
these genes. Also, there was no large fold increase when SHH and EGF were 
present in combination. This data shows that the presence o f fibroblasts within a 
co-culture system does not contribute to SHH pathway activation, at least on its 
own.
There are some interesting differences and similarities between the results 
obtained with HaCaT calls (Figure 3.10a-d) and those obtained with N/TERT1 
cells (see Chapter 2). Similar results may have been expected because HaCaT and 
N/TERT1 cells are essentially both keratinocyte cell lines grown in monolayer 
conditions. The major difference between HaCaT cells grown in the absence o f  
fibroblasts in submerged cultures and N/TERT1 keratinocytes grown in monolayer 
cultures are: a decrease in expression of EGR-3, S100A7 and PTCH but a large 
increase o f  IL-1R2 in the presence o f EGF (EGF or SHH/EGFs. This changes 
were not found with N/TERT1 cells. The results for IL-1R2 in HaCaT cells 
(Figure 3.10b) resembled those obtained for seen N/TERT1 cells (see Figure 
2.14a) except the fold changes measured were much greater. For EGR-3 there was
140
little variance in expression when treated with SHH or EGF in N/TERT1 (Figure 
2.12a), decreased expression in HaCaT caused by EGF (Figure 3.10a) was small 
(0.6 fold). The S100A7 results were quite different between the two keratinocyte 
cell lines, with small increases in expression in N/TERT1 in the presence o f  SHH 
or SHH plus EGF, and a larger increase in expression in the presence o f  EGF 
(Figure 2.16a) compared to no increased expression in the presence o f SHH in 
HaCaT cells (Figure 3.10c). In N/TERT1 cells, PTCH showed no significant 
difference from the control in the presence o f SHH, EGF or SHH/EGF (Figure 
2.18a), not the same as found in HaCaT cells (Figure 3.10d).
3.3.1.7 Stratified Co-culture QPCR
Since paracrine signalling alone does not result in SHH pathway activation and 
cilia appear to be required for activation o f  SHH signalling, experiments were 
performed to determine whether SHH would become activated in conditions that 
favour polarisation (a requirement for cilia formation). Keratinocytes were 
cultured at the air-liquid interface by lowering the level o f  the culture medium to 
expose HaCaT keratinocytes to the air, whilst still reaching the underside o f the 
filter insert to feed them from below (Figure 3.11). They were cultured for 5 days 
in filter inserts, allowing them to stratify (to enable polarisation o f  the cells) which 
should encourage cilia formation. HaCaT cells were also cultured in the presence 
and absence o f HCA2 fibroblasts to determine whether paracrine signalling 
contributes to the polarisation. The filter inserts allow movement o f growth factors 
between the two cell lines and may enable polarisation o f HaCaT cells.
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Figure 3.11: HaCaT Keratinocytes Cultured on a Filter Insert at the Air-Liquid 
Interface above HCA2 Fibroblasts, (a) HaCaT keratinocytes were covered in culture 
medium so that they could adhere to the filter insert, (b) After 24hours the culture medium 
level is reduced to feed the HaCaT keratinocytes from below the filter insert and leave 
them open to the air. (c) The cultures were then incubated for 5 days to allow 
stratification.
The expression of the same four SHH-responsive genes (EGR-3, IL-1R2, S100A7 
and PTCH) was assessed by qPCR in HaCaT cells under these co-culture 
conditions. EGR-3 expression in HaCaT keratinocytes in the absence of HCA2 
fibroblasts was increased slightly by recombinant SHH. IL-1R2 expression was 
decreased slightly, while S100A7 and PTCH expression remained unchanged.
In the presence of recombinant EGF (whether SHH was present or not), the 
expression o f all four genes (EGR-3, IL-1R2, S100A7 and PTCH) was reduced. In
the presence o f HCA2 fibroblasts, expression o f EGR-3 remained unchanged 
compared to control HaCaT keratinocytes in the absence o f HCA2 fibroblasts. IL- 
1R2, S100A7 and PTCH expression decreased compared to control levels for 
HaCaT keratinocytes grown in the absence o f HCA2 fibroblasts.
In the presence o f SHH, expression o f EGR-3 levels remained unchanged, while 
levels o f IL-1R2, S100A7 and PTCH levels decreased below control levels (when 
HCA2 were absent). EGF had no effect on EGR-3 expression, but expression of  
IL-1R2, S100A7 and PTCH did decrease. SHH and EGF applied to HaCaT cells in 
combination caused a further reduction in expression o f EGR-3, IL-1R2, S100A7 
and PTCH.
SHH increased EGR-3 expression compared to the control (no SHH protein). 
However, EGF decreased EGR-3 levels and inhibited the effect o f SHH (Figure 
3.12a). HCA2 fibroblasts had little effect on EGR-3 expression in control cells (no 
EGF or SHH) but the presence o f fibroblasts altered the response in the presence 
o f SHH and EGF. Thus, in the presence o f HCA2 cells, EGR-3 levels decreased 
when both SHH and EGF were present together.
SHH halved IL-1R2 levels and EGF reduced IL-1R2 10 fold (Figure 3.12b). 
When both SHH and EGF were present in combination, the reduction was also 10 
fold. In the absence o f recombinant SHH and EGF, HCA2 cells inhibited IL-1R2 
expression and the addition o f SHH or EGF separately caused little change. 
However, when both were present, IL-1R2 levels dropped by half.
SHH had no effect on S100A7 expression levels, but EGF decreased S100A7 
expression 10 fold. EGF also had the same effect when present in combination 
with SHH (Figure 3.12c). In the presence o f HCA2 fibroblasts, S100A7 
expression decreased 3 fold in the absence o f the recombinant proteins and 
addition o f SHH had no effect. However, EGF decreased S100A7 to the same 
level it did when HCA2 cells were not present.
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SHH had no effect on PTCH expression but EGF reduced expression 10 fold. The 
same decrease was apparent (10 fold) when SHH and EGF were added to the cell 
medium in combination (Figure 3.12d). PTCH levels halved in the presence o f  
HCA2 fibroblasts and SHH still had no effect. Interestingly, EGF alone had no 
effect on PTCH levels in the presence o f  HCA2 cells, but PTCH decreased 5 fold 
when both SHH and EGF were added in combination.
3.3.1.8 Scanning Electron Microscopy (SEM)
SEM was used to examine the surface o f cells in order to determine the presence 
or absence o f cilia in HaCaT keratinocytes under different conditions: co-culture 
where HaCaT were allowed to stratify at the air-liquid interface or monolayer 
culture withN/TERTl keratinocytes.
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Figure 3.12: Effects o f  Keratinocyte Co-culture with HCA2 Fibroblasts (Stratified at 
Air-Liquid Interface for 5 days) on SHH Target Gene Expression. Co-cultures of 
HaCaT keratinocytes with HCA2 fibroblasts were allowed to stratify at the air-liquid 
interface for 5 days and the expression of (a) EGR-3, (b) IL-1R2, (c) S100A7 and (d) 
PTCH was measured in the presence and absence of SHH and/or EGF. Dark blue boxes 
represent experiments carried out in the absence of HCA2 cells and light blue boxes in the 
presence o f HCA2 cells. Data expressed as a mean +/- SD for n=2 experiments.
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There were no primary cilia found on HaCaT cells in monolayer culture (Figure
3.13). HaCaT cells cultured on filter inserts at the air-liquid interface did stratify 
and differentiate further but these cells did not have primary cilia either. The cells 
appeared flattened and gaps occurred between adjacent cells but this is an artefact 
caused by dehydration during SEM processing. Cilia-like surface structures could 
be seen on HaCaT keratinocytes cultured at the air-liquid interface for 10 days in 
the presence o f  HCA2 fibroblasts (Figure 3.13c and in Figure 3.13d). There also 
appeared to be some cell surface ruffling at the bottom o f each image, structures 
that look similar to primary cilia. These cells were grown for a longer period in 
culture (10 days rather than 5 days) and this may have provided better conditions 
for cilia formation. Ideally, the experiment should be repeated under these 
conditions (HaCaT cultured for 10 days at the air-liquid interface) and qPCR used 
to determine whether SHH signalling was activated (increased) in the presence o f  
primary cilia.
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Figure 3.13: Scanning Electron Microscopy o f HaCaT Cells Grown in Culture 
Conditions to Achieve Primary Ciliation. (a) No cilia structures were observed in HaCaT 
cells grown in monolayer culture, (b) No cilia were observed in HaCaT keratinocytes 
grown on fdter inserts at the air-liquid interface for 10 days (allowing stratification) in 
the absence of HCA2 fibroblasts, (c, d) Cilia were present in 10-15% of HaCaT cell 
cultures grown in filter inserts at the air-liquid interface for 10 days (allowing 
stratification) in the presence o f HCA2 fibroblasts.
In addition, it would be preferable to use immunofluorescence with an antibody to 
acetylated-a-tubulin detected by confocal microscopy to confirm that the cilia-like 
structures seen in SEM were cilia and not due to dehydration-induced surface 
ruffling.
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Initial attempts to use confocal microscopy were carried out on monolayer cultures 
but primary cilia were not observed. No primary cilia were seen on the surface o f  
any o f  the HaCaT cells grown in monolayer culture on glass coverslips (Figure
3.14). The acetylated-a-tubulin antibody localised to the cytoskeleton and was 
particularly intense at the junctions between cells (Figure 3.14a, c). The 
cytoskeleton was particularly visible in HaCaT cells due to strong antibody 
localisation (Figure 3.14b, d).
One major concern was the lack o f specificity o f the acetylated-a-tubulin antibody 
to the primary cilium since many microtubules were labelled. This would 
potentially make it hard to distinguish the primary cilia from other microtubule 
structures. At this time, confocal appeared to be a veiy time consuming method for 
the detection o f primary cilia and a lack o f positive control to confirm that the 
method would show primary cilia against the microtubule labelling led to the use 
o f scanning electron microscopy (SEM) for more rapid results. However, the 
confocal microscopy did show a higher intensity o f labelling at cell-cell junctions 
suggesting that if  the conditions favouring cilia formation had been used it may 
have been possible to confirm the SEM results.
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Figure 3.14: Immunofluorescence with Antibodies to Acetylated-a-Tubulin in HaCaT 
Keratinocytes Grown in Monolayer Culture on Glass Coverslips. Confocal laser 
scanning microscopy (CLSM) with an acetylated-a-tubulin antibody linked to alexa 488 
(green) showed no primary cilia present on the cells. However, high levels o f acetylated 
tubulin were observed at intercellular junctions (a, b, c; arrow in d) and low levels 
immunolocalised to microtubules throughout the cytoplasm (b, d).
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3.4 Discussion
Optimisation o f  the qPCR experiments for each set o f primers with the DNA was 
challenging due to the low levels o f expression o f these genes in the HaCaT cells 
under all conditions in the cell culture experiments. This meant that for all genes 
other than the housekeeping gene (ACTB), the amplification plots for the dilution 
series were at a high cycle number and for EGR-3 and PTCH the 1:1000 dilution 
gave a plot at a cycle number which was too high to include. However, standard 
curves for all genes except PTCH were still within recommended guidelines. A 
larger quantity o f  DNA may have resolved this problem.
The results o f this study show differences in gene expression between the two 
keratinocyte cell lines (where N/TERT1 were used in Chapter 2 and HaCaT (in the 
absence o f fibroblasts and not grown at the air: liquid interface) in this chapter. 
This might be expected as they are immortalised in different ways and N/TERT1 
keratinocytes are thought to behave more like primary keratinocytes than the 
polyploidy HaCaT cell line.
It is very interesting that EGF has a large inhibitory effect on gene expression in 
HaCaT keratinocytes for EGR-3, S100A7 and PTCH but not for IL1-R2. This may 
have been caused by the presence o f HCA2 fibroblasts. The abnormal phenotype 
o f  HaCaT cells may mean that there are slightly different signal transduction 
interactions compared to in N/TERT1 cells, removing their sensitivity to EGF. It 
would be expected that EGF inhibits PTCH expression, but the inhibition o f EGR- 
3 and S100A7 expression is not continuous with N/TERT1 experimental results in 
chapter 2 or those published by Kasper et al., (2006). IL1R2 and PTCH results 
may have produced results as expected due to effects on expression caused by 
different arms o f  the EGF pathway compared to EGR-3 or S100A7. Paracrine 
signalling alone showed little effect on these results, showing that this was not 
enough to enable polarisation or cilia formation.
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Downregulation o f  all expression when there was development o f stratification in 
the presence o f  HCA2 fibroblasts confirms that paracrine signalling in 
combination with polarised cells caused changes in target gene expression. 
However, this still does not confirm that SHH signalling is activated since there 
was no increase expression in the presence o f SHH. Strangely, in the presence o f  
SHH/EGF expression was downregulated even though in the presence o f EGF 
expression was close to that o f  the control. This was true for all genes (Figure 
3.10a-d). This result o f little change in expression from the control in the presence 
o f SHH or EGF but a decrease in the presence o f both proteins shows that there 
must be an interaction between SHH and EGF, this suggests that SHH signalling 
was activated, if  only by a small amount. These results are encouraging and using 
this method with a longer stratification time (10 days rather than 5) for more cilia 
development would be the next step in moving towards a skin cell model with 
SHH pathway activation. With EGF signalling also activated, further qPCR studies 
could be carried out to find out more about augmentation o f SHH signalling. This 
would be a good reproducible cell model for testing inhibitors for the treatment o f  
BCC.
There may also be non-canonical SHH pathways that don’t need cilia for 
activation. The SHH pathway in drosophila does not require cilia and non- 
canonical pathways are known in humans (Jenkins et al. 2009).
Unfortunately due to time restrictions, these experiments were only carried out 
twice each. But if  they were to be repeated in future it would be beneficial to also 
repeat them on a more ‘normal’ keratinocyte cell line than HaCaT if possible. A 
means o f  carrying this out without the problems o f N/TERT1 and HCA2 cells 
requiring separate culture media, would be to create organotypic cultures. This 
would use HCA2 fibroblasts suspended in a collagen matrix with N/TERT1 
keratinocytes applied to the upper surface o f  the collagen. The collagen matrix 
would be lifted onto a steel mesh support so that the keratinocytes were allowed to 
grow at the air: liquid interface for stratification and the cells could be fed from the
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underside o f the collagen matrix. This means only one medium type would need to 
be used to feed the cells through the collagen and epithelial-mesenchymal 
interactions could occur (Dickson et al. 2000).
The results o f the SEM experiments showed that HaCaT cells need to be grown at 
the air: liquid interface and allowed to stratify for 10 days (to encourage cilia 
formation) before SHH addition. This should be in the presence o f fibroblasts to 
enable successful cilia formation, which may then lead to successful activation o f  
SHH signalling. Interestingly, Strugnell et al. (1996) who found that addition o f  
Ca2+ to keratinocyte culture medium was required to achieve differentiation o f  
cells and enable cilia formation so this may be an avenue which could be followed 
to increase cilia formation (Strugnell et al., 1996). However, it had not previously 
been shown whether N/TERT1 keratinocytes form cilia in monolayer cultures or 
whether they also require the presence o f fibroblasts and growth at the air: liquid 
interface. The results o f chapter two which show little SHH pathway activation in 
monolayer cultures suggest a lack o f primary cilia, but this needs to be confirmed 
by SEM in order to determine whether this genuinely is the cause o f low pathway 
activation or whether it may be due to a lack o f GLI1.
Primary cilia are only present under certain culture conditions, (they form when 
cells aren’t dividing). It seems likely that cells that are committed to terminal 
differentiation that are truly growth arrested are more likely to produce primary 
cilia. This may be the reason for a lack o f augmentation o f GLI response genes by 
EGF in chapter 2. There were a small number o f primary cilia formed in the 
presence o f fibroblasts but none in their absence showing that fibroblasts are 
required for cilia formation. However, the time spent in culture at the air: liquid 
interface may increase stratification and polarisation leading to increased cilia 
formation. Keratinocytes appeared to be polarised (basal cells were columnar and 
well organised) in a complex culture study using HaCaT keratinocytes which were 
allowed to stratify at the air: liquid interface when they were grown on a collagen 
gel containing fibroblasts fed from the underside o f the collagen by culture
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medium, however cilia formation was not confirmed (Bigelow et al. 2005). 
Keratinocyte stratification in the presence o f fibroblasts may increase the number 
o f  ciliated pells compared to in the absence o f fibroblasts, thus increasing SHH 
activation. Cilia form when cells aren’t dividing so it follows that they must be 
growth arrested. Therefore, serum starving for a greater length o f  time may be 
required to ensure growth arrest in order to induce a larger number o f cilia 
(Pedersen et al. 2008). From the results o f this chapter we could speculate that the 
number o f cilia in the cell lines used may also be increased by direct contact with 
fibroblasts, by use o f a fibroblast feeder layer for the keratinocytes; 3D complex 
cultures such as those used by Bigelow et al. (2005) or by growing keratinocytes 
and fibroblasts on either side o f collagen coated porous nylon membranes.
Primary cilia have been found on primary mouse keratinocytes, therefore it seems 
likely that primary human cells would also have cilia and this could be tested by 
SEM. If cilia are found to be present then SHH pathway activation should be 
achievable. However, using immortalised cell lines has the advantage o f  
experimental repeatability and reliability (Wong et al., 2009).
Although SEM showed the presence o f cilia after 10 days o f growth at the air: 
liquid interface, they may be abnormal or not polarised. There may not be SHH 
signalling in cells grown at the air: liquid interface in the presence o f fibroblasts 
due to incomplete polarisation and/or abnormal protein behaviour within the cilia. 
If the IFT proteins do not behave normally the SHH pathway molecules cannot be 
transported to their sites o f  action so the GLIs may not be able to act as 
transcription factors. Tests are needed to show the ability to polarise and normal 
functionality o f  the cilia to confirm whether this is the reason that SHH signalling 
does not seem to be active even in the presence o f fibroblasts. This may include 
further SEM to confirm the cilia alignment or confocal microscopy to confirm co­
localisation o f cilia proteins and the SHH pathway proteins, although confocal 
microscopy o f cilia is very time consuming due to high levels o f  background 
fluorescence.
153
Despite the low numbers o f cilia, the SHH pathway may still be active in this 
experiments carried out for this chapter. This could be shown by 
immunofluorescence with GLI antibodies to detect whether nuclear translocation 
indicating GLI activation has occurred or by western blotting to look for 
upregulated GLI expression. The reason this was not tested is that GLI antibodies 
tend to be o f poor quality.
N/TERT1 keratinocyte cell lines or primary keratinocytes may form greater 
numbers o f  cilia when allowed to stratify in the presence o f fibroblasts due to their 
more normal phenotype (they are not polyploid like HaCaT). Cilium formation 
requires the centrosome so there may be a problem with forming a primary cilium 
in polyploid cells, which would have more than one centrosome/centriole. HaCaT 
cells also have a P53 mutation, which N/TERT1 keratinocytes do not. Apart from 
P53 mutation frequency in cancers, P53 deactiviation is also known to cause 
polyploidy. (Lehman et al. 1993; (Dickson et al. 2000). The challenge here would 
be to find a culture medium in which either o f these types o f keratinocyte could 
grow in combination with fibroblasts as both N/TERT1 and primary keratinocytes 
tend to grow well in serum-free medium.
In this chapter, there has been a change in use o f immortalised cell line from 
N/TERT1 keratinocytes used in the previous chapter to the HaCaT keratinocyte 
cell line. Unfortunately HaCaT cells are polyploidy and so are thought to behave 
less like ‘normal’ keratinocyte cells than N/TERT1 keratinocytes. Polyploidy may 
be caused by the p53 deactivating mutation, which is found in this cell line. 
Abherrent cilia formation may also occur due to formation o f multiple 
centrosomes as a result o f  polyploidy (Oberringer et al. 1999; Dutertre et al. 2005). 
As explained in 3.1.2, the mother centrosome is required for cilia development. 
However, HaCaT are still a commonly used keratinocyte cell line due to their 
ability to differentiate (Boukamp et al. 1988). Another benefit o f their use in this 
study was that in co-culture experiments the keratinocyte cells needed to be grown
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in the same medium as HCA2 fibroblasts. HaCaT keratinocytes and the HCA2 
fibroblast cell line were both cultured in DMEM plus 10% FBS, whereas 
N/TERT1 keratinocytes require serum-free medium. Although use o f HaCaT was 
not ideal, due to time constraints, medium requirements and N/TERT1 
keratinocyte infections at the time o f experimentation, it was the most viable 
option. In future it would be very useful to try repeating these experiments with 
primary (more likely to have cilia than cell lines) or N/TERT1 keratinocytes, if a 
practical method could be found which could utilise both N/TERT1 and HCA2 
cell lines in a co-culture. Co-culture experiments using filter inserts allowed 
diffusion o f growth factors between the HaCaT and HCA2, therefore paracrine 
interactions could occur.
3.5 Conclusion
Primary cilia can be induced on HaCaT keratinocytes; however SHH pathway 
activation should next be confirmed under these culture conditions (10 days 
stratification at the air: liquid interface) and increased by optimisation o f  
conditions to achieve maximum primary cilia numbers. This would make an 
extremely useful model for BCC.
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Chapter 4 
Epidermal Growth Factor Signalling 
in Basal Cell Carcinomas
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4.1 Introduction
Epidermal growth factor (EGF) signalling is thought to augment SHH signalling in 
the epidermis thus promoting tumorigenesis and BCC development (see Figure 
1.13 for details o f pathways involved). EGF receptors are expressed throughout 
the epidermis, with prominent expression on cells o f the basal layer, the postulated 
origin o f BCCs (Nanney, 1984). EGF is also required in addition to SHH for hair 
follicle development which can be disrupted by loss o f  either signalling pathway 
(Chiang et al., 1999; Murillas et al., 1995).
Organotypic culture models (in vitro studies) have shown that HaCaT cells over­
expressing SHH have the ability to invade a collagen matrix and inhibition o f EGF 
signalling blocks this cellular infiltration (Bigelow et al., 2005). Furthermore, 
while eight GLIl/EGF-regulated genes were found to have GLI binding sites in 
their promoter regions, making them direct GLI targets, they also required EGF 
signalling for activation. Also, treatment o f GLI1 expressing N/TERT1 cells with 
Gefitinib (EGFR inhibitor) caused a reduction in activation o f GLI/EGF target 
genes but not GLI target genes inferring EGFR could augment the SHH pathway 
under some conditions.
MEK/ERK activation was found to modulate SHH signalling when U 0126  
(MEK1/2 inhibitor) abolished the synergistic effect o f increased activation o f  
GLI/EGF target genes, and LY294002 (PI3K/AKT inhibitor) had no effect 
(Kasper et al., 2006). However, EGFR signalling has not been directly compared 
in different BCC subtypes, so it is possible that not all BCC subtypes express 
EGFR equally or respond to EGF signalling in the same way. Since EGF can 
affect GLI responsive genes and SHH can also affect EGF signalling, the relative 
activity o f  the two pathways could lead to differential responses and individual 
effects on cell growth patterns in vivo (Bigelow et al., 2005; Kasper et al., 2006; 
Neill et al., 2008). Although PI3K/AKT pathway activity does not appear to 
modulate SHH signalling in vitro, it is important for actin cytoskeleton function 
and may still be involved in BCC growth or invasion (Jimenez et al., 2000).
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The self-activating transcription factor c-Jun is a target o f  MEKK1/JNK 
signalling. In BCC, c-Jun may also be activated by the MEK/ERK arm o f the EGF 
pathway (inhibition o f  MEK/ERK signalling has been shown to reduce c-Jun 
expression) and both o f these arms o f the EGF pathway are activated by RAS (see 
Figure 1.12 for details; Neill et al., 2008). c-Jun is required for up-regulation o f a 
subset o f GLI target genes and is also a direct GLI 1/2 target. However, while c-Jun 
and GLI2A interact, GLI1 and c-Jun do not. Since c-Jun is activated by EGF, it 
may have an important role as one o f the transcription factors involved in EGF 
augmentation o f  GLI transduced genes (Neill et al., 2008).
The different growth patterns o f the BCC subtypes (superficial, nodular and 
morpheaform) may be explained by differences in signal transduction. PTCH 
mutations activate SHH signalling which drives BCC formation. However, as the 
level o f SHH signalling may vaiy due to different PTCH mutations or due to the 
activity o f other signalling pathways such as EGF, different phenotypes may 
result. The location o f  cells harbouring mutations (e.g. stem cells o f the hair 
follicle bulge or epidermis) may also have an effect on SHH signalling. There may 
also be some influence from paracrine signalling in the epidermis or from SHH 
signalling produced by adjacent hair follicles in the anagen growth phase.
Superficial subtypes are currently treatable with a topical formulation o f the drug 
imiquimod (Aldara™), so this study has concentrated on the more invasive BCC 
types, morpheaform and nodular. A topical formulation would be particularly 
useful for eradicating or shrinking large BCCs (prior to surgery), for treating 
BCCs in areas such as the eyelid where surgery is not advisable, or for treating 
areas where tumours recur. Also, effective topical treatment is preferable to 
surgery for multiple tumours at one or more sites.
Since it is possible that EGF signalling is involved in causing the invasive 
subtypes o f  BCC (nodular and morpheaform), it is important to identify which 
genes encoding EGF pathway components are expressed in these BCC subtypes.
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This information can then be used to confirm whether PD98059 and LY294002 
are useful in a topical formulation in addition to SHH inhibitors.
SHH and EGF signalling pathways were proposed as targets for inhibitors within a 
topical formulation because published studies show that the EGF pathway can 
augment SHH signalling and that EGF causes invasion o f SHH expressing 
keratinocytes (Bigelow et al., 2005). Therefore, it seems plausible that one or more 
components o f EGF signalling may cause more invasive BCC subtypes, making 
these particularly useful therapeutic targets.
4.1.1 Aims
• To confirm whether there are any signalling pathway differences between 
BCC subtypes that might cause variation in response to the proposed 
formulation containing SHH and EGF signalling inhibitors.
• To determine whether EGF signalling through MEK/ERK or PI3K/AKT is 
likely to be involved in the invasion o f morpheaform and nodular BCCs.
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4.2 Methods
4.2.1 Immunohistochemistry
Biopsies were collected from patients only after ethical approval was obtained 
from the South East Wales Local Research Ethics Committee. Patients were given 
a Patient Information Sheet and asked to sign a Consent form. BCCs were 
removed by curettage and rapidly frozen in liquid nitrogen within 15 minutes. In 
total, 21 samples o f  six different morphologies were analysed: 11 Nodular, 2 
combined Nodular-Micronodular, 3 Micronodular, 1 Morpheaform, 3 combined 
Micronodular-Morpheaform and 1 combined Morpheaform-Nodular.
4.2.1.1 Haematoxylin & Eosin Staining
Human BCC skin sections were cut at 5- 10pm on a ciyostat, air dried onto 
superfrost slides (Fisher Scientific, Loughborough, UK) and stored at -80°C until 
required.
Slides were brought to room temperature (RT), fixed in dried acetone (Fisher 
Scientific, Loughborough, UK) for 15 minutes at RT and washed 3 times in PBS 
(Phosphate Buffered Saline) for 5 minutes each. Sections were immersed in 
Mayer’s haematoxylin (Fisher Scientific, Loughborough, UK) for 5 minutes, 
washed in running water for 5 minutes and then immersed in 1% eosin for 1 
minute. The sections were washed quickly in water, dehydrated in graded alcohols 
for 5 minutes each (70%, 90%, 100% and 100%) and immersed in three 
consecutive baths o f  xylene (Genta Medical, York, UK) for 5 minutes each. 
Sections were then mounted in DPX (di-n-butyl phthalate in xylene) (Fisher 
Scientific, Loughborough, UK) and sealed with a cover slip.
4.2.1.2 Immunohistochemistry (IHC)
Slides were brought to RT, fixed in dried acetone at RT for 15 minutes and washed 
3 times in PBS for 5 minutes each. The sections were blocked for non-specific 
binding o f  secondary antibody in 5% o f  appropriate serum relative to the species
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in which the primary antibody was raised (donkey, rabbit or goat) diluted in 5% 
BSA (bovine serum albumin) and PBS (Sigma-Aldrich Company Ltd, Gillingham, 
UK) for 1 hour in a humidified chamber. This was followed by three 5 minute 
washes in PBS, blocking with avidin and biotin for 15 minutes each with a 5 
minute PBS wash between (Avidin Biotin Blocking Kit, Vector Labs, 
Peterborough, UK).
Sections were washed 3 times in PBS (5 minutes each), and antibodies diluted in 
PBS containing 5% BSA (see Table 4.1) were applied to the sections and 
incubated for 1 hour. The sections were washed 3 times in PBS (5 minutes each) 
and the appropriate biotinylated antibody (anti-rabbit or anti-mouse 
immunoglobulins; see Table 4.1) diluted 1:200 in PBS plus 5% BSA was applied 
for 30 minutes and then washed 3 times in PBS (5 minutes each).
Streptavidin-conjugated to horseradish peroxidise (GE Healthcare Life Sciences, 
Little Chalfont, UK) in PBS plus 5% BSA (1:100) was applied for 30 minutes, 
followed by washing 3 times in PBS (5 minutes each) and then 200jnl DAB (3, 3 ’- 
diaminobenzidine from Sigma-Aldrich Company Ltd, Gillingham, UK) solution 
(0.5ml in 4.5ml PBS/BSA and 6pl H2O2) was applied for about 10 minutes (until 
sections were sufficiently stained).
This was followed by three 5 minute washes in PBS, submersion in Mayer’s 
haematoxylin (counter stain) for 5 minutes (or light green for 1 minute when using 
the c-Jun antibody) and a 5 minute wash under running tap water. Sections were 
dehydrated by submersing slides in 70%, 90%, 100% and 100% alcohol baths for 
5 minutes each, followed by submersing slides in three consecutive xylene baths 
for 5 minutes each (clearing) and mounting in DPX with a cover slip. To test for 
non-specific binding o f  the secondary antibody and streptavidin-HRP, negative 
control sections were run without primary antibody.
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Table 4.1: Antibodies for Immunohistochemistry and Immunofluorescence.
Antigen Cat Code Company Species Dilute Store
(°C)
EGFR 1005 Sc-03 Santa Cruz 
Biotechnology Inc, 
CA, USA
Rabbit 1:50 4
EGFR-P Sc-12351-R Santa Cruz 
Biotechnology Inc, 
CA, USA
Rabbit 1:50 4
p-AKT 193H12 Cell Signalling 
Technology Inc, 
Danvers, MA, USA
Rabbit 1:200 -20
ERK 9102 Cell Signalling 
Technology Inc, 
Danvers, MA, USA
Rabbit 1:200 -20
p-ERK 9106S Cell Signalling 
Technology Inc, 
Danvers, MA, USA
Mouse 1:200 -20
c-Jun Sc-1694 Santa Cruz 
Biotechnology Inc, 
CA, USA
Rabbit 1:50 4
K14
(LL002)
Gift from Prof E.B. 
Lane, University o f  
Dundee
Mouse 1:10 4
Vimentin M0725 Dako UK Ltd, 
Cambridge House, 
Cambridge, UK
Mouse 1:100 4
Biotinylated
Anti-Mouse
IgG
RPN1001V GE Healthcare UK 
Ltd, Buckingham, 
UK.
Sheep 1:200 4
Biotinylated
Anti-Rabbit
IgG_
RPN1004V GE Healthcare UK 
Ltd, Buckingham, 
UK.
Donkey 1:200 4
Alexafluor 
488 (green) 
conjugated 
anti-mouse 
or anti­
rabbit IgG
A21206 Invitrogen, Paisley, 
UK
Donkey 1:500 -20
Alexafluor 
594 (red) 
conjugated 
anti-mouse 
or anti­
rabbit IgG
A21203 Invitrogen, Paisley, 
UK
Donkey 1:500 -20
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4.2.1.3 Immunofluorescence Microscopy
Double immunofluorescence uses two different coloured fluorochromes, which 
allows images to be overlaid to show co-localisation o f two different proteins. The 
above protocol (4.2.1.2) was followed until the addition o f a biotinylated 
secondary antibody.
This was replaced by the appropriate goat anti-mouse or anti-rabbit IgG 
conjugated to alexafluor 488 (green) or 594 (red). These were added to sections at 
a 1:500 dilution in PBS plus 5% BSA (Invitrogen, Paisley, UK) and incubated for 
30 minutes. The slides were washed three times in PBS (5 minutes each) and 
200pl DAPI (4', 6-diamidino-2-phenylindole; Roche Applied Science, Mannheim, 
Germany) was applied to each section (1:5000 in PBS plus 5% BSA) to label the 
nuclei blue. This was immediately tapped o ff onto tissue and the sections were 
mounted in hydromount (Fisher Scientific, Loughborough, UK) containing 2.5% 
DABCO (Sigma-Aldrich Company Ltd, Gillingham, UK) to prevent photo 
bleaching. Cover slips were placed gently on top and the slides were allowed to 
stand for 30-60 minutes on the bench. Sections were then viewed using a Zeiss 
microscope with fluorescence optics and digital images obtained using an 
Axiocam HRc Zeiss camera with Axiovision software on an IBM PC.
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4.3 Results
4.3.1 BCC Tumour Morphology
BCC tumours fit into three broad categories based on their morphology. It is 
important to remember that even the most infiltrative BCC grows slowly and they 
rarely metastasize. Superficial tumours grow across the epidermis, nodular 
tumours grow in large islands which may penetrate into the dermis (micronodular 
tumours are made up o f  lots o f smaller tumour islands) and morpheaform tumours 
grow with finger-like projections down into the dermis. Often a tumour is a 
mixture o f more than one subtype. The majority (20) o f  BCC samples collected for 
this study were nodular combined with micronodular although four o f  these were 
morpheaform combined with nodular or micronodular but only one was 
completely morpheaform (Table 4.2).
Typical examples o f different tumour morphologies represented in the BCC 
samples collected show how variable they were within each type o f  BCC (Figure 
4.1). This variability demonstrates how different the tumour environments may be 
between different patient samples or even within each sample. Haematoxylin and 
eosin staining showed tumour islands as blue/purple areas within a pink dermis 
(nuclei stain blue). Morpheaform tumours (Figure 4.1 a, b) have thin finger-like 
projections consisting o f thin strands only 2 or 3 cells thick infiltrating into the 
dermis and some pieces o f tumour can appear isolated from the main tumour 
islands. Nodular tumours (Figure 4.1 c-e) have large tumour islands that appear to 
be separated with larger dermal areas, where the bulk o f the tumour is much larger. 
Some nodular tumours have a very different appearance (e), with the bulk o f the 
tumour being a large but more complex in shape. Micronodular tumours have lots 
o f tiny tumour nodules (Figure 4.1 f).
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Table 4.2: Basal Cell Carcinoma Specimen Subtypes. BCC morphology according to 
visual analysis of haematoxylin and eosin stained sections. Variation was found between
tumour samples within the same subtype.
Sample Subtype Description
1 Nodular Nodules o f BCC with several tumour islands.
2 Nodular Two large nodular BCC tumour islands.
3 Morpheaform Tumour strands (only 2 cells thick) weaving 
through dermis.
4 Nodular Nodules o f BCC with several tumour islands 
with epidermis present.
5 Nodular Tumour nodules interlaced with stroma and 
epidermis present.
6 Nodular Large tumour islands with little epidermis.
7 Nodular One large tumour nodule.
8 Nodular Small tumour islands.
9 Micronodular/
Morpheaform
Thick strands o f tumour through the dermis 
with smaller tumour islands at the infiltrative 
edge.
10 Nodular/
Micronodular
Large nodular tumour islands with infiltrating 
regions o f small tumour nodules.
11 Micronodular/
Morpheaform
Small tumour with some infiltrative regions.
12 Nodular Large nodule with epidermis present.
13 Micronodular/
Morpheaform
Many small nodular tumour islands, some 
with lacy infiltrative appearance and the 
epidermis intact.
14 Micronodular Many small tumour islands with some 
epidermis present.
15 Nodular/
Micronodular
Large nodular tumour island with small 
infiltrative islands at edge and little 
epidermis.
16 Micronodular Many small nodular tumour islands with little 
epidermis.
17 Nodular Large tumour islands.
18 Nodular Small very separate tumour islands within the 
dermis.
19 Nodular Both large and very small tumour islands with 
the epidermis present.
20 Micronodular Many small nodular tumour islands with the 
epidermis present.
21 Morpheaform/
Nodular
Large tumour islands with very infiltrative 
edges.
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Figure 4.1: Haematoxylin and Eosin Stained BCC Tumour Sections showing the Range 
o f Morphologies in this Study. Two were morpheaform: tumours #5 (a) and #9 (b). 
Three were nodular but had very different histology: tumour #8 had widely spaced tumour 
islands (c), #6 had large tumour islands (d) and #9 had large tumour islands which were 
‘infdtrative ’ (e). The other was micronodular with many closely spaced tumour islands, 
#20 (f). Scale bars (100pm) shown for each section.
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4.3.2 EGF Pathway Components in Normal Human Skin
The expression and phosphorylation o f proteins in the EGF signalling pathway 
have been examined in normal skin using antibodies to detect EGFR and three 
phosphorylated proteins (p-EGFR, p-ERK and p-AKT). Particular emphasis was 
placed on examining levels in the epidermis, sebaceous gland and hair follicle.
The EGFR antibody stained all the cells o f the epidermis from the lower basal 
cells to the granular layer (Figure 4.2a). Staining was particularly intense in the 
periphery o f  some cells indicating an association with the plasma membrane. The 
use o f a phospho-specific antibody to detect p-EGFR showed that not all o f the 
EGFR present in the epidermis was phosphorylated (Figure 4.2c). Staining with 
the p-ERK antibody showed that phosphorylation o f  ERK occurred mainly in the 
upper layers o f the epidermis with intense peripheral staining o f granular cells 
(Figure 4.2e). Finally, the p-AKT antibody stained cells only in the lower 
epidermis (basal and immediate suprabasal cells) again with greater intensity at the 
cell periphery (Figure 4.2g).
The sebaceous gland was also examined in the sections stained with antibodies to 
EGFR, p-EGFR, p-ERK and p-AKT. The periphery o f the individual sebocytes 
and the whole duct epithelium was stained with the EGFR antibody (Figure 4.2b). 
However, as with the epidermis, not all o f the EGFR present was phosphorylated 
(Figure 4.2d). The staining with p-ERK (Figure 4.2f) was very similar to that 
with EGFR but p-AKT differed. This antibody stained the epithelial basal cells o f  
the sebaceous duct and the epithelium between the sebocytes in the sebaceous 
gland (Figure 4.2h). The individual sebocytes remained unstained.
4.3.3 Immunoperoxidase Detection of EGFR in BCC Samples
Immunolocalisation o f  EGFR was variable in the group o f BCC biopsy specimens 
examined (Figure 4.3).
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Figure 4.2: Intmunoreactivity o f  EGF Pathway Components on Sections o f  Normal 
Human Skin. EGFR (a, b) and p-EGFR (c, d) staining was positive throughout the 
cytoplasm o f epidermal cells (a, c) and cells o f the sebaceous gland (b, d). p-ERK staining 
(e, f) was cytoplasmic in the upper epidermal cell layers and throughout the sebaceous 
gland. p-AKT staining (g, h) was positive at the cell membrane in the basal layer and in 
some suprabasal cell layers, as well as in cells o f the sebaceous gland and duct. Scale 
bars (50pm) shown for each section.
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In general, tumours showed cytoplasmic and/or membrane positive 
immunoreactivity throughout tumour islands or in patches within the islands. 
Cytoplasmic localisation o f EGFR suggests activation by EGF ligand leading to 
transcription in the cell nucleus. Membranous localisation suggests no activation 
o f EGFR. It is therefore likely that p-EGFR would be present if  EGFR is located in 
the cytoplasm. In these experiments localisation was judged by visual appearance, 
with expression being judged as membranous if  the margins o f the cells were 
stained brown with the centre lighter in colour and cytoplasmic if  the cell itself 
was stained brown.
EGFR staining in one nodular tumour (Figure 4.3a) showed a very strong 
cytoplasmic reaction throughout all tumour islands. A micronodular tumour 
(Figure 4.3b) also showed strong immunoreactivity which appears to be at the cell 
periphery in all tumour islands. However, one nodular tumour (Figure 4.3c) had 
patchy positive immunoreactivity in the cytoplasm o f one large tumour island and 
another nodular tumour (Figure 4.3d) was positive for EGFR in the cytoplasm o f  
one tumour island but was negative in the others. This shows a lack o f  correlation 
between EGFR location and the nodular subtype, although all these nodular 
tumours did vary histologically.
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Figure 4.3: Immunohistochemistry o f EGFR in Human BCC Samples from Four 
Different Patients. Nodular tumour #4 (a) with cytoplasmic EGFR expression throughout 
all tumour islands, Micronodular tumour #9 (b) with EGFR immunoreactivity throughout 
the tumour islands, Large nodular tumour #6 (c) showing patchy positive cytoplasmic 
immunoreactivity for EGFR and Nodular BCC #18 (d) showing EGFR immunoreactivity 
in one tumour island but not the others.
4 .3 .4  Im m u n o p e r o x id a se  D etec tio n  o f  p -E G F R  in B C C  S am p les
Two different tumour samples were examined (#5 and #6). EGFR 
immunoreactivity was positive in the lower epidermis and was patchy in the 
tumour islands (Figure 4.4a, c). In general cells with a basal phenotype were 
stained. EGFR is autophosphorylated to p-EGFR when activated by its ligand and
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this can be detected using a phospho-specific antibody. The same two tumour 
samples (#5 and #6) were examined for the presence o f p-EGFR but 
immunoreactivity was very low and could be considered negative (Figure 4.4b,
d).
lOOjim
Figure 4.4: Immunohistochemistry (EGFR and p-EGFR) on two Human BCC 
Samples. Variable EGFR expression and little or no p-EGFR expression were observed in 
both samples. Tumour #5 showed patchy cytoplasmic expression o f EGFR (a) but no 
staining was observed with p-EGFR (b). Tumour #5 was similar (c, d).Scale bars are 
shown for each sample (100pm).
lOfyun
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EGFR immunoreactivity was variable in the 21 tumours examined and was 
considered to be low in 4, moderate in 11 and high in 6 (Table 4.3). There was 
also little correlation between the level o f  immunoreactivity and tumour subtype 
and the localisation was also variable with the majority (14 tumours) showing 
cytoplasmic staining, a few (4 tumours) showing membrane staining and the others 
(3 tumours) being stained at both locations.
Immunoreactivity to p-EGFR was cytoplasmic and only observed in 8 out o f 21 
tumour samples (low in 7 and moderate in 1). The 8 positive tumours were o f all 
subtypes so there was no correlation between EGFR phosphorylation and subtype. 
The 6 tumours that showed high EGFR expression (Table 4.3) were either 
negative for p-EGFR (5) or only had very low levels o f staining (1). This would be 
expected to lead to little or no activation o f downstream pathways leading to 
reduced phosphorylation o f ERK and/or AKT and therefore little c-Jun 
translocation to the nucleus in BCCs.
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Table 4.3: EGFR and p-EGFR Immunoreactivity in BCC Tumour Samples. EGFR 
immunoreactivity is variable and unrelated to phenotype and p-EGFR immunoreactivity
in BCC tumour samples is low or absent (* = low, ** = moderate and *** = high).
Sample Subtype EGFR p-EGFR
Tissue
level
Subcellular
localisation
Tissue
level
Subcellular
localisation
1 Nodular ** Cytoplasm None N/A
2 Nodular ** Cytoplasm * Cytoplasm
3 Morpheaform ** Cytoplasm * Cytoplasm
4 Nodular *** Membrane None N/A
5 Nodular ** Cytoplasm None N/A
6 Nodular * Cytoplasm * Cytoplasm
7 Nodular ** Membrane None N/A
8 Nodular ** Membrane None N/A
9 Micronodular/
Morpheaform
*** Membrane None N/A
10 Nodular/
Micronodular
* Cytoplasm None N/A
11 Micronodular/
Morpheaform
** Cytoplasm * Cytoplasm/
Nuclei
12 Nodular ** Cytoplasm * Cytoplasm
13 Micronodular/
Morpheaform
*** Cytoplasm * Cytoplasm
14 Micronodular ♦♦♦ Membrane/
Cytoplasm
None N/A
15 Nodular/
Micronodular
** Cytoplasm None N/A
16 Micronodular ** Membrane/
Cytoplasm
None N/A
17 Nodular *** Cytoplasm None N/A
18 Nodular *** Membrane/
Cytoplasm
None N/A
19 Nodular * Cytoplasm ** Cytoplasm
20 Micronodular * Cytoplasm * Cytoplasm
21 Morpheaform/
Nodular
** Cytoplasm None N/A
4.3.5 Immunoperoxidase Detection of ERK and p-ERK in BCC
There was variable positive cytoplasmic ERK immunoreactivity in the tumour 
specimens examined, being weak in most tumours, patchy in some and positive 
throughout the tumour islands in others. ERK levels in micronodular tumours were
173
weak and patchy (Figure 4.5a, b) but in nodular tumours, ERK levels were more 
variable and ranged from high (Figure 4.5c) to little expression (Figure 4.5d).
Figure 4.5: Immunohistochemistry o f ERK in Human BCC Samples. ERK levels in 
BCC tumours were variable. Low levels of cytoplasmic ERK were found in micronodular 
tumours #16 (a) and #20 (b), high levels of expression in nodular tumour #17 (c) while 
nodular tumour #19 was negative (d).
Considering all 21 BCC tumour samples (Table 4.4), moderate ERK expression 
was localised to the cytoplasm and nuclei o f 2 nodular tumours while low levels 
were found in the cytoplasm of 9 tumours (nodular, morpheaform, 
micronodular/morpheaform, micronodular) and ERK was absent in the other 10 
tumours (nodular, micronodular, nodular/micronodular and 
micronodular/morpheaform). In some tumours, nuclear staining was also noted in 
addition to cytoplasmic staining. Thus, there was little correlation between tumour 
morphology and the level and localisation o f ERK expression.
174
Table 4.4: Tumour Sample Morphology and Immunoreactivity (ERK and p-ERK) in 
Human BCC Samples. Immunohistochemistry showed variable levels o f ERK (* = low 
expression, ** = moderate expression). No samples were positive with the p-ERK
antibody.
ERK p-ERK
Sample BCC Subtype Tissue
Level
Subcellular
Localisation
Tissue
Level
Subcellular
Localisation
1 Nodular * Cytoplasm/
Nuclei
None N/A
2 Nodular ♦ * Cytoplasm None N/A
3 Morpheaform * Cytoplasm/
Nuclei
None N/A
4 Nodular ** Cytoplasm/
Nuclei
None N/A
5 Nodular None N/A None N/A
6 Nodular None N/A None N/A
7 Nodular * Cytoplasm None N/A
8 Nodular * Cytoplasm None N/A
9 Micronodular/
Morpheaform
* Cytoplasm None N/A
10 Nodular/
Micronodular
None N/A None N/A
11 Micronodular/
Morpheaform
None N/A None N/A
12 Nodular None N/A None N/A
13 Micronodular/
Morpheaform
None N/A None N/A
14 Micronodular None N/A None N/A
15 Nodular/
Micronodular
None N/A None N/A
16 Micronodular * Cytoplasm None N/A
17 Nodular * Cytoplasm/
Nuclei
None N/A
18 Nodular * Cytoplasm/
Nuclei
None N/A
19 Nodular None N/A None N/A
20 Micronodular * Cytoplasm None N/A
21 Morpheaform/
Nodular
None N/A None N/A
No positive immunoreactivity was obtained using an antibody specific for the 
phosphorylated form o f ERK (p-ERK) inferring that ERK activation was not 
apparent in any o f  these BCC samples (Table 4.4).
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ERK cannot be activated by phosphorylation unless EGFR is phosphorylated 
leading to a series o f protein activations downstream o f the receptor, so p-ERK 
would not be expected in tumours that were p-EGFR negative. However, this does 
not explain the absence o f p-ERK in p-EGFR positive tumours. Some samples 
showed patchy positive expression o f both EGFR and ERK, and as ERK is 
downstream o f EGFR, it might be expected that similar patterns o f expression and 
location were observed in each sample. However, this did not seem to be the case 
because high EGFR expressing samples (4, 9, 17 and 18) showed low to moderate 
ERK expression and sample 13 showed no ERK expression at all. Also, no 
correlation by location was observed in sequential sections o f tumour sample.
Thus, ERK was expressed at low level and was not activated by phosphorylation 
in the BCC samples examined. This infers that the MEK/ERK arm of the EGF 
pathway is unlikely to be involved in modulation o f the SHH pathway at this stage 
o f  tumour growth or in promotion o f an infiltrative phenotype.
4.3.6 Immunoperoxidase Detection of p-AKT in BCC Samples
Moderate p-AKT levels were observed in spindle shaped cells o f nodular tumour 
#1, with staining o f both the cytoplasm and plasma membrane (Figure 4.6a). 
Clusters o f  p-AKT positive cells were found in micronodular tumour #2 (Figure 
4.6b) and another nodular tumour (#8) also showed small clusters o f p-AKT 
positive cells (Figure 4.6c). Finally, a small epidermal down-growth above 
nodular tumour #19 also contained a cluster o f p-AKT positive cells (Figure 
4.6d).
Positive staining for p-AKT was found in 14 tumour samples (3 had moderate 
levels) while the other 7 tumour samples had no p-AKT immunoreactivity (Table 
4.5). Generally, staining was cytoplasmic and localised at the centre and 
infiltrating edges o f  tumour islands.
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Figure 4.6: Immunohistochemistry o f Human BCC Samples with p-AKT. (a) nodular 
tumour #1 showed extensive strong p-AKT staining o f spindle shaped cells. Smaller 
numbers o f similar cells were positive in micronodular tumour #20 (b) and nodular 
tumour #8 (c). p-AKT positive cells were also observed in an epidermal down-growth 
above nodular tumour #19 (d).
Again, there appeared to be very little correlation between p-AKT staining and 
tumour morphology. The morphology o f the three samples that showed moderate 
levels o f p-AKT all differed (nodular, nodular/morpheaform and 
micronodular/morpheaform). Tissue localisation in these moderately expressing 
samples did correlate to subtype, with micronodular and morpheaform being the 
most infiltrative or aggressive. No samples had high levels o f p-AKT (Table 4.5).
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Table 4.5: Levels and Sub-cellular Localisation o f p-AKT in Human BCC Specimens.
Immunohistochemistry o f p-AKT in all 21 BCC samples showed that moderate staining 
(**) was present in 3 specimens, low levels (*) in 11 specimens and no staining (None) in
7 samples. Where p-AKT was positive, only cytoplasmic staining was observed.
p-AKT
Sample Subtype Tissue
Level
Subcellular
Localisation
1 Nodular ** Cytoplasm
2 Nodular * Cytoplasm
3 Morpheaform None N/A
4 Nodular * Cytoplasm
5 Nodular * Cytoplasm
6 Nodular * Cytoplasm
7 Nodular None N/A
8 Nodular/Morpheaform ** Cytoplasm
9 M icronodu lar/Morpheaform None N/A
10 Nodular/Micronodular * Cytoplasm
11 Micronodular/Morpheaform None N/A
12 Nodular None N/A
13 Micronodular/Morpheaform ** Cytoplasm
14 Micronodular * Cytoplasm
15 Nodular/Micronodular * Cytoplasm
16 Micronodular * Cytoplasm
17 Nodular * Cytoplasm
18 Nodular None N/A
19 Nodular None N/A
20 Micronodular * Cytoplasm
21 Morpheaform/nodular * Cytoplasm
If p-AKT positive cells were involved in infiltration and invasion, it would be 
expected that they would be located at the tumour margins. However, this pattern 
was not observed in the samples studied and p-AKT reactivity was found both at 
the margins and in the centre o f tumour islands. This p-AKT immunoreactivity is 
unlikely to be due to a lack o f  antibody specificity, as western blotting analysis 
showed reactivity with a single protein band o f the correct size (data not shown).
Interestingly, all cells positive for p-AKT were spindle shaped, more reminiscent 
o f fibroblasts than keratinocytes. Tumour cells are known to undergo epithelial-
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mesenchymal transition (EMT) and such altered cells grow more aggressively 
causing increased tumour down-growth into the dermis and subcutaneous tissues 
(Larue and Bellacosa, 2005). However, there was only one BCC with 
morpheaform characteristics (the most aggressive BCC subtype) in this study and 
this was only moderately positive.
4.3.7 Double Immunofluorescence Detection of p-AKT and 
Keratin (K14) or Vimentin
In order to ascertain whether the spindle shaped p-AKT expressing cells were due 
to EMT, the sections were treated with an antibody to vimentin (intermediate 
filament protein present in fibroblasts but not keratinocytes). Double 
immunofluorescence with the antibody to p-AKT would ascertain whether p-AKT 
positive tumour cells had converted to a fibroblast phenotype. In addition, a K14 
antibody was used to identify keratinocyte characteristics that should be found 
throughout the tumour islands as these cells are o f epidermal origin. However, if  
the p-AKT expressing cells had undergone EMT, they would express little or no 
K14 and should be vimentin positive. Tumour cells in the process o f EMT might 
express both the fibroblast marker vimentin and the epidermal cell marker K14.
Staining sections o f a nodular BCC tumour with both a K14 antibody (red 
fluorescent tag) and an p-AKT antibody (green fluorescent tag) showed that all 
cells expressed K14 in their cytoplasm but only a limited number o f spindle 
shaped cells contained p-AKT (Figure 4.7a). However, it remains unclear as to 
whether the spindle cells express K14 or not. Staining a similar section with a 
vimentin antibody (red fluorescent tag) gave only background red fluorescence 
and the spindle cells again were stained bright green showing the presence o f p- 
AKT (Figure 4.7b). A higher power view o f the tumour stained with both p-AKT 
(green) and vimentin (red) showed that these two proteins appear to be mutually 
exclusive in terms o f  expression with the spindle shaped cells being p-AKT +ve
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and vimentin -v e  while the other cells in the section were p-AKT -ve  and 
vimentin +ve (Figure 4.7d).
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F igure 4.7: D ouble Im m unofluorescence o f  p -A K T  and an Epiderm al Cell 
M arker (K14) or a Fibroblast Cell M arker (Vimentin) in N odular Human BCC  
Sam ple (#15). Nodular BCC tumour islands (a, b, c) were stained with antibody to p- 
AKT (a-d) with a green fluorescent tag and either an antibody to K14 (a,) or an antibody 
to vimentin (b, c) with a red fluorescent tag. Combined images o f both red and green 
fluorescence are shown with yellow indicating the presence o f both antigens. Scale bars 
are indicated on each section.
4 .3 .8  Im m u n o p e r o x id a se  D etec tio n  o f  c-Ju n  in B C C  S a m p les
Immunoreactivity for c-Jun was strongly positive and localised to the nucleus in 
virtually all tumour islands in all BCCs (Figure 4.8). Expression o f c-Jun was
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similar in tumours of different morphology (nodular, nodular/micronodular and 
morpheaform).
The transcription factor complex AP-1 is composed o f c-Jun and c-Fos and nuclear 
localisation suggests that the AP-1 complex is active in the BCC samples 
examined.
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Figure 4.8: Immunohistochemistry Detection o f c-Jun in Sections o f Human BCC.
Immunoreactivity o f c-Jun (with light green counter stain) showed strong nuclear 
expression in most samples: nodular tumour #1 (a), micronodular/morpheaform tumour 
#9 (b) and micronodular tumour #14 (c), but expression was low in some such as the 
morpheaform tumour #3 (3).
All 21 tumour samples in this study expressed nuclear c-Jun and levels were high 
in 15 tumours and moderate in 6. There appeared little relationship between the 
level o f c-Jun and tumour morphology (Table 4.6).
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The AP-1 transcription complex is targeted by EGF signalling and interaction 
between c-Jun and GLI2 may lead to augmentation o f  SHH signalling. 
Augmentation was originally thought to occur via the MEK/ERK arm o f the EGF 
pathway but the patchy expression o f EGFR, p-EGFR, ERK and p-ERK found in 
this study suggests that the MEK/ERK pathway did not activate c-jun. Localisation 
o f p-AKT to a few randomly spread tumour cells also suggests that activation o f  
the PI3K/AKT arm o f the EGF pathway cannot explain why all tumour cells are 
positive for c-jun. Thus, it seems likely that there is a different mechanism of 
activation in these tumours.
Table 4.6: Morphology, c-Jun Expression and Subcellular Localisation in Human BCC 
Specimens. Immunoreactivity with the c-Jun antibody was found in the nuclei o f all 
tumour island cells at a moderate (**) or high (***) level. Again there appeared little
correlation between levels o f  c-Jun and tumour morphology.
c-Jun
Sample Subtype Expression
Level
Subcellular
localisation
1 Nodular ♦♦♦ Nuclear
2 Nodular *♦ Nuclear
3 Morpheaform ** Nuclear
4 Nodular *** Nuclear
5 Nodular *♦ Nuclear
6 Nodular ** Nuclear
7 Nodular ♦** Nuclear
8 Nodular ♦** Nuclear
9 Micronodular/Morpheaform *** Nuclear
10 Nodular/Micronodular *** Nuclear
11 Micronodular/Morpheaform *** Nuclear
12 Nodular *♦ Nuclear
13 Micronodular/Morpheaform *** Nuclear
14 Micronodular *** Nuclear
15 Nodular/Micronodular *** Nuclear
16 Micronodular *** Nuclear
17 Nodular *** Nuclear
18 Nodular ** Nuclear
19 Nodular *** Nuclear
20 Micronodular *** Nuclear
21 Morpheaform/Nodular *** Nuclear
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4.5 Discussion
Signalling pathway differences between BCC subtypes were considered by 
comparison o f  a variety o f nodular and morpheaform BCC samples.
Immunoreactivity for EGF signalling components EGFR, p-EGFR, p-ERK and p- 
AKT was confined to the dermis and to structures such as the sebaceous gland. In 
BCCs they would be expected to be found within tumour islands and particularly 
at the tumour island margins o f the most aggressive phenotypes (nodular and 
morpheaform) if  they were to be involved in augmenting SHH signalling causing a 
more aggressive phenotype as hypothesised.
Immunohistochemistry has shown a lack o f EGFR auto-phosphorylation, which 
has led to reduced levels o f ERK and AKT phosphorylation (in fact no p-ERK was 
found in any o f the 21 samples) compared to levels expected in normal human 
skin.
EGFR was absent from BCCs in a study which used paraffin sections (Neill et al.,
2008), but another group who also used frozen sections (better for maintaining 
antibody epitopes) found EGFR immunoreactivity in BCCs agreeing with the 
findings in this chapter (Rittie et al., 2007). Immunolocalisation o f EGFR in this 
study was highly variable but neither location nor amount was linked to BCC 
subtypes o f  nodular, morpheaform or micronodular (Table 4.2). The different 
immunolocalisation o f this protein between BCCs (membraneous or cytoplasmic) 
may be explained by internalisation and degradation o f the protein caused by 
ligand binding. However, the lack o f phosphorylation (only phosphorylation in 8 
out o f  21 tumours) suggests that this is not true and high EGFR levels also did not 
equate to phosphorylation. Lack o f phosphorylation o f  this receptor in these 
samples meant that downstream signalling would not be activated by this pathway. 
Downstream proteins ERK and AKT may have been activated by a separate 
signalling pathway, which is quite possible as EGF-independent AKT activation
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by p38MAPK (which was activated in the absence o f EGFR by Her2) has been 
found previously in HER2 expressing human mammary epithelial cells (Diehl et 
al., 2006). In support o f this hypothesis, Her2 expression was shown in 14 out o f  
16 BCCs using RT-PCR (Krahn et al., 2001).
EGFR was commonly expressed in the tumour samples used for this study, but 
downstream signalling component ERK was expressed only at low levels and in 
few tumours with variable localisation, whereas phosphorylation o f ERK was 
absent in all o f the samples. The low levels o f ERK in BCCs in this study are 
continuous with previous observations using immunohistochemistry by Neil and 
co-workers. (Neil et al., 2008). This group also found a lack o f p-ERK except in 
one sample where they found p-ERK localised to infiltrating cells, suggesting that 
phosphorylation o f  ERK may be involved in causing tumours to be more invasive. 
However, because this result was not repeated in any o f the 21 samples analysed in 
this study, which were all nodular or morpheaform subtypes (the most invasive 
BCC subtypes) it seems unlikely that ERK phosphorylation would be involved in 
causing an invasive BCC phenotype. This is also at odds with the previously 
published observation that MEK1/2 inhibitor U 0126 abolished the synergistic 
effect o f increased activation o f GLI/EGF target genes (Kasper et al., 2006). 
Activated ERK (p-ERK) is a target o f MEK and thus MEK/ERK signalling is 
unlikely to promote an infiltrative BCC phenotype by modulation o f the SHH 
signalling.
In order to confirm or deny Neill and colleagues interpretation o f p-ERK 
expression in one tumour being the cause o f an aggressive phenotype, this study 
would require extending to a larger sample number for immunohistochemistry 
with the p-ERK antibody to further compare the characteristics o f the most and 
least aggressive BCCs. The same is true to confirm whether sub-cellular 
localisation o f  EGFR correlates to tumour subtype.
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Reduced p-ERK and p-AKT in tumour islands and the overlying epidermis 
compared to normal human skin was found in BCCs but not in squamous cell 
carcinomas by immunohistochemistry (Rittie et al., 2007). However, p-AKT levels 
were not affected by GLI expression in HaCaT cell experiments suggesting that 
this branch o f the EGF pathway is not affected by SHH signalling (Schnidar et al.,
2009). The effects seen in tumour samples may be due to a paracrine effect or 
extracellular matrix interactions in BCCs which were not present in cultures o f  
keratinocytes alone.
The spindle cell morphology o f the few p-AKT positive cells shown by 
immunohistochemistry in two thirds o f the samples in this study was particularly 
interesting because this morphology is associated with EMT. However, they were 
localised in the centre o f tumour islands as well as the margins and in tumours o f  
different morphologies, which does not correlate with an infiltrative phenotype, 
which EMT is associated with. In EMT there is a loss o f  cell to cell adhesions 
because AKT represses E-cadherin (cell junction protein), a loss o f E-cadherin 
leads to epithelial-mesenchymal transition. In that situation, cell-cell adhesion is 
reduced and so the mesenchymal cells are more invasive, thus metastases are more 
likely to occur (Julien et al., 2007). However, EMT rarely occurs in BCCs, 
possibly explaining why there was little positive immunoreactivity for AKT in 
BCC tumour specimens. If the cells positive for AKT are indicators o f EMT in the 
tumour specimens used for this study, then the low number o f affected cells would 
correlate with the slow growth and poor invasive properties o f BCCs. If this is the 
case, superficial BCC, the least aggressive subtype would likely express no p- 
AKT. However, immunofluorescence showed a lack o f  co-localisation o f  p-AKT 
with a fibroblast marker vimentin thus indicating that the p-AKT positive cells 
have not undergone EMT. Supporting this observation, it was shown that GLI1 
repressed induction o f the EMT marker vimentin in EGF-stimulated cells, making 
EMT unlikely in BCCs (Neill et al., 2008). The same group found that EGF/GLI 
expressing keratinocytes demonstrated an elongated morphology. Live cell- 
imaging confirmed that the cells could not detach or retract efficiently giving them
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a stretched appearance (Neill et al., 2008). Again, a larger BCC sample number 
with a good variety o f tumour invasiveness would be useful to repeat this 
immunohistochemistry in order to determine whether the more invasive or 
metastatic tumours have higher positive immunoreactivity for AKT and to find out 
why this would be related to a more aggressive phenotype.
The appearance o f  p-AKT immunoreactivity in cytoskeletal regions suggests that 
p-AKT may have migratory or a contraction function because it may be located on 
the stress fibres. In order to confirm or disprove the theory that p-AKT may be 
associated with EMT in BCC, double immunofluorescence with E-cadherin and p- 
AKT antibodies would be useful to confirm whether p-AKT positive cells express 
E-cadherin. If they do not express E-cadherin it is likely that they have undergone 
EMT. Unfortunately as yet we have not found a good E-cadherin antibody which 
is not the same species as the p-AKT antibody used in this study.
Previous publications have shown PI3K/AKT signalling enhanced remodelling o f  
the actin cytoskeleton (Scita et al., 2000). It has also been shown that PI3K has 
multiple roles, including the strengthening o f cell-cell adhesions; and in addition, 
p-AKT may indeed be involved in cell migration, as it has been shown to mediate 
lamellipodium formation (Cain and Ridley, 2009; Wennstrom et al., 1994). One 
report found evidence o f p-AKT and p-actin co-localisation in neural growth cones 
(Zhou et al., 2004). PI3K signalling is required for axon growth, where it is 
activated at the leading edge o f migrating neuronal cells. A PI3K regulatory 
subunit is involved in the control o f actin organisation and cell migration. 
However, co-localisation with cytoskeletal filaments is not normally seen (Cain 
and Ridley, 2009; Jimenez et al., 2000). Together, the results o f this study and 
these publications suggest that within those strangely spindle shaped cells there is 
p-AKT and p-actin co-localisation which may enable tumour cell migration deeper 
into the dermis or possibly even in the few moderately expressing tumours (3 out 
o f  21 BCCs), leading to the rare event in BCC o f  metastasis. It is unlikely that the 
p-AKT antibody did in fact cross-react with a keratin or another protein because
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this antibody has been used successfully for western blotting producing a single 
band o f the correct molecular weight. For future work immunofluorescence could 
be used to label BCC biopsies with both actin and p-AKT to confirm that they are 
co-localised.
C-Jun was strongly expressed in all BCC nuclei in all tumour samples which 
supports previously published findings where immunohistochemistry and qPCR 
also showed c-Jun expression throughout tumour islands but not in the stroma 
(Laner-Plamberger, 2008). As c-Jun is required for the up-regulation o f a subset o f  
GLI target genes, it makes sense that it is present in all BCC nuclei. The presence 
o f  c-Jun but not upstream p-EGFR or p-ERK means that it is unlikely that it was 
activated by the MEK/ERK pathway in BCCs. Therefore c-Jun must be activated 
by another means, this could be another arm o f the EGF signalling pathway, which 
is unlikely due to the lack o f p-EGFR, but may be possible as one group have 
shown in prostate cancer cells (prostate cancer is an epithelial carcinoma like 
BCC) that EGF induced mitogenic signalling could be induced by grape seed 
extract, which at the same time activated JNK, which in turn activates c-Jun 
(Tyagi et al., 2003). Therefore, it is possible that c-Jun is activated by the 
MEKK1/JNK branch o f the EGF pathway in BCCs. EGFR activation in the 
overlying epidermis is unlikely to be the cause o f c-Jun expression in all the 
tumour samples because the epidermis is often disrupted in BCC and p-EGFR 
expression was not found in the overlying epidermis. In order to confirm why c- 
Jun is present in BCCs it would be useful to complete further 
immunohistochemistry using antibodies to proteins involved in MEKK1/JNK 
signalling. Other signalling pathways and the possibility o f ligand independent 
activation o f  c-Jun may also need to be considered because signalling networks 
can be extremely complex.
The lack o f  correlation between BCC subtype and expression levels or sub-cellular 
localisation o f  all proteins considered in this study shows that MEK/ERK and 
PI3K/AKT EGF pathway components may not have any involvement in producing
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the differing subtypes as originally hypothesised. Expression levels o f other genes 
must therefore be involved in producing different tumour subtypes. One example 
which may be involved is bcl-2 (known to promote cell viability) which was found 
to be expressed in a greater number o f cells within non-aggressive BCCs than in 
aggressive BCCs (Pratistadevi et al., 2000). The stroma surrounding the tumour 
cells is another possible cause o f varying tumour morphology. In morpheaform 
BCCs the stroma may enable the 2-3 cell wide strands to infiltrate deeper into the 
normal tissue. This could be due to the structure o f the stroma allowing tumour 
cells to infiltrate, or it could be caused by protein expression. For example, avp6 
integrin, which is normally up-regulated in wound healing as well as in 
carcinogenesis, was found to be increased in morpheaform BCCs compared to 
nodular BCCs (Marsh et al., 2008). In order to confirm whether altered stroma is 
the cause o f  more invasive subtypes, further immunohistochemistry would need to 
be carried out on proteins found in the stroma to confirm whether any of these are 
up-regulated in invasive subtypes compared to non-invasive BCCs. A further 
possibility is that signalling from the epidermis overlying the tumour may be 
involved in causing the different BCC subtypes, although, overlying epidermis is 
often disrupted. Low levels or no EGF pathway components, EGFR and p-EGFR, 
ERK and p-ERK, p-AKT were expressed in the overlying epidermis o f BCCs in 
this study or in the BCCs themselves. Paracrine signalling has previously been 
shown in other epithelial carcinomas such as pancreatic cancer and was discussed 
as a possibility in BCCs in the previous chapter (Walter et al., 2010).
At this stage it is worth re-assessing the merit o f a formulation that would inhibit 
both EGF and SHH signalling. The increased activity o f EGFR in the overlying 
epidermis suggests that the keratinocytes may contribute to the tumour 
environment by paracrine signalling (Rittie et al., 2007). In chapter 3 o f this study, 
a paracrine effect upon the expression o f GLI target genes (expression was 
reduced in the presence o f fibroblasts) was observed when keratinocytes were 
allowed to stratify at the air: liquid interface. The action o f p-AKT needs to be 
confirmed in order to decide whether to include it in a topical formulation for
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treatment o f  BCC. Immunohistochemistry and qPCR and/or western blotting 
would need to be carried out to look at the expression o f proteins and cDNA on a 
larger sample o f BCCs in order to eliminate possibilities and confirm the cause o f 
invasive subtypes o f  BCC. Ideally a larger tumour sample would enable us to 
overcome the difficulty o f  making comparisons between levels o f protein 
immunoreactivity and localisation between samples which have a large amount o f  
morphological variability even within a single tumour.
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Chapter 5
In Vitro Topical Delivery of Signal 
Transduction Inhibitors
190
5.1 Introduction
5.1.1 Basal Cell Carcinomas as Targets for Topical Drug Delivery
BCCs present an ostensibly accessible target for topically administered drugs. 
However, while these lesions are on the skin surface, problems developing topical 
formulations still exist due to the variable structure and depth o f different types o f  
BCC, as well as inherent variation from tumour to tumour. Penetration o f drugs 
through the epidermis o f superficial BCCs is more achievable than penetration into 
the deeper dermis, which would be essential to treat the more invasive BCCs such 
as the nodular and morpheaform subtypes.
5.1.2 Signal Transduction Pathways as Targets for Inhibition
As stated in the general introduction, constitutive activation o f the SHH signalling 
pathway by deactivating mutations in the gene encoding PTCH, or occasionally 
activating mutations in the gene encoding SMO, are the principle causes o f BCC. 
SMO inhibitors such as cyclopamine were considered useful in topical 
formulations to ‘switch o f f  the SHH pathway. However, at the start o f this 
research project, it was hypothesised that the MEK/ERK branch o f the EGF 
pathway was involved in modulation o f the SHH pathway in BCCs and may be a 
factor contributing to formation o f the more invasive subtypes. It was also thought 
possible that the PI3K/AKT pathway had some involvement in tumour formation, 
so EGF pathway inhibitors might also prove to be useful therapeutic targets. Thus, 
a cocktail o f  drugs could be developed that would theoretically prevent further 
invasion whilst inhibiting tumour growth or even killing the tumour cells.
5.1.3 Inhibitors of EGF and SHH Signal Transduction Pathways
Many natural and synthetic compounds have now been reported as highly selective 
inhibitors o f cellular signalling processes. These include LY294002 (derived from 
quercetin, a naturally occurring bioflavonoid), which is a selective PI3K inhibitor 
that can also affect AKT, a direct target o f PI3K. Another flavonoid (PD98059) is 
a potent and selective inhibitor o f MEK phosphorylation by cRAF or MEK kinase
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and this causes inhibition o f MAPK phosphorylation, directly downstream of  
MEK (Alessi et al., 1995; Dudley et al., 1995). Furthermore, cyclopamine binds 
directly to SMO, leading to reduced SHH signalling and known to inhibit 
tumorigenesis in BCCs (Chen et al., 2002a; Chen et al., 2002b; Taipale et al., 
2000).
5.1.4 Routes for Topical Delivery
Generally, there are three main routes for topical drug delivery:
1. Dermatological: epidermis is the main target
2. Transdermal: dermal microvascular system is the main target
3. Transcutaneous: drugs bypass the dermal microvascular system and go into 
the underlying tissues
For effective transcutaneous delivery, drugs must permeate the lipophilic stratum 
comeum, followed by the more hydrophilic viable epidermis and then finally 
partition into the hydrophilic dermis. The nodular and morpheaform BCC 
subtypes, which go deep into the dermis, would require a combination o f  
epidermal, dermal and subcutaneous targeting.
5.1.5 Skin Permeation
In order to maintain a fixed level o f drug within the skin, the rate o f permeation 
must not exceed the rate o f clearance by the dermal vasculature. The permeation of  
compounds can be affected by numerous physiological factors: age, body site, 
race, pathological disorders, eruptions, infections, ichthyoses and tumours (such as 
eruptive BCCs). Other important factors are related to the delivery system and 
include concentration gradient, logP (lipophilicity), drug size (molecular weight) 
and type o f vehicle (can increase or decrease speed of delivery).
The stratum comeum provides an effective skin barrier, and is very resistant to 
penetration, particularly for polar/hydrophilic compounds. It consists o f 75-80% 
protein (mostly keratin) and 5-15% lipid. The lipid content is a complex mixture o f
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ceramides, fatty acids, cholesterol, cholesterol sulphate and sterol/wax esters 
(Benson, 2005; Hatfield and Fung, 1995). It varies depending on body site and 
also from person to person. Water is homeostatic and acts as a plasticizer for the 
stratum comeum to stop it from drying out and cracking, and natural moisturising 
factors (e.g. urea and urocanic acid) retain moisture and help to preserve 
suppleness (Benson, 2005).
5.1.6 Routes of Skin Permeation
There are three main routes o f permeation through the outer layers o f the skin 
(stratum comeum and epidermis). The trans-cellular route requires passage 
through both polar and lipophilic environments. Drugs must partition through the 
lipid membranes into comeocytes which contain highly hydrated keratin 
molecules (hydrophilic or polar environment). They must diffuse through the 
keratin matrix that fills the cell and then partition out o f the cell via the lipid rich 
(hydrophobic) membranes into the lipid rich (lipophilic) intercellular spaces.
The intercellular route suits small uncharged molecules and involves passing 
through the stratum comeum by going around the epidermal cells rather than 
through them. This requires movement only through a hydrophobic (lipophilic) 
environment and it is likely that small molecule inhibitors (such as PD98059, 
LY294002 and cyclopamine) would be able to permeate the skin principally via 
this route due to their small size and lipophilicity.
The trans-appendageal route requires passage through skin appendages such as 
hair follicles and sweat ducts. However, while these structures only occupy about 
0.1% o f the skin’s surface, it can provide a faster route for larger molecules to 
penetrate deeper into the skin.
There is no known active transport system to carry compounds through the skin. 
While it is likely that drugs may use one route preferentially, in reality, they will 
probably permeate via a combination o f routes. It should also be noted when
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delivering drugs to the skin that there are enzymes present (e.g. esterases, aiyl 
hydrocarbon hydroxylases) which may be able metabolise drugs (Woolfson, 
1990). These are localised in the stratum comeum, living epidermis, sebaceous 
glands and hair follicles, and can cause drugs to lose their efficacy as they pass 
through these structures.
5.1.7 Properties of Drugs that Permeate Skin
Physicochemical properties o f compounds are important for their ability to 
permeate the skin. These properties include: lipophilicity, polarity, ionic state, 
molecular size, solubility and melting point. The compounds used in this project, 
(LY294002, PD98059 and cyclopamine) are all small lipophilic molecules. 
LY294002 and PD98059 are soluble in fish oil, DMSO and alcohol while 
cyclopamine is only soluble in DMSO and ethanol when heated to 50-60°C 
(Online source: LC Labs. (2004)). Due to their general lipophilicity, oil (with 
cyclopamine dissolved in DMSO or ethanol prior to addition), alcohols or DMSO 
would be the most useful vehicles for transporting these molecules into the skin.
5.1.8 Methods of Drug Delivery to the Skin
Drugs or other molecules may be transported through the stratum comeum by 
using creams, ointments, patches, nanogels or physically, eg microneedles. A 
cream, ointment or patch would be the most appropriate method for delivering 
drugs to the site o f BCCs because they are the most cost effective mode of 
delivery and BCCs are likely to require repeated application to the skin.
5.1.9 Franz-type Diffusion Cell
In order to model the permeability o f drugs in vivo, glass Franz-type diffusion cells 
(see Figure 5.1) can be used for in vitro permeation experiments on excised skin 
(Franz, 1975). The membrane (typically full thickness skin or heat separated 
epidermis) is sandwiched between the donor and receptor phases. The vehicle 
containing the dissolved drug is applied to the skin via the donor chamber. The
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sampling arm can then be used to remove a receptor solution containing any drugs 
that had passed through the skin.
iDonor chamber
\
Skm section
Preceptor compartment
Clamp”
Sampling aim
Stirrer bar
Figure 5.1: Franz-type Diffusion Cell. The diffusion cell consists o f two glass sections 
clamped together with excised skin in the middle. Vehicle containing drug is applied to the 
skin surface via the donor chamber and permeants are removed from the receptor 
compartment below for analysis.
5.1.10 Vehicles for Topical Delivery
Vehicles are used to increase permeant flux across the stratum corneum barrier. 
They do this by partitioning into the stratum corneum and causing changes which 
allow increased permeability. Such changes should be reversible and not affect the 
lower layers o f the skin. There are various options for vehicles o f this type, 
depending on the lipophilicity of the drugs selected.
Sulfoxides such as DMSO (dimethyl sulfoxide), give maximal penetration but can 
be skin irritants. They act by denaturing skin proteins and partitioning with 
intercellular lipid domains. DMSO damages the stratum corneum, which increases 
permeation and is known as a ‘Universal solvent’ because both lipophilic and 
hydrophilic permeants are soluble in DMSO (Williams, A C, 2003).
Alcohols (such as ethanol) can be used as an enhancing vehicle. They are often 
used for maintenance o f a concentration gradient to speed up penetration o f a drug.
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Alcohols penetrate the skin very quickly so this high solubility may need to be 
balanced with other vehicles to reduce the overall speed o f penetration.
Fatty acids such as fish oil are skin friendly enhancing vehicles as they cause no 
damage and may in fact be beneficial in terms o f moisturisation (Thomas and 
Heard, 2005). Their strong odour is a negative point from a patient perspective so 
these creams are often mixed with eucalyptol, which disguises the smell. Fish oil 
contains eicosapentaenoic acid, which reduces COX-2 expression and can also be 
used as a vehicle to deliver drugs through the skin. COX-2 activity leads to the 
formation o f prostaglandins (Kim et al., 2006) and there is evidence o f COX-2 
over expression in morpheaform BCC (Jenkins, 2009; Yu et al., 2008). However, 
it is not entirely clear whether COX-2 has a positive or negative effect on BCC 
growth. Since inflammation is part o f the innate immune response, any decrease in 
inflammation due to COX-2 inhibition, might also reduce the effectiveness o f the 
immune system in carcinoma clearance. Although COX-2 inhibitors may cause an 
increased risk o f cardiovascular disease and gastrointestinal disease, fish oil 
applied topically would carry a reduced risk, making this a potentially useful base 
for this formulation (Thomas et al., 2007).
Emulsifying ointment is a standard British Pharmacopaeia mixture o f paraffin oils 
which reduces water loss from the skin. This is a skin friendly vehicle but may 
need other vehicles added such as sulfoxides, alcohols or oil to enhance drug 
penetration.
A series o f vehicles can be tested to determine whether drugs permeate the skin 
sufficiently for effective BCC treatment and at what flux (speed). DMSO and 
ethanol represent maximal penetration for PD98059 and LY294002 due to their 
solubility in these solvents. These were therefore tested first to confirm that the 
drugs can permeate through full thickness skin. Once permeation had been 
demonstrated then a safe vehicle could be designed with the aim o f delivering
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drugs through the skin but minimising loss to the systemic circulation by slowing 
transit through the skin.
5.1.11 Flux and Dosing
Drug flux is the amount o f drug delivered across the skin at steady state, as a 
function o f application area and time. It may be increased by occlusion (increases 
stratum comeum water content by decreasing transepidermal water loss), an effect 
that has been seen for both hydrophilic and lipophilic permeants (Roberts et al., 
1993; Wester et al., 1995).
The applied dose o f drug can either be finite or infinite. A finite dose will be 
depleted over the course o f a permeation study, but can mimic ‘in-use’ application. 
An infinite dose will not be depleted over the course o f the permeation study or 
over the time o f application and steady-state permeation should be achieved.
Fick’s first law o f diffusion states that the rate o f transfer o f a diffusing substance 
through a unit area o f skin (flux) is proportional to the concentration gradient. This 
depends on the diffusion coefficient o f the permeant as in the following equation:
J = -D dc 
dx
J= flux o f permeant
D= diffusion coefficient o f permeant
dc/dx = the incremental change in concentration with distance (concentration 
gradient)
The pseudo-steady-state flux is the gradient o f the linear portion o f the permeation 
profile. The permeability coefficient (an estimate o f the permeation rate o f a solute 
across a membrane) can be determined from the concentration o f the permeant in 
the applied vehicle.
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5.1.12 Depth Profiling
Depth profiling is a method to quantify the amounts o f drug localised within zones 
or layers o f the stratum comeum and epidermis. The most common technique uses 
tape strips to repeatedly remove sequential skin tissue (layers) from the same 
surface area o f dosed skin. Typically, this commences at the stratum comeum 
although it is possible to do this in reverse and commence at the basal layer o f  
heat-separated epidermis.
The receptor solution must provide a suitable sink in which the permeants should 
be soluble, without modulating the barrier function. To ensure no retardation o f the 
flux occurs due to imbalance o f the concentration gradient, permeating species 
should not exceed 20% o f their solubility in the receptor phase. The receptor phase 
should exert no effect on the membrane, which would alter their permeation, and 
should if  possible mimic the in vivo situation.
5.1.13 Aims
• To determine the penetration of cyclopamine, LY294002 and PD98059 
into the skin and whether the inhibitors affect each other’s penetration.
• To probe which vehicles would be most appropriate for delivering these 
inhibitors to cutaneous BCCs in vivo.
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5.2 Materials
PD98059, LY294002 and cyclopamine were all purchased from LC Labs 
(Woburn, MA, USA). All solvents were from Fisher Scientific (Loughborough, 
UK).
5.3 Methods
5.3.1 Solubility and Stability of LY294002, PD98059 and 
Cyclopamine
The stability o f LY294002 and PD98059 over 48 hours at 37°C has been 
previously determined (Davison et al., 2008). However, the stability o f  
cyclopamine is unknown, and due to the lack o f a useable chromophore, this could 
not be measured by HPLC. Solubility (as determined by Davison et al., 2008) for 
LY294002, PD98059 and cyclopamine was repeated in this study (Table 5.1).
Table 5.1: Solubility o f Cyclopamine, PD98059 and LY294002. Data for cyclopamine 
taken from LC Labs data sheets and data for PD98059, and LY294002 taken from 
Davison et al., 2008.
Cetrimide 
mg m L 1
Cetrimide 
30%  
ethanol 
mg mL'1
DMSO  
mg mL'1
Fish Oil 
mg mL'1
Ethanol 
mg mL'1
Cyclopamine 0 11 4 0 20
PD98059 4.57 3 6.98 2.47 0.6
LY294002 9.42 15 14.76 5.16 25
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5.3.2 In Vitro Skin Penetration and Permeation
Porcine ear skin was used as a model for normal human skin as it closely 
resembles human skin both enzymatically and structurally (Hawkins and 
Reifenrath, 1986; Dick and Scott, 1992; Schmook et al., 2001). The stratum 
comeum is similar in thickness and has similar permeation properties (Sekkat et 
al., 2002). Porcine ears were used throughout these experiments to maintain 
consistency in the permeability properties based on body site. Fresh ears were 
always used because it had been shown previously that frozen skin has different 
permeation properties, usually allowing compounds to permeate at an increased 
rate compared to fresh skin.
Cetrimide with 30% ethanol (necessary for cyclopamine solubility) was used as 
the receptor phase in the experiments (see Figure 5.1). Heard and co-workers 
showed that cetrimide does not give rise to any adverse affects on the skin and 
does not affect drug flux (Davison et al., 2008b; Heard et al., 2002). A micro 
stirrer was used to constantly agitate the receptor phase to mimic dermal clearance 
by the vasculature in vivo.
Porcine ears were obtained from an abattoir within an hour o f  slaughter and placed 
in ice-cold HEPES modified Hanks balanced buffered salt solution (Sigma- 
Aldrich Company Ltd, Gillingham, UK). Full thickness skin was excised by blunt 
dissection and continually bathed in Hank’s buffer to maintain viability. The hairs 
were removed using clippers and the skin was cut into 2cm2 sections. In order to 
give a representation of BCC variation (some BCCs have disrupted stratum 
comeum, others do not), half o f the skin sections had the stratum comeum 
disrupted by tape stripping to mimic morpheaform or superficial BCC. This was 
achieved by pressing firmly on the stratum comeum side with adhesive tape 
(Sellotape) and then rapidly removing it (repeated 25 times with clean tape). The 
skin sections were then placed between the greased flanges o f  a glass Franz type 
diffusion cell, stratum comeum side up, and the flanges were clamped together to 
form an airtight seal. A magnetic stirrer bar and the receptor phase (30 mg mL'1
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cetrimide with 30% ethanol, degassed) were added to the receptor compartment 
via the sampling arm, ensuring the receptor solution touched the underside o f the 
skin and that there were no bubbles (can affect permeation by interfering with the 
concentration gradient). Parafilm (Fisher Scientific, Loughborough, UK) was 
placed over the sampling arm to prevent evaporation o f the receptor phase. The 
Franz cell was then placed on a VarioMag Telesystem submersible stirrer plate 
(Camlab Ltd, Cambridge, UK) in a 37°C waterbath containing virkon to prevent 
microbial contamination of the skin (Nickel Electro Ltd, Weston-super-Mare, UK, 
Fisher Scientific, Loughborough, UK). The water just covered the receptor 
compartment and did not reach the skin. The Franz cell was allowed to equilibrate 
for half an hour after which 200pl o f the donor phase (ethanol, DMSO, 200pl 
ethanol in fish oil) containing equimolar concentrations o f LY294002 (1 mg mL'1), 
PD98059 (0.8 mg mL'1) or cyclopamine (1.34 mg mL'1) was applied to the skin 
surface via the donor chamber. Parafilm was used to cover the donor chamber to 
mimic occlusion. Dosing o f the donor phase (200pl aliquots) was repeated at 3 and 
6 hour timepoints for half the Franz cells containing native skin and half the cells 
containing disrupted stratum comeum to mimic infinite dosing. The remainder o f  
the cells mimicked finite dosing. This gave four dosing protocols: normal skin 
single dose, normal skin repeat dose, tape stripped skin single dose and tape 
stripped skin repeat dose. In addition, 4-6 replicates were used for each 
measurement.
The receptor phase was removed from the Franz cells via the sampling arm using a 
glass pasteur pipette (Fisher Scientific, Loughborough, UK) and 1ml samples were 
stored in autosampler vials at -20°C to await analysis. The receptor compartment 
was immediately replenished with fresh receptor phase and samples at various 
times (3, 6, 12, 24, 36 and 48 hours) over two days.
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5.3.3 Standard Depth Profiling
Tape stripping is a method o f depth profiling used to sequentially collect cell 
layers from the stratum comeum side o f the epidermis. The cells are then removed 
from the tape and the quantity o f drug which has penetrated to different cell layers 
measured by HPLC.
Franz-type cells were set up with porcine skin and LY294002 (1 mg mL'1) added 
to 5 cells, PD98059 (1 mg mL'1) to another 5 cells and a combination o f  
LY294002 and PD98059 (0.5 mg mL'1 each) to another 5 cells. These inhibitors 
were dissolved in methanol and 300pl o f this donor phase was applied to the skin 
surface in each Franz-type cell. A receptor phase o f degassed cetrimide with 30% 
ethanol was added to the bottom o f the Franz-type cell until the solution just 
touched the underside o f the skin, taking care not to introduce any bubbles. The 
Franz-type cell was placed on a microstirrer in a 37°C waterbath containing 
Virkon to prevent microbial infection and agitated for 24 hours. The pig skin was 
removed from the Franz-type cells, a cotton bud was used to gently remove excess 
donor phase and tape strips were taken from the stratum comeum side o f the skin. 
Three sequential strips were added to a vial o f methanol until 30 strips had been 
removed (10 vials) and the final (11th) vial contained the remainder o f the skin. 
The covered vials were left overnight on a rocker to wash o ff the cells, and then 
left uncovered until all the methanol had evaporated. Methanol (1ml) was added to 
each vial to re-dissolve the drugs and the concentration was measured by reverse 
phase HPLC.
5.3.4 Reverse Phase HPLC Method for Measuring LY294002 and 
PD98059
The quantity o f LY294002 and PD98059 removed from the Franz-type cell 
receptor phase was measured by reverse phase HPLC (Agilent 1100 series 
automated system) using a Phenomenex Sphereclone 5 pm particle size column 
with a flow rate o f 0.5ml/minute. In order to quantitate the amount o f each 
inhibitor separately, a mobile phase gradient was created to enable elution at
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different time points. The mobile phase ratio started at zero with 80:20 methanol: 
dH20 and changed over 8 minutes to 70:30 methanol: dH20, at 8:01 minutes the 
ratio changed to 90:10 methanol: dfhO and remained at this ratio until 12 minutes. 
Using this protocol, PD98059 eluted at 7.3 minutes (retention time) and 
LY294002 eluted at 8.9 minutes.
The two inhibitors were detected by absorbance at 254nm and the peak areas 
under each trace (one for each Franz-type cell receptor phase removal timepoint) 
were calculated using Agilent ChemStation software. Microsoft excel was used to 
calculate the mass o f permeant (PD98059 or LY294002) with the equation (mAU 
= milli-absorbance units):
Mass o f permeant (mg cm'2) = peak area (mAU)/gradient o f calibration graph x 
receptor phase volume (ml)/area o f application (mm2)
The mean for 4-6 replicates was plotted. Steady state flux for the permeation o f  
PD98059 and LY294002 was determined by plotting the cumulative permeation 
(pg cm'2) against time. The linear portion o f the resulting plot was taken as steady 
state flux. Calibration curves were plotted using known quantities o f  each inhibitor 
against the area under the peaks o f the HPLC trace.
5.3.5 Reverse Depth Profiling
In order to clarify whether the drugs had reached the basal layer where BCCs 
reside, a different approach was used. The epidermis was heat separated from the 
dermis and then the underside o f the epidermis was tape stripped (as previously 
explained), thus removing the basal layer first (reverse depth profiling).
Pieces o f freshly excised porcine skin (2cm2) were heated to 55°C for 30-60 
seconds in a waterbath filled with distilled water. The epidermis was carefully 
separated from the dermis using forceps. The underside o f  the epidermis was 
sequentially tape stripped by applying pressure and then removing the tape. This
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was repeated for several tape strip layers applying equal pressure with the thumb 
to each strip before removing. The cells were washed o ff the tape strip into 1.5ml 
eppendorf tubes using 0.9ml SDS sample buffer (4.12ml H2O, 1ml 0.5M Tris, 
0.8ml glycerol, 1.6ml 10% SDS, 0.08ml 1M DTT and 0.2ml bromophenol blue) 
and boiled for 5 minutes. The denatured protein solution was stored at -20°C until 
analyzed by SDS-PAGE and western blotting.
5.3.6 Polyacrylamide Gel Electrophoresis and Western Blotting
Total protein extracts were separated by electrophoresis (SDS-PAGE), transferred 
to membranes and analysed with a group o f specific antibodies (western blotting).
5.3.6.1 Sodium Dodecyl Sulphate-Polyacrylamide Gel Electrophoresis (SDS- 
PAGE)
SDS-PAGE was carried out using the XCell Sure lock mini-cell (Invitrogen, 
Paisley, UK). Proteins were separated on an SDS gel by electrophoresis and 
transferred to a membrane for western blotting using the XCell II Blot module. 
Immunochemistry was performed to detect the presence o f proteins and to 
measure expression levels and the extent o f phosphorylation in cells under 
different culture conditions.
Enough mixture for two 10% separating gels was made containing 0.1ml 10% 
SDS, 2.5ml 1.5M Tris, 3.3ml 30% acrylamide gel solution (Sigma-Aldrich 
Company Ltd, Gillingham, UK), 75pl APS (ammonium persulphate; Fisher 
Scientific, Loughborough, UK) and 7.5pi NjNjN’jN’-tetramethylethylenediamine 
(TEMED; Sigma-Aldrich-Company Ltd, Gillingham, UK) and 4.1ml H2O. This 
was pipetted into cassettes and overlaid with water. Once set, the water was 
removed and a 4% stacking gel (50pl 10% SDS, 1.25ml 0.5M Tris, 0.65ml 30% 
aciylamide gel solution, 3.05ml H2O, 50pl 10% APS and lOpl TEMED) was 
added above the separating gel. A 12 prong comb was placed into the top o f the 
cassette and after the stacking gel had set (about 5 minutes), the comb was
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carefully removed and the wells washed with distilled water (dfkO). The cassettes 
were placed into the apparatus and lx  running buffer (30g tris, 144g glycine and 
lOg SDS per litre o f dt^O) was poured into the apparatus, ensuring that the wells 
were full o f  buffer. The protein extracts (lOpl) were loaded into the wells 
(volumes should give equal quantities o f protein in each well for comparison) and 
molecular weight standards loaded on the gel (usually the end lanes). Three 
markers were used in combination: 10pl Precision Plus protein marker (Bio-rad, 
Hemel Hempstead, UK) or 5pl low molecular weight marker (Promega UK Ltd, 
Southampton, UK) together with 2pi Magicmark (Invitrogen, Paisley, UK). The 
outer and inner chambers were filled with running buffer and 125V at a starting 
current o f 25mA per gel applied until the tracker dye reached the bottom o f the 
separating gel. Cassettes were opened and the gel was stained with 0.25% 
Coomassie brilliant blue R250 (Sigma-Aldrich Company Ltd, Gillingham, UK) in 
40% methanol (Fisher Scientific, Loughborough, UK) and 10% acetic acid (Fisher 
Scientific, Loughborough, UK) for one hour. The gel was then destained for 30 
minutes in 40% methanol and 10% acetic acid. Duplicate gels were important as 
one was used for staining o f the protein to check for even loading while the other 
gel remained unfixed and was used for western blotting.
5.3.6.2 Western Blotting
Immobilon membrane (PDVF from Millipore, UK) was immersed in methanol and 
then vigorously shaken in water to hydrate. Whatman paper and pads were soaked 
in western blot buffer (14.4g glycine, 3g Tris and 100ml methanol per litre dH20). 
Two pads were placed in the bottom o f the western blot module, and then a 
gel/membrane sandwich was assembled (Whatman paper, gel, Immobilon 
membrane, Whatman paper) and placed on top of the pads. The module was then 
filled with further pads and the top locked. Buffer was added to the blotting 
module and the tank filled with dH20 to keep the gel cool during transfer. Transfer 
continued for 1-2 hours at 25 v with a starting current o f approximately 100mA.
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5.3.6.3 Protein Detection by Immunochemistry
Western blots on Immobilon membrane were rehydrated with methanol and 
washed in water, then placed in 5% skimmed milk (Marvel from Tesco, UK) in 
Tris-buffered saline with 0.1% Tween 20 (TBST from Sigma-Aldrich Company 
Ltd, Gillingham, UK) for 1 hour to block antigenic sites. Primary antibody (see 
Chapter 2, Table 2.6 for dilutions o f antibodies used) in 10ml 5% marvel was 
added and left for 1 hour, after which the membrane was washed (five times in 
TBST for 5 minutes each). Another 10ml 5% marvel containing the secondary 
antibody (see Chapter 2 and Table 2.6 for details) was added and left to incubate 
for 1 hour, then the membrane was washed in TBST (again five times for 5 
minutes each).
The membrane was laid on Saran wrap in the dark room and covered with ECL 
reagent for 5 minutes. The reagent was made by combining 1ml solution 1 (1ml 
250mM stock luminol (Sigma-Aldrich Company Ltd, Gillingham, UK) in DMSO, 
0.44ml 90mM coumaric acid stock (Sigma-Aldrich Company Ltd, Gillingham, 
UK) in DMSO, 10ml Tris, pH 8.5 plus dH20 to a total o f 100ml) and 1ml solution 
2 (64pl 30% H2O2 and 10ml Tris, pH8.5 plus dH20 to a total o f 100ml). The 
reagent was poured off, the membrane enclosed in Saran wrap and placed in a 
cassette together with sensitive X-ray film (Amersham Biosciences, GE 
Healthcare Life Sciences, Little Chalfont, UK). This was left for 2 to 10 minutes 
(longest incubation carried out first) and then the X-ray film was placed in Kodak 
D-19 developer, rinsed in water and finally treated with Kodak Processing 
Chemical Fixer (Sigma-Aldrich Ltd, Gillingham, UK). Films were then left to dry.
5.3.7 Tissue Immunofluorescence
Stored slides containing frozen porcine skin (7pm thick cryostat sections stored at 
-80°C) were thawed at room temperature (RT) for 10-15 minutes, fixed in acetone 
(Fisher Scientific, Loughborough, UK) for 15 minutes, dried for 5 minutes and 
washed in PBS three times for 5 minutes each. Undiluted primary antibody raised 
to K15 (sheep) or K10 (mouse) were applied to the sections, which were then
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incubated for 1 hour in a humidified chamber and washed in PBS (three time for 5 
minutes each). Biotinylated anti-sheep (GE Healthcare, Little Chalfont, UK) 
(1:200) or anti-mouse alexa 594 (1:500) were applied, incubated for 30 minutes 
and washed three times in PBS (5 minutes each). Slides were then incubated with 
avidin alexa 488 (Invitrogen, Paisley, UK) 1:500) for 30 minutes and washed in 
three times PBS (5 minutes each). Finally, sections were mounted with 
Hydromount (Fisher Scientific, Loughborough, UK) containing 2.5 % Dabco 
(Sigma-Aldrich Company Ltd, Gillingham, UK) and a cover slip added and 
allowed to dry for at least 1 hour before viewing under a microscope. The basal 
layer (stained by K15 antibody) and the suprabasal layers (stained by K10 
antibody) o f the epidermis could then be identified by fluorescence microscopy.
5.3.8 Derivatisation
Cyclopamine has an extremely low UV absorbance, because it lacks a 
chromaphore, and only absorbs at short wavelengths. Thus, traces o f impurities 
with high UV absorbance can represent major contaminants, even though they 
were only 0.1% or less o f the material present. Also, certain potential cyclopamine 
impurities such as acyl derivatives o f the amino group are far more hydrophobic 
than cyclopamine itself, and these impurities would never elute from the column 
under the HPLC conditions typically used for cyclopamine analysis. HPLC can 
seriously under estimate and/or over estimate different types o f impurities, and 
therefore cannot give reliable analytical results. Therefore, LCMS (liquid 
chromatography-mass spectrometry) is recommended for quantification o f  
cyclopamine. However, due to the high cost o f LCMS (and its lack o f availability), 
three methods o f cyclopamine derivatisation were tested as an alternative method 
o f quantitation.
5.3.8.1 Dansylation (Bartzatt, 2001a; Bartzatt, 2001b)
An aliquot (250pl) o f cyclopamine solution [lmg/ml in 17:3 acetonitrile: dH20] 
(LC Labs, Woburn, MA, USA; Fisher Scientific, Loughborough, UK) was added 
to 250pl 2M sodium carbonate solution, p H ll (Fisher Scientific, Loughborough,
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UK) and 150pl dansyl chloride solution (1.54g/10mls H2O from Sigma-Aldrich 
Company Ltd, Gillingham, UK). The tube was kept in the dark for 1.5 hours and 
mixed occasionally. Then, 600pl diethyl ether (Fisher Scientific, Loughborough, 
UK) was added and the solution mixed again. The top (organic layer) was 
removed for reverse phase HPLC analysis using a Phenomenex Sphereclone 5 pm 
particle size column at 492nm, in a mobile phase o f 70:30 acetonitrile: dH20 run 
at 1 ml/minute for 15 minutes.
5.3.8.2 Phenylisocyanate in Pyridine
This method was adapted from previously published work (Heard and Suedee, 
1996). In brief, freeze dried cyclopamine (2mg) was reacted with an excess (1ml) 
o f  phenylisocyanate (Sigma-Aldrich Company Ltd, Gillingham, UK) in pyridine 
(10ml) at 120°C for 6 hours and then allowed to cool. The reaction mixture was 
then poured into 5ml methanol (Fisher Scientific, Loughborough, UK) to remove 
unreacted isocyanate and the quantity o f derivatised cyclopamine was measured by 
reverse phase HPLC using a Phenomenex Sphereclone column with 5 pm particle 
size at 254nm, with a mobile phase o f 70:30 acetonitrile: dH20 with 0.1% 
trifluoroacetic acid run at 1 ml/minute for 15 minutes.
5.3.8.3 4’-bromophenacyl trifluoromethanesulfonate
This method was also adapted from published work (Ingalls, 1984). In brief, a 
20pl aliquot o f 0.1 M 4 ’-bromophenacyl trifluoromethanesulfonate in acetonitrile 
(Sigma-Aldrich Company Ltd, Gillingham, UK) was added to a glass tube and 
lOpl 0.5M diisopropylethylamine in acetonitrile (Sigma-Aldrich Company Ltd, 
Gillingham, UK) was added to neutralise the acid. Then 1ml cyclopamine (5mg/ml 
dissolved in ethanol at 50-60°C) was added, mixed by vortex and the reaction kept 
at RT. The quantity o f  derivatised cyclopamine was measured at timepoints (5, 10, 
30, 60, 120 and 180 minutes) after vortex mixing, by reverse phase HPLC analysis 
using a Phenomenex Sphereclone 5pm particle size column at 254nm, with a 
mobile phase o f  70:30 acetonitrile:dH20 run at lml/minute for 15 minutes.
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5.3.9 Statistical Analysis
Flux was compared between each formulation and any differences were 
determined by using Ordinary ANOVA, Parametric, Tukey tests (Instat 3 for 
Macintosh, GraphPad Software, USA).
5.4 Results
5.4.1 In Vitro Dermal Delivery
The assessment o f drug delivery through living epidermis is complex. However, 
tape stripping can be used to collect cells from skin surface and drug levels 
measured using methods such as HPLC to assess penetration. This works well for 
the stratum comeum and upper living layers o f the skin but not so well for the 
lower epidermis due to the undulating nature o f the dermal-epidermal junction. 
This makes it difficult to selectively remove cells from a specific layer. Thus, the 
reverse tape stripping method, where cells are removed from the underside o f heat- 
separated epidermis (basal cells first) is particularly poor.
Other methods o f separating skin such as EDTA or proteolytic enzymes would not 
work well, as the aqueous solutions would leach out the drugs being assayed. 
While tape stripping is commonly used for depth profiling to assess the penetration 
o f  drugs into the epidermis, satisfactory results are not always obtained. Removal 
o f  inhibitors from cells isolated by depth profiling (on tape strips) for measurement 
by high performance liquid chromatography (HPLC) may lead to inaccurate 
results because the drugs might not have permeated as far as the basal cells 
(Figure 5.2).
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Figure 5.2: Depth Profiling o f Heat-Separated Porcine Epidermis. This haematoxylin 
and eosin stained section of skin demonstrates the convoluted nature of the epidermis, 
showing that depth profiling removes cells from more than one layer in the lower 
epidermis (adapted from online source: Melanoma, A Skin Cancer Review).
5.4.1.1 Immunofluorescence and Western Blotting with Keratin Antisera to 
Define Epidermal Layers
Immunofluorescence confirmed that porcine skin was very similar to human skin 
in terms o f keratin expression (Porter et al., 2004). K14 was immunolocalised to 
the basal layer and K10 was only present in suprabasal cell layers (Figure 5.3). 
K14 and K10 antibodies were therefore useful for determining the cells present in 
the tape stripped samples by western blotting (see section 2.2.4 for methods).
(a) K14 (Green) (b)K lO (R ed) (c) Combined Image
Figure 5.3: Immunofluorescence Detection o f Keratins in Porcine Skin. K14 (green) 
staining was prominent in the basal layer (a) while K10 (red) was specifically localised to 
the suprabasal layers o f the epidermis (b). The combined image (c) showed some dilution 
o f the K10 signal by K14 in suprabasal cells (background staining) but not the reverse.
SDS-PAGE and western blotting of proteins extracted from reverse tape stripped 
epidermis at two different sites in porcine skin was carried out to show whether 
cells could be specifically removed from the basal layer. It could then be
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determined whether the inhibitors (LY294002 and PD98059) could reach these 
cells.
Western blotting results showed high levels of K14 in the first strips (Figure 5.4: 
lanes 1, 2, 5, 6) as would be expected because these strips were taken from the 
basal layer side o f the epidermis. However, K14 was still present in the protein 
extracted from cells removed on later tape strips (lanes 3, 4, 7, 8) although at a 
decreased level. This may be because the basal layer of the epidermis undulates, 
thus causing basal cells to be removed in later tape strips and it is probable that 
cells from the spinous layer of the epidermis were also present in the first tape 
strips. However, a K10 blot would have been more useful as this would show how 
much suprabasal contamination there was in the basal layer.
M 1 2 3 4 5 6 7 8
M.Wt.
60KDa
50KDa
40KDa
30KDa
20KDa
Figure 5.4: Western Blot o f K14 in Reverse Tape Stripped Skin. K14 presence was 
shown in all tape strips. Lane M: low molecular weight marker (Promega UK Ltd, 
Southampton, UK), lanes 1 to 4: sequential tape strips starting at the basal layer and 
lanes 5-8: sequential tape strips starting at the basal layer but from a different region of 
skin. K14 levels are highest in early strips (basal layer) from both skin regions (lanes 1 
and 2, lanes 5 and 6).
2 1 1
5.4.1.2 Depth Profiling Porcine Skin after Application of EGF Inhibitors
(PD98059 and LY294002) in a Fish Oil Vehicle.
Depth profiling was carried out to demonstrate whether LY294002 (PI3K 
inhibitor) and PD98059 (MEK1/2 inhibitor) could successfully penetrate to the 
lower epidermis.
In order to determine the amount o f inhibitor which had penetrated the epidermis 
by HPLC, standard curves were made for both inhibitors (LY294002 and 
PD98059). A range o f standard solutions o f each were made up using ethanol (at 
concentrations o f 0.034, 0.068, 0.137 and 0.275 mg/ml). The inhibitors were 
separated by HPLC and detected at an absorbance o f 254nm. The data was plotted 
using Agilent Chemstation software that showed a peak on the trace where the 
inhibitors had been detected. The area under each peak was measured using 
Agilent Chemstation software and a standard curve was plotted o f area versus the 
concentration o f each inhibitor solution (see Figures 5.5 and 5.6). The value o f  
the gradient o f the graph (m, where y = mx + c) was then used to calculate the 
amount o f each inhibitor that had permeated through the skin (using the equation 
described in section 5.3.4). The R2 values for each inhibitor were both very close
to 1, which means that both calibration curves were accurate.
EGF inhibitors (LY294002 and PD98059 alone or in combination) in a methanol 
vehicle were then applied to porcine skin mounted in a Franz type diffusion cell. 
The inhibitors were allowed to permeate over 24 hours after which the skin was 
removed and depth profiling carried out using tape stripping (from the stratum 
comeum surface where the drugs were applied). Epidermal cells were washed off  
the tape strips and the inhibitors were extracted. For each drug applied, the level o f  
drug that had permeated through different cell layers was measured by HPLC. 
Agilent Chemstation software was used to measure the area under each peak o f the 
HPLC trace and the quantity o f each inhibitor in the sequential tape strips was 
calculated using the equation described above (see section 5.3.4). The quantity and
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percentage o f each inhibitor in the sequential layers o f epidermal cells was then 
plotted using Microsoft Excel.
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Figure 5.5: Standard Curve for PD98059 (n=3). Known concentrations o f PD98059 
(mg) in ethanol were plotted against the area under curve on the HPLC trace (in milli- 
absorbance units [mAU] at an absorbance of254nm).
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Figure 5.6: Standard Curve for LY294002 (n=3). Known concentrations o f LY294002 
(mg) in ethanol were plotted against the area under curve on the HPLC trace (in milli- 
absorbance units [mAU] at an absorbance of254nm).
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Depth profiling results obtained by measuring drug concentrations in ten 
consecutive tape strips showed that both drugs penetrated through the epidermis 
and into the living cells below (Figure 5.7). The profile o f drug retention was 
typical, with 25-40% remaining on the skin surface (tape strip #1), about 36% 
being retained in the epidermis (tape strips #2-10) and 23-38% penetrating into the 
remaining epidermis and dermis (layer R).
When applied alone, there was approximately 7.0 pmol (40%) o f PD98059 in the 
first tape strip (Figure 4.7a) and retention in the next two layers decreased rapidly 
(3 fold less in tape strip #2 and 2 fold less again in tape strip #3). Retention in tape 
strips #4-10 was similar (approximately 0.5 pmol per layer). Statistics showed 
there was a significant reduction in retained material in each o f the early tape 
stripped layers but deeper layers were broadly similar. The epidermis as a whole 
(tape strips #2-10) retained a total o f 6.4 pmol (36%) while the remainder (mainly 
dermis) contained about 4.0 pmol o f PD98059 (23% of total) which represents the 
amount o f drug that had penetrated the epidermal barrier.
The total amount o f PD98059 retrieved when applied in the presence o f LY294002 
was reduced by about 30% (12.1 pmol compared to 17.4 pmol) compared to 
PD98059 applied alone (Figure 4.7b). However, more PD98059 penetrated into 
the dermis (layer R) in the presence o f LY294002: 4.8 pmol (38% o f total) 
compared to 4.1 pmol (23% of total) while retention by the epidermis was broadly 
similar (4.3 pmol or 36% o f the total).
The amount o f LY294002 retained in the epidermal tape strips was much less than 
for PD98059, with all layers containing less than 0.001 pmol (1 pmol). The total 
LY294002 retrieved from tape strips 1-10 was almost 10 fold less: 1.5 pmol 
compared to 13.4 pmol for PD98059 (Figure 4.7c). The total LY294002 retrieved 
from the remaining skin was 0.7 pmol compared to 4.1 pmol o f  PD98059. 
However, this represented almost 50% o f the drug retrieved compared to 23% for 
PD98059 alone. In overall terms, the permeation profile was similar and the
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amount of drug was reduced in sequential layers. In the presence o f PD98059, the 
profile and quantity o f LY294002 uptake and retention in the epidermis was 
reduced slightly but appeared broadly similar (Figure 4.7d).
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Figure 5.7: Depth Profiling for PD98059 and LY294002 in Methanol on Porcine Skin.
Layers 1 to 10 were tape stripped from the epidermal surface ofporcine skin and layer R 
was the remaining skin after stripping, (a) PD98059 alone, (b) PD98059 with LY294002 
present, (c) LY294002 alone and (d) LY294002 with PD98059 present. Statistical analysis 
using Ordinary ANOVA Tukey Test: * P=<0.05, ** P= <0.005, *** P= <0.001. Data 
expressed as the mean +/- SD for n=3 experiments with 6 replicates for each experiment. 
Statistical data has been included to compare each layer to layer 1 and to the previous 
layer. The lowest rows of stars were compared to layer 1.
In total, less than 1% of each o f the applied inhibitors was retrieved from full 
thickness skin (layers 1 to 10 and R, the skin remainder). A total o f 150pg of each 
inhibitor was applied to the skin surface. The percentage of total drug applied that 
was then retrieved from sequential layers (1 to 10 plus the remainder, R) o f tape
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stripped skin followed a typical pattern of drug retention. These percentage values 
were plotted separately for each inhibitor (Figure 5.8) under conditions where 
both were applied simultaneously (allows for any inhibition or increase in uptake 
into the skin layers caused by the presence of both inhibitors). The values obtained 
were 0.38% for PD98059 and 0.07% for LY294002. The first layer contained the 
highest percentage of applied drug (0.072% for PD98059 and 0.011% for 
LY294002) compared to the lower epidermal layers (#2-10). There was also a 
significant decrease in the percentage of PD98059 retained in deeper epidermal 
layers when compared to layer 1 (P = <0.001), but the decrease was not significant 
for LY294002. The percentage of PD98059 retained in the epidermis as a whole 
(#2-10) was 0.173% (0.026 mg) compared to 0.0344% (0.0052 mg) for 
LY294002. The remainder of the skin (dermis) retained 0.1287% (0.019 mg) of 
the applied PD98059 and 0.0227% (0.0034 mg) LY294002.
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Figure 5.8: Depth Profiling for PD98059 and LY294002 in Methanol on Porcine Skin.
(a) The percentage o f applied PD98059 (in the presence ofLY294002) permeated, (b) The 
percentage of applied LY294002 (in the presence of PD98059) permeated. Statistical 
analysis was done by Ordinary ANOVA, Tukey test. * P=<0.05, ** P — <0.005, *** P= 
<0.001. Data expressed as the mean +/- SD for n=3 experiments with 6 replicates for 
each experiment. Statistical data has been included to compare each layer to layer I and 
to the previous layer. The lowest rows o f stars were compared to layer 1.
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5.4.1.3 In Vitro Skin Permeation Tests
Intact stratum comeum is the main barrier to skin permeation and disrupted 
stratum comeum enables easier penetration o f inhibitors into the skin. Some BCCs 
have a disrupted stratum comeum (especially nodular subtypes, which often have 
an ulcerated centre) but this is extremely variable between subtypes and individual 
BCCs (e.g. morpheaform BCCs rarely show ulceration). Thus, experiments were 
carried out on both native (intact) skin, and on skin which had been taped stripped 
(to cause disruption to the stratum comeum). This should mimic the best and worst 
case scenarios for permeation into BCCs.
Penetration o f LY294002 (PI3K inhibitor) and PD98059 (MEK inhibitor) through 
porcine skin using a selection o f vehicles including fish oil, DMSO and ethanol 
was carried out using Franz cells. The receptor phase was removed and replaced at 
3, 6, 12, 24, 36 and 48 hour time points. A typical HPLC trace (Figure 5.9) o f the 
receptor phase removed from a Franz cell showed separate column elution times 
for LY294002 (7.3 minutes) and PD98059 (8.9 minutes) in fish oil even though 
both compounds are o f similar size and lipophilicity (clogP: 2.57 and 3.03 
respectively). The area under each peak increased with time and was largest at the 
later time points (24, 36 and 48 hours). The peaks with elution times between 2.5 
and 5.5 minutes were due to the solvent front and skin debris.
A small shift in retention time was found for both LY294002 and PD98059 when 
individual traces for each experimental time point were overlaid (Figure 5.10). 
However, both inhibitors were clearly separated from each other at all times so 
peak areas could be accurately measured.
5.4.1.3.1 DMSO Vehicle
Tests using Franz-type diffusion cells enabled measurement (by HPLC) o f  
LY294002 and PD98059 permeation through full thickness porcine skin into the 
receptor phase. Thus, the cumulative amount o f drug permeating in a given time
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could be measured. The steady-state flux for each skin sample was also measured 
and the standard deviation between skin sample-Franz cell replicates was assessed.
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Figure 5.9: HPLC Elution Profile for LY294002 and PD98059 in a Fish Oil Vehicle.
HPLC traces for the receptor phases from one Franz cell taken at different time points (3, 
6, 12, 24, 36 and 48 hours) showing elution of PD98059 (—7.3 minutes) and LY294002 
(-8.9 minutes). The peak height (milli-absorbance units [mAU]) increased with time after 
permeation o f a single dose through tape stripped porcine skin. Peaks between 2.5 and 5.5 
minutes were caused by the solvent front and skin debris.
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Figure 5.10: HPLC Traces for LY294002 and PD98059 in a Fislt Oil Vehicle. Overlaid 
traces for the receptor phase of one Franz cell at different time points (3, 6, 12, 24, 36 and 
48 hours) showing some peak shift but peak separation for PD98059 (7.3-7.7 minutes) 
and LY294002 (8.8-9.4 minutes) was maintained. Absorbance was measured in milli- 
absorbance units (mAU) at a wavelength of254nm.
Tape stripped skin with repeat dosing in a DMSO vehicle enabled the largest 
cumulative amount of PD98059 (MEK1/2 inhibitor) to permeate through full 
thickness skin (Figure 5.11). Tape stripped skin with a single dose o f PD98059 
achieved almost the same cumulative amount of inhibitor to permeate the skin. In 
fact, the inhibitor permeated the skin slightly faster at earlier time points (12 and 
24 hours) but the cumulative amount did not increase as much between 24 and 36 
hours (not statistically significant). Native (intact) skin allowed a lower cumulative 
amount to permeate the skin at 48 hours (approximately 25% or 0.05mg cm'2 less 
than tape stripped skin with repeat dosing) and with a single dose of PD98059 
applied to the skin this was even less (0.08mg cm'2 less with native skin single 
dose than tape stripped single dose, not statistically significant).
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Figure 5.11: Cumulative Permeation o f PD98059 in a DMSO Vehicle through Porcine 
Skin. Cumulative amounts o f inhibitor permeated over 48 hours through tape stripped or 
intact (native) porcine skin with single or repeat dosing. Statistical analysis was done by 
Ordinary ANOVA, Tukey test and data was expressed as the mean +/- SD for n=3 
experiments with 6 replicates for each experiment.
Tape stripped skin had a greater flux than native skin for PD98059 and repeat 
dosing gave increased flux over a single dose (Table 5.2),
Table 5.2: Mean Flux and Standard Deviation (SD) for Permeation o f PD98059 in a 
DMSO vehicle through Porcine Skin
Mean Flux 
(mg/cm2/hr) SD
Normal (Native) Skin (Repeat Dose) 0.00455 0.00146
Normal (Native) Skin (Single Dose) 0.00390 0.00249
Tape Stripped Skin (Repeat Dose) 0.00678 0.00172
Tape Stripped Skin (Single Dose) 0.00590 0.00161
Tape stripped full thickness porcine skin with repeat dosing allowed the greatest 
permeation o f LY294002 (Figure 5.12), Tape stripped skin with a single dose 
enabled 0.05mg/cm'2 less LY294002 to permeate, which was the second greatest 
cumulative amount after 48 hours. However, there was no significant difference 
between a single dose o f LY294002 and a repeat dose. Native skin with repeat
2 2 0
dosing allowed less permeation o f the inhibitor (P<0.05 when compared to tape 
stripped repeat dose) and native skin with single dosing showed the least 
permeation (P<0.05 when compared to tape stripped skin repeat dose). Tape 
stripped skin had a slightly higher flux than native skin, but repeat dosing had little 
effect on the flux for this inhibitor (Table 5.3).
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Figure 5.12: Cumulative Permeation o f LY294002 in a DMSO vehicle through Porcine 
Skin. Increased permeation of LY294002 was found with Tape stripped skin compared to 
native skin. Increased permeation was achieved for both tape stripped and native skin by 
repeat dosing. Statistical analysis was done by Ordinary ANOVA, Tukey test (* P<0.05). 
Data expressed as the mean +/- SD for n=3 experiments with 6 replicates for each 
experiment.
Table 5.3: Mean Flux and Standard Deviation for Permeation o f L Y294002 in DMSO 
through Porcine Skin.
Mean Flux 
(x10'3mg/cm2/hr)
SD
(x10'3)
Normal (Native) Skin (Repeat Dose) 3.17 0.67
Normal (Native) Skin (Single Dose) 3.45 1.69
Tape Stripped Skin (Repeat Dose) 3.97 0.25
Tape Stripped Skin (Single Dose) 3.97 0.25
12 24 36 48
Time/ Hours
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5.4.1.3.2 Ethanol Vehicle
Tape stripped skin with repeat dosing gave a higher cumulative amount o f  
PD98059 penetration through full thickness porcine skin when using an ethanol 
vehicle compared to DMSO or fish oil.
Tape stripped skin with a single dose o f the inhibitor gave a lower cumulative 
amount o f drug penetration at 48 hours than repeat dosing (Figure 5.13). 
However, at earlier time points the cumulative amount which had permeated the 
skin was actually higher with a single dose o f inhibitor than with repeat dosing. 
The increase in cumulative amount was greatest at between 12 and 24 hours but 
then did not seem to increase further between 24 and 48 hours.
Native (intact) skin gave the lowest cumulative amounts o f PD98059 penetration 
at 48 hours with single dosing being 0.1 mg cm'2 less than for tape stripped skin. 
The cumulative amount o f PD98059 permeation with repeat dosing was also 
reduced compared to tape stripped skin (0.2 mg cm'2 less). Repeat dosing on native 
skin gave a lower cumulative amount o f inhibitor permeation than a single dose 
after 48 hours (P<0.05 for native skin with single or repeat dosing when compared 
to tape stripped skin with repeat dosing). Tape stripped skin with repeat dosing 
gave a higher cumulative amount o f LY294002 penetration through full thickness 
porcine skin when using an ethanol vehicle compared to DMSO or Fish Oil.
Tape stripped skin had nearly twice the flux o f native skin and repeat dosing 
increased the flux over a single dose o f PD98059 (Table 5.4).
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Figure 5.13: Cumulative Permeation o f PD98059 in an Ethanol vehicle through 
Porcine Skin. Tape stripped skin, native skin and single dosing or repeat dosing were 
compared. Statistical analysis was done by Ordinary ANOVA, Tukey test. * P<0.05. Data 
expressed as the mean +/- SD for n=3 experiments with 6 replicates for each experiment.
Table 5.4: Mean Flux and Standard Deviation for Permeation o f PD98059 in an 
Ethanol vehicle through Pig Skin
Mean Flux (x10‘3 
mg/cm2/hr)
SD
(x1 O'3)
Normal (Native) Skin (Repeat Dose) 6.40 1.20
Normal (Native) Skin (Single Dose) 5.60 325
Tape Stripped Skin (Repeat Dose) 10.15 3.96
Tape Stripped Skin (Single Dose) 17.05 1.83
Tape stripped skin with a single dose o f LY294002 gave a slightly lower 
cumulative amount of penetration at 48 hours than repeat dosing (Figure 5.14). 
Single dosing on native skin also gave a lower cumulative amount o f penetration 
than repeat dosing on native skin. Native skin with a single dose of LY294002 
gave lower cumulative penetration of the inhibitor than tape stripped (0.2 mg cm'2 
less) at 48 hours. LY294002 cumulative permeation with repeat dosing was also 
0.2mg cm'2 less at 48 hours through native skin compared to tape stripped skin.
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Figure 5.14: Cumulative Permeation o f LY294002 in an Ethanol Vehicle through 
Porcine Skin. Tape stripped skin enabled increased penetration o f LY294002 compared 
to native skin. Repeat dosing gave an increase in penetration for both tape stripped and 
native skin. Statistical analysis was done by Ordinary ANOVA, Tukey test. *** P<0.001. 
Data expressed as the mean +/- SD for n=3 experiments with 6 replicates for each 
experiment.
The rate of transfer of LY294002 diffusing through a unit area o f skin (flux) was 
higher through tape stripped skin than native skin and repeat dosing provided little 
increase in flux (Table 5.5).
Table 5.5: Mean Flux and Standard Deviation for Permeation o f LY294002 in an 
Ethanol vehicle through Porcine Skin.
Mean Flux
(x10'3 mg/cm2/hr)
SD
(x10‘3)
Normal (Native) Skin (Repeat Dose) 6.23 1.55
Normal (Native) Skin (Single Dose) 9.70 5.90
Tape Stripped Skin (Repeat Dose) 15.13 2.60
Tape Stripped Skin (Single Dose) 15.13 2.61
■NativeSkin, Repeat Dose 
Native Skin, Single Dose 
■Tape Stripped, Repeat Dose 
Tape Stripped, Single Dose
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5.4.1.3.3 Fish Oil Vehicle
Fish oil was a much less effective vehicle compared to both DMSO and ethanol, 
with more than ten times less cumulative amount of PD98059 recovered from the 
receptor phase (0.06mg cm’2) compared to DMSO (0.25mg cm'2) and ethanol 
(0.4mg cm'2 ).
The largest cumulative amount of PD98059 permeation with a fish oil vehicle was 
achieved when using tape stripped skin with repeat dosing (Figure 5.15). Tape 
stripped skin with a single dose of inhibitor gave significantly poorer permeation 
at 0.025 mg cm'2 less (PO.OOl) than for repeat dosing. There was little difference 
in cumulative inhibitor permeation between tape stripped and native skin.
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Figure 5.15: Cumulative Permeation o f PD98059 in a Fish Oil Vehicle through 
Porcine Skin. An increase in permeation was achieved with repeat dosing on both tape 
stripped and native skin compared to single dosing on both tape stripped and native skin. 
Statistical analysis was done by Ordinary AN OVA, Tukey test. *** P <0.001. Data 
expressed as the mean +/- SD for n=3 experiments with 6 replicates for each experiment.
Tape stripped skin with a single dose o f PD98059 had a slightly higher flux than 
native skin treated with repeat dosing, while tape stripped skin with repeat dosing
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had a similar flux (Table 5.6). Native skin treated with only a single dose o f  
PD98059 had the lowest flux (standard deviation low for this experiment).
Table 5.6: Mean Flux and Standard Deviation for Permeation of PD98059 in a Fish 
Oil Vehicle through Porcine Skin.
Mean Flux 
(x10'3 mg/cm2/hr)
SD 
(x10'3)
Normal (Native) Skin (Repeat Dose) 1.68 0.22
Normal (Native) Skin (Single Dose) 1.00 0.59
Tape Stripped Skin (Repeat Dose) 1.65 0.33
Tape Stripped Skin (Single Dose) 2.20 0.18
LY294002 permeated to a greater extent than PD98059 with a fish oil vehicle 
(tape stripped, repeat dosing), with a greater flux although its permeation and flux 
was still less with fish oil than with DMSO or ethanol vehicles.
When using a fish oil vehicle, tape stripped skin with repeat dosing gave the 
highest cumulative amount o f LY294002 penetration through full thickness 
porcine skin (Figure 5.16). Normal skin with repeat dosing o f LY294002 gave a 
slightly lower cumulative amount at 48 hours (0.025mg cm'2 less) and also had a 
slow cumulative increase between 24 and 36 hours, with an increased rate o f  
permeation between 36 and 48 hours. While levels in single dosed tape stripped 
porcine skin were 0.015mg cm'2 lower than repeat dosing, they were 0.050mg cm'2 
greater than single dosing with native skin. The level o f permeation through tape 
stripped skin treated with a single dose or repeat dosing was significantly higher 
than single dosing o f native (intact) skin (P<0.05).
The greatest cumulative amount o f LY294002 (0.125 mg cm'2) permeated through 
porcine skin with a fish oil vehicle after 48 hours was larger than the cumulative 
amount o f PD98059 (0.062 mg cm'2).
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Figure 5.16: Cumulative Permeation o f LY294002 in a Fish Oil Vehicle through 
Porcine Skin. An increase in penetration was achieved on repeat dosing with both tape 
stripped and native skin and single dosing on tape stripped skin compared to native skin 
with a single dose o f inhibitors. Statistical analysis was done by Ordinary ANOVA, Tukey 
test. * P<0.05. Data expressed as the mean +/- SD for n=3 experiments with 6 replicates 
for each experiment.
The lowest flux for LY294002 was on normal intact skin with a single dose and 
both repeat dosing and tape stripping almost doubled the flux (Table 5.7). The 
standard deviation was also low for these experiments. There was a reduction in 
penetration when using a fish oil vehicle compared to with DMSO or ethanol 
vehicles.
Table 5.7: Mean Flux and Standard Deviation for Permeation o f L Y294002 in a Fish 
Oil vehicle through Porcine Skin.
Mean Flux 
(x1 O'3 mg/cm2/hr)
SD
(x10'3)
Normal (Native) Skin (Repeat Dose) 4.80 0.35
Normal (Native) Skin (Single Dose) 2.85 0.08
Tape Stripped Skin (Repeat Dose) 4.08 0.070
Tape Stripped Skin (Single Dose) 5.93 0.094
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5.4.1.3.4 Cy dopam ine
HPLC estimation o f  drug molecules requires UV detection and as cyclopamine 
only has a very weak chromophore (single double bond), levels cannot easily be 
measured. LCMS is the recommended method for cyclopamine estimation but this 
was too costly to be used for the large number o f samples in these experiments. 
Therefore, methods o f derivatisation were used to boost the signal from 
cyclopamine so that HPLC could be used. However, no literature on cyclopamine 
derivatisation was found, so new methods were developed with a series of  
procedures using various agents: Dansyl Chloride (Maraschiello et al., 2003), 
phenylisocyanate in pyridine (Heard and Suedee, 1996) and diisopropylethylamine 
with 4 ’-bromophenacyl trifluoromethane-sulfonate (see methods). Unfortunately, 
none o f  these methods were successful in facilitating the UV detection of 
cyclopamine during HPLC analysis.
This was almost certainly due to unsuccessful conversion of the hydroxyl group 
present in the structure o f cyclopamine by the derivatising moieties. The reasons 
for this remain unclear, as the secondary OH would have been expected to react 
with the OH-specific reagents. However, on the grounds o f time constraints, no 
further analysis o f  cyclopamine was carried out.
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5.5 Discussion
The key finding from this study was that both PD98059 and LY294002 
successfully permeate through full thickness porcine skin (depth profiling using 
fish oil, ethanol or DMSO vehicles). This means that permeation-wise these 
inhibitors would be useful to target aggressive subtypes o f BCC which grow down 
into the dermis. Immunohistochemistry had already been used by Davison and co­
workers (2010) to show that PD98059 and LY294002 maintain their activity after 
penetration o f the stratum comeum. These inhibitors have also been found to be 
compatible and the depth profiling experiments in this study confirmed that they 
do not inhibit each other’s permeation.
Tape stripping as a method o f depth profiling has its drawbacks as demonstrated 
by the keratin distribution in Figure 5.3 and in the diagram o f the skin which 
shows that the lower epidermal layers follow the line o f the rete ridges so tape 
strips would remove cells from various epidermal layers at once (Figure 5.2 ). It 
would have been interesting to qualitatively measure the levels o f Keratin 10 and 
Keratin 14 by western blotting when conventional tape stripping was performed in 
order to confirm the depth o f  the cells collected on the strips.
As an alternative to tape stripping laser capture micro-dissection was considered. 
This enables selection o f  specific cells or areas o f cells and removing them by a 
cutting laser and then a second laser catapults these cells into a tube. Traditionally, 
these cells would be used for RNA extraction, but it seemed reasonable that this 
application could be adapted for capturing cells to quantify the amount o f drug 
which had permeated into them, as long as a large enough number of cells could 
be collected to measure the drugs. This method would allow detailed analysis o f  
penetration into the epidermis, dermis and hair follicle. However, the equipment 
available was not able to select these specific regions, so traditional tape stripping 
methods o f depth profiling were continued. Although it can be argued that tape 
stripping is a relatively crude technique, several replicates (6 Franz-type cells for
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each sample and 3 repeats for each experiment) were used and this is still the gold- 
standard experiment for depth-profiling probably because alternatives such as laser 
dissection are more costly and time consuming.
Depth profiling was carried out using a methanol vehicle for the inhibitors 
(LY294002 and PD98059) because this represents maximal penetration to show 
whether these inhibitors were capable o f penetrating through the epidermis into the 
living cells below. The results showed that approximately one third o f each 
inhibitor retrieved remained on the top layer o f skin after the excess was gently 
removed with a cotton bud. The inhibitors remaining on the surface were unable to 
penetrate the stratum comeum possibly due to saturation but also because the 
stratum comeum is the protective upper layer o f the skin which prevents 
penetration. Approximately one third o f the inhibitors were retained within the 
epidermis and one third penetrated the remaining epidermis and dermis where they 
were then retained. This is a very positive result because LY294002 and PD98059 
are able to penetrate to the site o f aggressive BCCs (throughout full thickness 
skin), but they were also retained in the skin so they would be able to act on BCC 
as long as MEK/ERK and PI3K/AKT signalling is activated. However, less than 
1% o f  each inhibitor applied was retrieved from full thickness skin, this may be 
problematic in terms o f  side effects such as irritation on the skin surface where the 
inhibitor remained, but this depends on the required quantities o f each inhibitor, 
which would be determined by tests on BCC cell culture models such as those 
discussed in Chapter 3. The inhibitors penetrated the full thickness o f the skin and 
into the receptor phase below, so the levels reaching the systemic circulation are 
equally important because they may cause side effects. LY294002 penetrated to a 
lesser extent than PD98059 and LY294002 also retarded penetration o f PD98059 
and PD98059 slightly retarded penetration o f LY294002. This means that the 
quantity o f inhibitors to be used in a topical formulation would require further 
consideration after testing their efficacy on cell culture models.
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DMSO and ethanol represented the maximal possible penetration of LY294002 
and PD98059 through intact skin because they are potent penetration enhancers. 
However, as shown by Davison and co-workers DMSO causes delamination of the 
stratum comeum and denucleation in the epidermis (Davison et al., 2008a). 
Ethanol also permeated full thickness skin quickly, with the risk o f partitioning the 
drugs into the systemic circulation. Fish oil gave a much lower flux for permeation 
o f  both inhibitors with a steady state flux o f 0.00168 for PD98059 compared to 
0.00455 for DMSO (normal skin repeat dose), but would be useful as a vehicle 
due to its safety. Fish oil permeation characteristics as a vehicle could be improved 
by the addition o f  enhancers such as 1, 8-cineole, ethanol or DMSO (in small 
amounts to reduce the deleterious effect on the stratum comeum). As cyclopamine 
is most soluble in ethanol and DMSO, one or both o f these in combination with 
fish oil would make a useful vehicle. The concentrations o f PD98059 and 
LY294002 can be increased in this sort o f vehicle because they are very soluble in 
fish oil, although cyclopamine is not. The quantity o f each drug needed would rely 
upon testing on a cell model.
It is clear from this study that ethanol and DMSO both disrupt the stratum 
comeum (the skin’s main barrier) enabling increased penetration of the inhibitors, 
as shown in published data (Oh et al., 2003; Williams, 2003). According to the 
results o f this study, ethanol doesn’t have such a disruptive effect on the stratum 
comeum barrier as DMSO but still behaves as an enhancing vehicle. Tape 
stripping the upper surface o f the skin also disrupted the stratum comeum, 
increasing the flux o f inhibitors and the cumulative amount o f permeation, 
particularly for fish oil which does not damage the stratum comeum. Increased 
percutaneous absorption through damaged stratum comeum has already been 
demonstrated (Bronaugh and Stewart. 1985). These results are important because 
inhibitor penetration into BCCs, which already have disrupted barrier function, 
will be increased compared to BCCs with an intact stratum comeum. Where the 
stratum comeum is intact enhancers will be required in the formulation (such as 
ethanol or DMSO) to increase drug permeation. Also, an increased mass o f drug or
231
repeat dosing (which was shown to increase cumulative amount of inhibitors 
permeated) will be required to increase the mass o f inhibitors that permeate.
Due to the skin drying effect o f ethanol and the toxicity o f DMSO, only very small 
amounts should be used or alternative enhancers which cause fewer side effects 
should be sought. Occlusion (by use o f a patch) may also be used to increase 
permeation by reducing transepidermal water loss. Water has been shown to 
increase permeation o f  hydrophilic and lipophilic molecules through the skin by 
increasing stratum comeum water content, although the mechanism o f action for 
lipophilic molecules remains unclear. This would also protect the area from 
contact which may mb the formulation off the skin. Commercial examples of  
successful occlusion include nicotine patches and occlusive dressings for 
Lignocaine and Prilocane cream for increased speed of anaesthesia (Williams, 
2004; Benson, 2005). Alternatively, to avoid too much PD98059 and LY294002 
reaching the systemic circulation, penetration retarders such as some DMSO 
derivatives (not all DMSO derivatives act as permeation enhancers, some are in 
fact retarders to skin permeation) may be added to the topical formulation 
(Benson, 2005).
Research groups have focussed on designing methods to bypass the stratum 
comeum in order to increase penetration. These include using microneedles to 
make holes in the stratum comeum but reaching nerves in the living epidermis 
must be avoided to prevent and causing pain (Haq et al., 2009). These holes in the 
stratum comeum enable increased permeation in a similar way to the tape stripping 
method used in this study. Therefore, microneedles may be a useful method for 
delivery o f drugs to BCCs in order to enable the same formulation to be used on 
all BCCs regardless o f  the level o f stratum comeum disruption. This is may be 
unnecessary for the EGF signalling inhibitors, LY294002 and PD98059 which 
penetrated the skin well. However, only a small percentage o f PD98059 or 
LY294002 (MEK and PI3K inhibitors) penetrated the skin, so a large amount 
would remain in the topical formulation on top o f the stratum comeum rather than
232
entering the skin, smaller amounts o f inhibitor could be applied using 
microneedles. If an excess o f these inhibitors is left on the skin surface there may 
be side effects (such as irritation) caused because EGF signalling affects healthy 
keratinocytes as well as carcinoma cells. Microneedles would be a useful method 
o f  delivery for cyclopamine or its derivatives which suffer from poorer solubility 
and therefore only poorly penetrate the intact stratum comeum.
Various studies for transcutaneous drug delivery have been carried out using 
assorted skin types and even skin equivalents such as graftskin™, a human living 
skin equivalent and Skinethic™, a human reconstructed epidermis. Pig skin has 
been shown to be a good model for human skin, is cost effective and easy to obtain 
(Schmook et al., 2001). A major problem is maintenance o f skin viability for the 
duration o f drug permeation experiments. The skin was less viable towards the end 
o f  the experiments, so to overcome this it would be useful to use a growth medium 
as the receptor phase in the Franz type cells. However, the inhibitors would need 
to be soluble in growth medium. It would also be beneficial eventually to confirm 
the findings on porcine skin by testing the penetration o f inhibitors for this study in 
an appropriate formulation on human skin, which can be obtained from surgery 
after ethical approval has been obtained.
PD98059 was chosen because it inhibits MEK1 phosphorylation, activation of the 
MEK/ERK branch o f  the EGF pathway (Chapter 3). An alternative would be 
U 0126, which could be used in parallel for cell experiments on a BCC culture 
model to confirm the results o f PD98059. LY294002 is specific for PI3K, an 
alternative inhibitor o f  PI3K would be Wortmannin. However, Wortmannin is a 
less specific inhibitor, but could be used to confirm experimental data in cell 
culture prior to development o f a topical formulation for LY294002.
Cyclopamine is a teratogen and possible carcinogen so it is desirable to use an 
alternative to reduce toxicity. Several dietary alkaloids with structural similarity to 
cyclopamine have been identified as weak inhibitors o f SHH signalling (Lipinski
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et al., 2007). It has been shown that solanidine, solasodine and tomatidine are all 
able to reduce PTCH expression to unstimulated levels in cells treated with 
recombinant SHH. Although cyclopamine is more potent, tomatidine was the most 
potent o f these derivatives (100 times less potent than cyclopamine; Lipinski et al., 
2007). During this study alternative cyclopamine derivatives became available 
which have more suitable characteristics for use in a topical formulation including 
reduced toxicity and increased solubility. GDC-0449, BMS-833923/XL139, 
CUR-61414 and IPI-926 are currently in clinical trials for the treatment o f BCC or 
other carcinomas which have activated SHH signalling. Furthermore, GDC-0449 
has been shown to induce tumour regression in medulloblastoma (Robarge et al., 
2009; Toftgard and Tegund, 2010).
Cyclopamine (SMO inhibitor) has a weak chromophore and is also very hard to 
measure by HPLC so alternatives such as BODIPY-cyclopamine (a fluorescent 
derivative) would be useful for future studies, although alternative SMO inhibitors 
may also be easier to assess (Chen et al., 2002b). A SMO inhibitor would be useful 
in a topical formulation for treating BCCs, because this would inhibit the majority 
o f the signalling pathway (there may be important interactions with other 
signalling pathways between SMO and the GLIs which we are currently not aware 
of). GLI inhibitors such as GANT61 and HPI-1, 2, 3, 4 would only be useful if  we 
could be sure that the SHH pathway has no upstream interactions with other 
signalling pathways such as the EGF pathways (Toftgard and Tegund, 2010).
In future, it may also be useful to conduct drug permeation through full thickness 
skin using a BCC cell model such as that described in Chapter 3. This would 
confirm that the inhibitors could successfully penetrate full thickness skin and still 
inhibit invasive tumour growth deeper in the subcutaneous layer. This is important 
because although the amount o f permeated drug in the receptor phase is 
measurable, it may not all be active due to the damaging effects o f skin enzymes. 
Although Davison et al. (2010) did previously show maintenance o f activity, it is 
not known whether the total amount o f permeants remain active. A foreseeable 
difficulty with this method is that porcine skin, although cleaned with the transport
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buffer solution, before permeation experiments, would still be colonised by micro­
organisms. Furthermore, microbial contamination must be avoided in any cell 
culture experiments. Harsher cleaning methods (with alcohols) would disrupt the 
stratum comeum thus artificially increasing permeation. To overcome this, 
0.22pm cyclopore track etched membrane or a filter insert would be used to 
separate the skin from the cell culture medium beneath. A benefit o f this approach 
is that the cell culture medium should maintain porcine skin viability for longer 
than the cetrimide receptor phase used in this study. Another option to prevent 
microbial infection would be to include antibiotics (penicillin and/or streptomycin) 
in the cell culture medium.
The cells could be grown on a glass coverslip in the base o f a Franz type diffusion 
cell or in a multi-well plate using a filter insert to separate the skin from the cells. 
This would be simple if  only a monolayer o f keratinocytes were required but to do 
this using a co-culture o f keratinocytes (at the air liquid interface) and fibroblasts 
would be much more complex. Fibroblasts could be grown on a glass coverslip in 
the base o f the receptor phase o f a Franz type cell, with keratinocytes in a filter 
insert (also in the receptor compartment), but grown at the air: liquid interface for 
10 days to allow stratification and cilia formation. Then the skin (on top o f a 0.22 
pm cyclopore track etched membrane) and donor compartment could be clamped 
on top and the medium in the receptor phase increased to cover the keratinocytes 
and reach the underside o f  the skin. Finally the inhibitors would be applied to the 
donor phase. However, there are lots o f  potential problems that could arise so this 
method would require rigorous optimisation. This idea was developed from work 
previously carried out in the laboratory, where it has was shown that MCF-7 breast 
cancer cells could be grown successfully in the base o f the receptor phase o f a 
Franz-type diffusion cell (Davison et al., 2010). Treated plastic flasks are usually 
used for growing cells in vitro. However, the keratinocytes and fibroblast cell lines 
used were successfully grown on glass coverslips for immunofluoresence work. In 
a previous study using MCF-7 cells, it is thought that cleaning the Franz-type
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diffusion cells with Decon 90 caused etching o f the glass surface making the glass 
rough, enabling the cells to successfully adhere.
Additional experiments are needed to ascertain the mass o f each inhibitor required 
for an efficacious BCC treatment and to determine the therapeutic window for safe 
administration prior to further development o f the delivery formulation. Initially, 
this would involve further development o f the in vitro BCC cell model with 
keratinocytes able to stratify in which SHH and EGF signalling could both be 
successfully activated enabling tumour down-growth to be visualised. Inhibitors to 
the SHH and EGF pathways would be added to the cell growth medium to 
discover whether they prevent growth o f the SHH expressing ‘tumour’ cells or 
cause them to regress. If SHH-expressing cell death occurred, further permeation 
studies could be carried out leading to the development o f a formulation which 
could be applied topically to carry these drugs to their site o f action without 
permeating into the systemic circulation.
Conclusions
• PD98059 and LY294002 successfully penetrate and permeate full
thickness skin.
• Ethanol and DMSO vehicles enable the fastest permeation for PD98059 
and LY294002 because they disrupt the stratum comeum, retardation may 
be required to prevent these inhibitors entering the systemic circulation.
• An alternative to cyclopamine is required to inhibit the SHH pathway due 
to its toxicity, lack o f  solubility and the challenges it presented in its 
analysis.
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6.1 General Discussion
The original hypothesis stated that EGF signalling might interact with SHH 
signalling and cause augmentation o f some SHH target genes. This could have 
occurred via either branch (MEK/ERK or PI3K/AKT) o f the EGF signalling 
pathway. It was hypothesised that the interaction between EGF and SHH 
signalling might increase the invasiveness o f BCCs and therefore contribute 
directly to the more invasive subtypes (nodular and morpheaform). These types of  
BCC are currently treated by surgical removal, which is both costly and time 
consuming, so any efficacious therapy that could reduce the onset o f these types o f  
BCC would be beneficial.
In order to test a combination therapy using an inhibitor o f the EGF pathway and 
together with an inhibitor o f  SHH signalling (at the level o f smoothened), both 
pathways needed to be active in keratinocyte cell lines. Attempts to activate the 
SHH signalling pathway by the addition o f recombinant SHH protein to the cells 
or by insertion o f an SHH gene into the nucleus o f the cells was not very 
successful. The current research identified that SHH pathway activation required 
culture conditions that would allow primary cilium formation and this required 
paracrine signalling. Primaiy cilia can be induced in cultured cells by growth 
arrest (induced by starvation due to an absence o f serum in the medium). The 
SEM data presented showed that approximately 10% o f cultured cells had cilia 
under the conditions used, a positive step forward towards achieving SHH 
signalling in keratinocyte cell lines. However, higher levels o f ciliation is required 
and further efforts should be made to increase the levels o f cilia (possibly by 
longer growth arrest) in order to achieve improved SHH signalling in culture. 
Testing the original hypothesis requires that SHH and EGF signalling operate at 
reasonable levels simultaneously and this would allow comparison o f the levels o f 
downstream gene expression in the presence and absence o f EGF.
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If the lack o f  a cellular response to SHH is due partially or fully to the absence or 
reduction in numbers o f cilia on cultured cells, it could be proposed that primary 
cilia would be a particularly good target option for therapy. However, it is likely 
that this is a general mechanism so targeted therapies may well affect other signal 
transduction pathways that rely on this structure (widespread in the epidermis and 
hair follicle). This would potentially cause side effects due to a more widespread 
action than intended so systemic affects cannot be ruled out. In addition, when 
BCCs were examined directly, only 3 out o f 8 had primary cilia (Wong et al, 
2009) so these structures may not be as widespread as indicated, which may limit 
the effectiveness o f  cilia inhibitors. It was also suggested that mutations in RAS, 
an effector molecule in the EGF pathway, might somehow facilitates SHH 
signalling in the absence o f  cilia, so GLI inhibitors may be more useful in such 
cases (see Wong et al., 2009). Development o f GLI inhibitors is currently in 
progress (Teglund and Toftgard, 2010) but this also has the disadvantage of 
targeting a downstream molecule and therefore upstream effects which would not 
be inhibited (Jenkins, 2009).
Thus, at his point in time, the role o f EGF signalling in the development o f BCCs 
is still unclear. Immunohistochemistiy comparison o f EGF signalling in nodular, 
micronodular, morpheaform and mixed morphology BCCs concluded that EGFR 
signalling was not responsible for the differences between nodular and 
morpheaform subtypes. Also the reduced levels o f p-ERK and p-AKT expression 
found in BCCs does not agree with previous work that has already demonstrated 
that components o f the EGF pathway are important for augmentation o f SHH 
signalling (Bigelow et al., 2005; Kasper et al., 2006). In addition, other cancers 
that involve SHH pathway activation (such as squamous cell carcinoma and 
medulloblastoma) also have highly active EGF pathway signalling. In particular, 
medulloblastomas have increased expression o f PI3K/AKT and MEK/ERK 
indicating that both arms o f  the EGF pathway are active (Baryawno et al., 2010; 
Wlodarski et al., 2008). Thus, EGF pathway inhibitors such as PD98059 and 
LY294002 might be useful for treating these cancers. However, further work
239
should be carried out to confirm that the low levels o f EGF pathway components 
in BCCs are not contributing to tumour growth. Work in this thesis has shown that 
PD98059 and LY294002 are able to permeate the skin and are reasonable EGF 
pathway inhibitors but if  levels o f EGF signalling are low in BCC, it may not be 
necessary to combine them with a SMO inhibitor for treating BCCs.
Published microarray data has suggested that RAS (downstream part o f the EGF 
signalling pathway) is activated in BCCs, which agrees with previously published 
work (Wong et al., 2009; Yu et al., 2008). It is also apparent form the work done 
by this group that other signalling pathways may be involved in BCC 
development. In particular, Wnt and Bcl-2 expression, which are important in 
apoptosis and increased p-catenin levels that have been found to be increased in 
the nuclei o f morpheaform cells (Yu et al., 2008). Thus, further research into the 
influence o f other signalling pathways on BCC development would be very 
important in order to develop the most appropriate topical formulations.
Finally, inhibitors o f  the MEK/ERK and PI3K/AKT arms o f the EGF pathway 
were tested for their ability to permeate full thickness skin. Both PD98059 and 
LY294002 successfully penetrated the skin and were retrieved from the receptor 
phase in laboratory experiments. As small molecule inhibitors easily penetrate the 
skin, they make ideal candidates for treating BCC, but this depends upon the 
action o f EGF signalling (particularly PI3K/AKT and MEK/ERK pathways) in 
these tumours. Although cyclopamine inhibits SHH signalling, it is toxic and not 
easy to measure so it would not be useful in a topical formulation. However, more 
soluble and less toxic derivatives are now becoming available and should be 
considered for future development o f a topical formulation for BCCs. These would 
have to be tested for their ability to permeate full thickness skin, and for their 
effects on a BCC cell line in which SHH signalling can successfully be activated.
In conclusion, while it seems that EGF is capable o f modulating SHH signalling, 
this pathway may not be important in BCC development, although further work
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should be done to confirm this. A cyclopamine derivative or another inhibitor of 
smoothened is likely to be useful for a formulation to treat most BCCs. Further 
work needs to be carried out in order to determine whether combination treatments 
blocking other signalling pathways would have an added benefit in BCCs. It 
would also be useful to develop a BCC cell model that can be activated by 
recombinant SHH would be ideal to test these therapeutic options.
Another alternative to topical formulations for the treatment o f BCCs which does 
not directly involve inhibition o f  signalling pathways is photodynamic therapy. It 
has been shown to be a useful non-invasive treatment for BCC. This therapy uses 
light sensitive cream, which in the presence o f intense visible laser light causes 
cancer cells to die by the creation o f reactive oxygen species. Until recently this 
therapy has only been effective on superficial BCC due to the limited penetration 
o f the active chemical (aminolevulinate). However, now that alternatives such as 
methyl aminolevulinate are available, which are thought to penetrate through the 
skin much further, this type o f  therapy is generating a lot o f interest (Foley et al., 
2009). Currently, photodynamic therapy is being tested in clinical trials, but even 
if found to be effective, this requires patients to undergo treatment in a clinical 
setting whereas the development o f  an effective topical formulation that could 
inhibit cellular signalling would be a useful alternative as treatment could be easily 
carried out at home and without the need o f a health professional to administer.
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